

[illegible]

pay us milestone payments of each of (i) \$5.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$100.0 million, (ii) \$10.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$200.0 million and (iii) \$15.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first \$80.0 million in annual net sales and 7.5% on annual net sales above \$80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimal annual royalties of \$3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products. **5** Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the "Transaction Agreement"), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize the Products in the United States, including, with the Population Council's consent, our exclusive license from the Population Council to commercialize ANNOVERA (the "Transferred Assets"). The total consideration from Mayne Pharma to TherapeuticsMD for the purchase of the Transferred Assets and the grant of the licenses under the Mayne Transaction Agreement was (i) a cash payment of \$140.0 million at closing, (ii) a cash payment of approximately \$12.1 million at closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments, (iii) a cash payment of approximately \$1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date. On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment No. 1 to the Mayne License Agreement (the "Mayne License Agreement Amendment"). Pursuant to the Mayne License Agreement Amendment, Mayne Pharma agreed to pay us approximately \$1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to \$257 thousand per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty payment was paid to us. We and Mayne Pharma settled the \$1.5 million of consideration due to Mayne Pharma for the assumed obligations under a long-term services agreement, including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023 Mayne Pharma held back our royalty payment of \$0.6 million and we funded an additional \$0.9 million in August 2023 to settle the original \$1.5 million payable. As part of the transformation that included the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in our condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in our condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of our condensed consolidated financial statements. We also have license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S. In July 2018, we entered into a license and supply agreement (the "Knight License Agreement") with Knight Therapeutics Inc. ("Knight") pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Knight obtained regulatory approval for IMVEXXY and BIJUVA and began commercialization efforts in 2024. In September 2019, we entered into an exclusive license and supply agreement (the "Theramex License Agreement") with Theramex HQ UK Limited ("Theramex") to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries. In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive officers were paid in full in January 2023 and severance obligations for terminated executive officers have been paid in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2023 and September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would serve as our Principal Financial Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan's resignation. **6** Going concern Following the transaction with Mayne Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us. On May 1, 2023, we entered into a Subscription Agreement (the "Subscription Agreement") with Rubric Capital Management LP (the "Rubric"), pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value \$0.001 per share (our "Common Stock"), from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a price per share equal to \$3.6797 pursuant to the Subscription Agreement. We received gross proceeds of \$1.15 million from the draw down, before expenses. On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to \$2.2761. We received gross proceeds of \$2.0 million from the drawdown, before expenses. In February 2024, the Company received Mayne Pharma's calculation of allowance for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement which differed significantly from the Company's estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. The Company continues to believe its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma's allowance calculation for payer rebates and wholesale distributor fees. In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company's estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns under the Transaction Agreement, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material. If Mayne Pharma's sales of Licensed Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements. **7** The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. **Basis of presentation** We prepared the condensed consolidated financial statements included in this 10-Q Report following the requirements of the United States ("U.S.") Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by accounting principles generally accepted in the U.S. ("U.S. GAAP") for complete financial statements can be condensed or omitted. However, except as disclosed herein, there has been no material change in the information disclosed in the notes included in our 2023 Annual Report on Form 10-K (the "2023 10-K Report"). As part of the transformation as a result of the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in the condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in the condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of the condensed consolidated financial statements. Revenues, expenses, assets, liabilities, and equities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. In our opinion, all adjustments necessary for a fair presentation of the financial statements, which are of a normal and recurring nature, have been made for the interim periods reported. The information included in this 10-Q Report should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 10-K Report. Certain amounts in the consolidated financial statements and accompanying notes may not add due to rounding, and all percentages have been calculated using unrounded amounts. Certain prior period amounts have been reclassified to conform to current-period presentation. **New accounting standards** Adoption of new accounting standards In November 2023, the Financial Accounting Standards Board ("FASB") issued Update 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" (Update 2023-07). Update 2023-07 applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in Update 2023-07 revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in Update 2023-07 do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. Update 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Update 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting Update 2023-07. In December 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures" (ASU 2023-09). ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company's income tax disclosures and on its consolidated financial statements. **Estimates and assumptions** The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. We evaluate our estimates and assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions. **Significant accounting policies** A

The significant accounting policies we use for quarterly financial reporting are disclosed in Note 1 of the notes to the consolidated financial statements included in our 2023 10-K report. 8 2. Discontinued Operations As discussed in Note 1, we changed our business in 2022 by licensing our products to receive royalties and future sales related milestone payments, after granting an exclusive license to commercialize our IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma. This plan represented a strategic shift having a major effect on our operations and financial results. Upon our conversion from a commercial pharmaceutical company to a licensing only company with the consummation of the Mayne Transaction, we classified all direct revenues, costs and expenses related to commercial operations, within income (loss) from discontinued operations, net of tax, in the condensed consolidated statements of operations for all periods presented. We have not allocated any amounts for shared general and administrative operating support expense to discontinued operations. Additionally, the related assets and liabilities have been reported as assets and liabilities of discontinued operations in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. As described in Note 1, the acquisition of net working capital by Mayne Pharma was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date. Our estimate of net working capital at closing was determined in accordance with the Transaction Agreement which establishes the process for the determination of final net working capital. Refer to Note 6 for a further discussion of net working capital contingencies. The following table presents results of discontinued operations (in thousands): 3 Three Months Ended September 30, 9 Nine Months Ended September 30, 2024 2023 2024 2023 Product revenue, net \$ 833 \$ (833) General and administrative expenses 42 39 2024 2023 Total operating expenses 42 39 2024 2024 296 Operating loss from discontinued operations 42 294 2024 2024 1,129 Other income (expense), net 42 1,150 2024 2024 1,150 Total other income (expense), net 42 1,150 2024 2024 1,150 Loss from discontinued operations, net of income taxes 42 1,944 2024 2024 1,944 The following table presents the carrying amounts of the classes of assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023 (in thousands): 9 September 30, 2024 9 December 31, 2023 Assets: 9 Accounts receivable \$ 344 Liabilities: 9 Accrued expenses and other current liabilities \$ 924 \$ 3,694 9 9 3. Prepaid and other current assets \$ Our prepaid and other current assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands): 9 September 30, 2024 9 December 31, 2023 Insurance \$ 161 253 Capitalized legal 2,334 2,334 Other 1,289 1,448 Prepaid and other current assets \$ 3,784 \$ 4,035 4. Licensed rights and other intangible assets The following provides information about our license rights and other intangible assets, net as of September 30, 2024 and December 31, 2023 (in thousands): 9 September 30, 2024 9 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Hormone therapy drug patents \$ 5,753 \$ 1,957 \$ 3,796 \$ 6,818 \$ 1,871 \$ 4,947 Hormone therapy drug patents applied and pending approval 323 42 323 842 42 842 Intangible assets subject to amortization 6,076 1,957 4,119 7,660 1,871 5,789 Intangible assets not subject to amortization: 1,129 1,129 Trademarks/trade name rights 309 42 309 42 309 License rights and other intangible assets, net \$ 6,385 \$ 1,957 \$ 4,428 \$ 7,969 \$ 1,871 \$ 6,098 We recorded, in continuing operations, amortization expense related to patents of \$96 thousand and \$110 thousand for the three months ended September 30, 2024 and 2023, respectively, and \$409 thousand and \$227 thousand for the nine months ended September 30, 2024 and 2023, respectively. The Company conducts regular reviews of the individual patents and portfolios. As a result of this review, also based on input from its licensing partners in the three months ended June 30, 2024, the Company determined it had an indicator of impairment, as it had abandoned the legal right and title to a portion of its granted patent portfolio and had ceased pursuit of a portion of its pending patents based on input from its licensing partners. The Company recognized an impairment loss of \$1,261 thousand related to those abandoned patents and applications, which is classified as an impairment of long-lived assets on the Company's condensed consolidated statements of operations for the nine months ended September 30, 2024. Our intangible assets subject to amortization are expected to be amortized as follows (in thousands): Year ending December 31, 2024 974 2025 384 2026 384 2027 384 2028 384 Thereafter 2,163 Total \$ 3,796 10 5. Accrued expenses and other current liabilities Other accrued expenses and other current liabilities consisted of the following (in thousands): 9 September 30, 2024 9 December 31, 2023 Payroll and related costs \$ 455 \$ 762 Professional fees 296 489 Operating lease liabilities 1,623 1,473 Other accrued expenses and current liabilities 444 409 Accrued expenses and other current liabilities \$ 2,818 \$ 3,133 6. Commitments and contingencies Mayne Pharma Agreement Mayne Pharma paid us approximately \$12.1 million at closing on December 30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction Agreement. While the Transaction Agreement calls for much of the net working capital to be trueed-up shortly after the Closing Date in 2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net working capital under the Transaction Agreement. In September 2023, we increased certain accrual estimates including increasing our working capital adjustment accrual by \$2.0 million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a \$5.5 million payment to Mayne Pharma to settle certain working capital amounts that were required to be trueed-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees. Of the \$5.5 million, \$2.0 million increased the allowance for net working capital allowances remaining to be trueed up. The Company's estimate of the allowance for payer rebates and wholesale distributor fees was determined in accordance with the Transaction Agreement which establishes the process for the determination of net working capital. In February 2024, the Company received Mayne Pharma's calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company's estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The timing and outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma's allowance calculation for payer rebates and wholesale distributor fees. In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company's estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material. Mayne Pharma has also made certain indemnification demands under the Transaction Agreement, which the Company disputes. As of September 30, 2024, the Company believes no additional accrual is required for such claims, as the Company cannot reasonably estimate a range of loss. 11 4 Legal proceedings In February 2020, we received a Paragraph IV certification notice letter (the "IMVEXXY Notice Letter") regarding an Abbreviated New Drug Application ("ANDA") submitted to the FDA by Teva Pharmaceuticals USA, Inc. ("Teva"). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA's Orange Book that claim compositions and methods of IMVEXXY (the "IMVEXXY Patents") are invalid, unenforceable, and/or will not be infringed by Teva's commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva's ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva's ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021, the District Court made available a public version of the order following the parties' agreement to a consent motion to redact information Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. We have incurred and recorded legal costs amounting to \$2,334 thousand in prepaid expenses and other current assets as of September 30, 2024, for the IMVEXXY Paragraph IV legal proceeding since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding, the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying condensed consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in this legal proceeding, then the related capitalized legal costs for this legal proceeding and any unamortized IMVEXXY patent costs that were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding. In June 2024, Mayne received a Paragraph IV certification notice letter (the "Sun Notice Letter") regarding an ANDA submitted to the FDA by Sun Pharma Inc. ("Sun Pharma"). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the Sun Notice Letter, Sun Pharma alleges that the IMVEXXY Patents are invalid, unenforceable, and/or will not be infringed by Sun Pharma's commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Sun Notice Letter expire in 2032 or 2033. In July 2024, we and Mayne Pharma filed a complaint for patent infringement against Sun Pharma in the United States District Court for the District of New Jersey arising from Sun Pharma's ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Sun Pharma's ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Sun Pharma from infringing the IMVEXXY Patents. Beginning on December 30, 2022 and per the Mayne License Agreement, Mayne Pharma is responsible for all enforcement of our patents, including the responsibility for and costs of litigation discussed above with respect to Teva and Sun Pharma. From time to time, we are involved in other litigations and proceedings in the ordinary course of business. We are currently not involved in any other litigations and proceedings that we believe would have a material effect on our condensed consolidated financial condition, results of operations, or cash flows. Off-balance sheet arrangements As of September 30, 2024 and December 31, 2023 there were no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material. 12 4 Employment agreements In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 30, 2022. Severance obligations for all employees other than executive officers were paid in full in the first quarter of 2023. As of September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. In the aggregate, as of September 30, 2024, we have accrued severance liabilities for executive termination obligations of \$56 thousand. 7. Stockholders' equity 4 Warrants As of September 30, 2024, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2023 (in thousands, except weighted average exercise price and weighted average remaining contractual life data): Warrants Outstanding and Exercisable Warrants Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Life (in Years) As of January 1, 2024 994 \$ 66.61 \$ 6.5 Expired 2 281.50 \$ 4 As of September 30, 2024 974 \$ 63.33 \$ 5.8 4

[illegible]

vitaMedMD brands (collectively, the “Licensed Products”) in the United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the “Products”) in the United States and its possessions and territories, and (iii) sold certain other assets to Mayne Pharma in connection therewith. Â 17 Â Pursuant to a License Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Mayne License Agreement”), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories. Pursuant to the Mayne License Agreement, Mayne Pharma will pay us one-time, milestone payments of each of (i) \$5.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$100.0 million, (ii) \$10.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$200.0 million and (iii) \$15.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first \$80 million in annual net sales and 7.5% on annual net sales above \$80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of \$3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below (the “Minimum Annual Royalty”). Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products. Â Pursuant to a Transaction Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Transaction Agreement”), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize the Products in the United States, including our exclusive license from the Population Council to commercialize ANNOVERA (the “Transferred Assets”). Â The total consideration from Mayne Pharma to us for the purchase of the Transferred Assets and the grant of the licenses under the Mayne License Agreement was (i) a cash payment of \$140.0 million at closing, (ii) a cash payment of approximately \$12.1 million at closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments, (iii) a cash payment of approximately \$1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date. Â On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment No. 1 to the Mayne License Agreement (the “Mayne License Agreement Amendment”). Pursuant to the Mayne License Agreement Amendment, Mayne Pharma agreed to pay us approximately \$1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to \$257 thousand per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty payment was paid to us. We and Mayne Pharma settled the \$1.5 million of consideration due to Mayne for the assumed obligations under a long-term services agreement, including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma held back our royalty payment of \$0.6 million and we funded an additional \$0.9 million in August 2023 to settle the original \$1.5 million payable. Â This action represented a shift in our business and therefore, the related assets and liabilities associated with commercial operations are classified as discontinued operations on our condensed consolidated balance sheets and the results of operations have been presented as discontinued operations within our condensed consolidated statements of operations for all periods presented. See Note 2 “Discontinued Operations to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further details. Â 18 Â We also have license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S. Â â— In July 2018, we entered into a license and supply agreement (the “Knight License Agreement”) with Knight Therapeutics Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Knight obtained regulatory approval for IMVEXXY and BIJUVA and began commercialization efforts in 2024. Â â— In September 2019, we entered into an exclusive license and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries. Â In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive officers were paid in full in the first quarter of 2023 and severance obligations for terminated executive officers have been paid in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2023 and September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants, including certain former members of our management team, who support our relationship with current partners and assist with certain financial, legal and regulatory matters and the continued wind-down of our historical business operations. Â Going concern Â Following the transaction with Mayne Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares. Â To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us. Â On May 1, 2023, we entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (“Rubric”), pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value \$0.001 per share (our “Common Stock”), from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a price per share equal to \$3.6797 pursuant to the Subscription Agreement. We received gross proceeds of \$1.15 million from the draw down, before expenses. On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to \$2.2761. We received gross proceeds of \$2.0 million from the drawdown, before expenses. Â Mayne Pharma paid us approximately \$12.1Â million at closing on December 30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in 2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net working capital under the Transaction Agreement. Â 19 Â In September 2023, we revised certain accrual estimates including increasing our working capital adjustment accrual from \$3.5Â million to \$5.5Â million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a \$5.5Â million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees. Â The Company’s estimate of the allowance for payer rebates and wholesale distributor fees was determined in accordance with the Transaction Agreement which establishes the process for the determination of net working capital. In February 2024, the Company received Mayne Pharma’s calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company’s estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. Â The Company believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The timing and outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma’s allowance calculation for payer rebates and wholesale distributor fees. Â In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company’s estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns under the Transaction Agreement, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material. Â If Mayne Pharma’s sales of Licensed Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements. Â The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Â Portfolio of our royalty-bearing products Â In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022, we granted an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma. Â IMVEXXY (estradiol vaginal inserts), 4-Âµg and 10-Âµg Â This pharmaceutical product is for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. Â On December 30, 2022, we granted an exclusive license to commercialize IMVEXXY in the United States and its possessions and territories to Mayne Pharma. We also have entered into licensing agreements with third parties to market and sell IMVEXXY outside of the U.S. We entered into the Knight License Agreement, with Knight pursuant to which, we granted Knight an exclusive license to commercialize IMVEXXY in Canada and Israel. We entered into the Theramex License Agreement with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY for human use outside of the U.S., except for Canada and Israel. As of September 30, 2024, no IMVEXXY sales had been made through the Theramex licensing agreement. Â 20 Â BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg Â This pharmaceutical product is the first and only FDA approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. Â On December 30, 2022, we granted an exclusive license to commercialize BIJUVA in the United States and its possessions and territories to Mayne Pharma. We also have entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize BIJUVA in Canada and Israel. We have entered into the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA for human use outside of the U.S., except for Canada and Israel. Â ANNOVERA (segesterone acetate (“SA”) and ethinyl estradiol (“EE”) vaginal system) Â On December 30, 2022, we assigned our exclusive license to commercialize ANNOVERA to Mayne Pharma. This pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (“CVS”) and the first and only patient-

controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year). ANNOVERA is commercially sold in the U.S. pursuant to the terms of the Population Council License Agreement. A Prenatal vitamin products A On December 30, 2022, we granted an exclusive license to commercialize, in the United States and its possessions and territories, our prescription prenatal vitamin product lines under our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD Prenatal name to Mayne Pharma. A Results of operations A A As part of the transformation that included the Mayne License Agreement, historical results of commercial operations have been reflected as discontinued operations in our condensed consolidated financial statements for all periods prior to the Closing Date. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in our condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 to the condensed consolidated financial statements included in this Quarterly Report. A The discussion below, and the revenues and expenses discussed below, are based on, and relate to, our continuing operations. A 21 A A Three months ended September 30, 2024 compared with three months ended September 30, 2023 A The following table sets forth the results of our operations (in thousands): A A A Three Months Ended September 30, A A 2024A A 2023A Revenue:A A A A A License and service revenueA \$547A A \$(53) Operating expenses:A A A A A A Selling, general and administrativeA A 1,310A A A 1,590A Impairment of long-lived assets (Note 4)A A A A A Depreciation and amortizationA A 96A A A 130A Total operating expensesA A 1,406A A A 1,720A Loss from operationsA A (859)A A (1,773) Other income (expense):A A A A A A Interest expense and other financing costsA A (3)A A (20) Miscellaneous incomeA A 295A A A 359A Total other income, netA A 292A A A 339A Loss from continuing operations before income taxesA A (567)A A (1,434) Provision for income taxesA A A A A Net loss from continuing operationsA A (567)A A (1,434) Loss from discontinued operations, net of income taxesA A (42)A A (1,944) Net lossA \$(609)A \$(3,378) A Revenue. As part of our transformation and the Mayne License Agreement, historical results of commercial operations have been reflected as discontinued operations in the condensed consolidated financial statements for all periods presented. A We recorded \$547 thousand in license revenue for the third quarter of 2024, primarily from the Mayne License Agreement, an increase of \$600 thousand, compared to \$(53)A thousand in license revenue for the third quarter of 2023. The increase is primarily attributable to changes in sales of licensed products. Reported negative license revenue of \$(53) thousand in the third quarter of 2023 was due to product sales adjustments reported by our licensees. A Operating expenses. Total operating expenses for the third quarter of 2024 were \$1,406 thousand, a decrease of \$314 thousand, or 18.3%, compared to the third quarter of 2023. This decrease was due to the further optimization of our business through the reduction of costs following our transition to a royalty-based business. A Selling, general and administrative. Selling, general and administrative expenses were \$1,310 thousand for the third quarter of 2024, a decrease of \$280 thousand, or 17.6%, compared to the third quarter of 2023. This decrease was due to the increased efficiencies realized following our transition to a royalty-based business. A Depreciation & amortization. Depreciation and amortization expense was \$96 thousand for the third quarter of 2024, a decrease of \$34 thousand, or 26.2%, compared to the third quarter of 2023. In the 2024 period, this balance is entirely comprised of amortization of license rights and intangible assets. A Loss from operations. In the third quarter of 2024, we had a loss from operations of \$859 thousand, as compared to a loss from operations of \$1,773 thousand for the third quarter of 2023. This change reflects the streamlining of our business and increased efficiencies realized as a royalty-based business. A 22 A A Other income (expense), net. During the third quarter of 2024, we had other income of \$292 thousand compared to other income of \$339 thousand in the third quarter of 2023. Other income in the 2024 period was mainly comprised of interest income, while other income in the prior year period was mainly comprised of royalties. A Provision for income taxes. During the third quarter of 2024 and 2023, we recorded no provision for income taxes for continuing operations. A Net loss from continuing operations. For the third quarter of 2024, we had a net loss of \$567 thousand, or \$0.05 per basic and diluted common share, compared to a net loss of \$1,434 thousand, or \$0.13 per basic and diluted common share, for the third quarter of 2023.A A Discontinued Operations A A Net loss from discontinued operations was \$42 thousand for the third quarter of 2024, compared to a net loss from discontinued operations of \$1,944 thousand for the third quarter of 2023. A Nine months ended September 30, 2024 compared with nine months ended September 30, 2023 A The following table sets forth the results of our operations (in thousands): A A A Nine Months Ended September 30, A A 2024A A 2023A Revenue:A A A A A License and service revenueA \$1,094A A \$800A Operating expenses:A A A A A A Selling, general and administrativeA A 3,865A A A 7,427A Impairment of long-lived assets (Note 4)A A 1,261A A A A Depreciation and amortizationA A 409A A A 285A Total operating expensesA A 5,535A A A 7,712A Loss from operationsA A (4,441)A A (6,912) Other income (expense):A A A A A A Interest expense and other financing costsA A (8)A A (115) Miscellaneous incomeA A 2,023A A A 869A Total other income, netA A 2,015A A A 754A Loss from continuing operations before income taxesA A (2,426)A A (6,158) Provision for income taxesA A A A A Net loss from continuing operationsA A (2,426)A A (6,158) Loss from discontinued operations, net of income taxesA A (7)A A (3,237) Net lossA \$(2,433)A \$(9,395) A Revenue. As part of our transformation and the Mayne License Agreement, historical results of commercial operations have been reflected as discontinued operations in the condensed consolidated financial statements for all periods presented. A We recorded \$1,094 thousand in license revenue for the first nine months of 2024, primarily from the Mayne License Agreement, an increase of \$294 thousand, or 36.8%, compared to \$800 thousand in license revenue for the first nine months of 2023. The increase is primarily attributable to changes in sales of licensed products. A 23 A A Operating expenses. Total operating expenses for the first nine months of 2024 were \$5,535 thousand, a decrease of \$2,177 thousand, or 28.2%, compared to the first nine months of 2023. This decrease was due to the further optimization of our business through the reduction of costs following our transition to a royalty-based business and is partially off-set by the patent impairment recognized in the second quarter of 2024. A Selling, general and administrative. Selling, general and administrative expenses were \$3,865 thousand for the first nine months of 2024, a decrease of \$3,562 thousand, or 48.0%, compared to the first nine months of 2023. This decrease was due to the increased efficiencies realized following our transition to a royalty-based business. A Depreciation & amortization. Depreciation and amortization expense was \$409 thousand for the first nine months of 2024, an increase of \$124 thousand, or 43.5%, compared to the first nine months of 2023. In the 2024 period, this balance is entirely comprised of amortization of license rights and intangible assets. A Loss from operations. In the first nine months of 2024, we had a loss from operations of \$4,441 thousand, as compared to a loss from operations of \$6,912 thousand for the first nine months of 2023. This change reflects the streamlining of our business and increased efficiencies realized as a royalty-based business. A Other income, net. During the first nine months of 2024, we had other income of \$2,015 thousand compared to other income of \$754 thousand in the first nine months of 2023. The difference is mainly due to a \$1,250 thousand one-time payment the Company received from its sublessee on its early termination on the sublease, which was recognized in the second quarter of 2024. Royalties reported as other income for intellectual property licensed by us totaled approximately \$660 thousand in the first nine months of 2024. A Provision for income taxes. During the first nine months of 2024 and 2023, we recorded no provision for income taxes for continuing operations. A Net loss from continuing operations. For the first nine months of 2024, we had a net loss of \$2,426 thousand, or \$0.21 per basic and diluted common share, compared to a net loss of \$6,158 thousand, or \$0.60 per basic and diluted common share, for the first nine months of 2023.A A Discontinued Operations - Net loss from discontinued operations was \$7 thousand for the first nine months of 2024, compared to a net loss from discontinued operations of \$3,237 thousand for the first nine months of 2023. This change reflects the continued wind-down of our legacy business. A For additional information, see Note 2 - Discontinued Operations, in the notes to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report. A Liquidity and capital resources A Our primary use of cash is to fund our continued operations. We have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities, the divestiture of our former subsidiary vitaCare, and the transactions with Mayne Pharma. As of September 30, 2024, we had cash and cash equivalents totaling \$5,047 thousand. We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation insured limits of \$250 thousand per bank. We have never experienced any losses related to these funds. A Mayne Pharma License Agreement A On December 30, 2022, we granted Mayne Pharma (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories. The total consideration from Mayne Pharma to us under the Mayne License Agreement consisted of (i) a cash payment of \$140.0 million at closing, (ii) a cash payment of approximately \$12.1 million at closing for the acquisition of net working capital as determined in accordance with the transaction agreement dated December 4, 2022, and subject to certain adjustments, (iii) a cash payment of approximately \$1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended. A 24 A A Pursuant to the Mayne License Agreement, Mayne Pharma will pay us one-time, milestone payments of each of (i) \$5.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$100.0 million, (ii) \$10.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$200.0 million and (iii) \$15.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first \$80 million in annual net sales and 7.5% on annual net sales above \$80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of \$3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products. A Subscription Agreement with Rubric Capital Management LP A On May 1, 2023, we entered into the Subscription Agreement with Rubric, pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of Common Stock, from time to time during the term of the Subscription Agreement in separate drawdowns at our election, at a purchase price of the five-day volume-weighted average price of our common stock at the time of the sale of such shares, at an aggregate purchase price of up to \$5,000,000 (collectively, the A A Private PlacementA A). A The initial draw down occurred on June 29, 2023 consisting of a sale of 312,525 shares of Common Stock at a price per share equal to \$3.6797. We received gross proceeds of \$1.15 million from the drawdown, before expenses. On November 15, 2023 Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to \$2.2761. We received gross proceeds of \$2.0 million from the drawdown, before expenses. A Managed Client Agreement with IWG A On September 30, 2024 (the A A Commencement DateA A), we entered into a Managed Client Agreement (the A A Managed Client AgreementA A) with RGN-MCA Florida VI, LLC (A A IWGA A) pursuant to which IWG agreed to provide managed services for flexible workspaces under the A A HQA A brand for 21,330 square feet of our office spaces located at 951 Yamato Road, Boca Raton, Florida 33431 (the A A PremisesA A). The Managed Client Agreement is subject to termination by us or IWG if either party does not approve the specification, plans and drawings for the fit out of the Premises on or before the date that is 120 days after the Commencement Date. A See A A Going ConcernA A above for further discussion related to our ability to generate and obtain adequate amounts of cash to meet our liquidity needs and our plans to satisfy our such needs in the short-term and in the long-term. As a result, there is substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements. A Cash flows A The following table reflects the major categories of cash flows for each of the periods (in thousands). A A A Nine Months Ended September 30, A A 2024A A 2023A Net cash provided by (used in) continuing operating activitiesA \$1,153A A \$(18,121) Net cash provided by financing activitiesA A A A A 1,149A Net cash used in discontinued operationsA A (433)A A (22,179) Net increase (decrease) in cashA \$720A A \$(39,151) A Operating Activities from continuing operations. For the first nine months of 2024, net cash provided by operating activities was \$1,153 thousand, compared to net cash used in operating activities of \$18,121 thousand for the first nine months of 2023. This change of \$19,274 thousand was primarily due to a \$3,732 thousand decrease in our net loss from continuing operations following our transition from a manufacturing and commercialization business to a royalty-based business combined with the pay-down of current liabilities in the prior-year period. A 25 A A Financing Activities from continuing operations.A For

the first nine months of 2024, there was no cash received from financing activities, compared to net cash received from financing activities of \$1,149Â thousand for the first nine months of 2023, reflecting the sale of common stock during the first nine months of 2023. Â Net cash used in discontinued operations. Net cash used in operating activities from discontinued operations for the first nine months of 2024 was \$433 thousand as compared to net cash used in operating activities of \$22,179 thousand for the first nine months of 2023. This change relates primarily to a decrease in expenses incurred and the payment of current liabilities associated with our transition from a manufacturing and commercialization business to a royalty-based business. Â For additional details, see the condensed consolidated statements of cash flows in Item 1, Financial Statements, appearing elsewhere in this 10-Q Report. Â Other liquidity measures Â Receivable from Mayne. On December 30, 2022, Mayne Pharma acquired our accounts receivable balance of approximately \$29.3 million which is subject to certain working capital adjustments. As of September 30, 2024, we had a royalty receivable of \$3,160 thousand relating to the short-term portion of receivable from Mayne Pharma and \$16,610 thousand relating to the long-term portion of royalty receivable which includes royalties recognized from the Minimum Annual Royalty. See Note 1 Business, basis of presentation, new accounting standards and summary of significant accounting policies (Revenue Recognition) to the consolidated financial statements included in our 2023 10-K Report.Â Â Inventory. On December 30, 2022, Mayne Pharma acquired our inventory balance of approximately \$6.6 million, which is subject to certain net working capital adjustments. Â Contractual obligations, off-balance sheet arrangements and purchase commitments and employment agreements Â Our contractual obligations and off-balance sheet arrangements are set forth below. For additional information on any of the following and other obligations and arrangements, see “Note 6. Commitments and Contingencies” to the condensed consolidated financial statements included in this 10-Q Report. Â In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal and customary for companies in our industry sector. Pursuant to these agreements, we agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is sometimes unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we had no liabilities recorded for these provisions as of September 30, 2024 and December 31, 2023. Â In the normal course of business, we may be confronted with issues or events that may result in contingent liability. These generally relate to lawsuits, claims, environmental actions, or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by U.S. GAAP, an estimate is made of the loss and the appropriate accounting entries are reflected in our condensed consolidated financial statements. Â Critical accounting policies and estimates Â Management’s discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements included elsewhere in this 10-Q Report, which has been prepared in accordance with U.S. GAAP and SEC rules and regulations related to interim financial reporting. We make estimates and assumptions that affect the reported amounts on our condensed consolidated financial statements and accompanying notes as of the date of the condensed consolidated financial statements. The critical accounting policies and estimates used are disclosed in Item 7 “Management’s discussion and analysis of financial condition and results of operations” “Critical accounting policies and estimates in our 2023 10-K Report. Â 26 Â Â ItemÂ 3. Quantitative and qualitative disclosures about market risk Â As a “smaller reporting company,” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and pursuant to Instruction 6 to Item 201(e) of Regulation S-K, we are not required to provide this information. Â ItemÂ 4. Controls and procedures Â Management’s evaluation of disclosure controls and procedures Â Disclosure Controls and Procedures Â Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, in order to allow timely decisions regarding required disclosure. Â Evaluation of Disclosure Controls and Procedures Â Our Chief Executive Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this 10-Q Report. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures as of the end of the period covered by this 10-Q Report were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Our Chief Executive Officer does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our Company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures. Â Changes in internal controls over financial reporting Â In connection with our transformation into a pharmaceutical royalty company, we terminated our executive management team and all other employees, except for our former General Counsel and current Chief Executive Officer. As of September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal and regulatory matters and the continued wind-down of our historical commercial business operations. As a result of these changes, we have updated our risk assessment and design of internal controls over financial reporting that align with reduced transaction volume and reliance on external consultants to manage the day-to-day operations of the Company. The Company is and will continue to evaluate changes to processes, information technology systems and other components of internal controls over financial reporting as part of its ongoing business transformation activities, and as a result, controls may be periodically changed. The Company believes, however, that it will be able to maintain sufficient controls over its financial reporting throughout this transformation process. Â During the first quarter of fiscal year 2024, we deployed a “new” ERP system which is anticipated to enhance our operating and financial processes over time. Processes and internal controls have been updated and are consistent with our internal control framework, and we have evaluated the operating effectiveness of related key controls. Control processes continue to be evaluated to give appropriate consideration of modifications needed to maintain the effectiveness of internal controls over financial reporting. Â 27 Â Â Part II - Other Information Â Item 1. Legal proceedings Â From time to time, we are involved in litigation and proceedings in the ordinary course of our business. Other than the legal proceedings disclosed in Note 6, Commitments and contingencies in Part I, Item 1, Financial Statements, appearing elsewhere in this 10-Q Report, we are not involved in any legal proceeding that we believe would have a material effect on our business or financial condition. Â Item 1A. Risk factors Â Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in Part I, Item 1A of the 2023 10-K Report under the heading “Risk Factors,” any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price. There have been no material changes to our risk factors since the 2023 10-K Report. Â Item 2. Unregistered sales of equity securities and use of proceeds Â None. Â Item 3. Defaults upon senior securities Â None. Â Item 4. Mine safety disclosures Â None. Â Item 5. Other information Â Rule 10b5-1 Trading Plans Â During the three months ended September 30, 2024, none of the Company’s directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K). Â 28 Â Â Item 6. Exhibits Â Exhibit No. Â Description Â 31.1â€ Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) Â 31.2â€ Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) Â 32.1â€ â€ Section 1350 Certification of Chief Executive Officer Â 32.2â€ â€ Section 1350 Certification of Principal Financial Officer Â 101â€ Â Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q Â 104â€ Â Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set Â â€ Filed herewith. Â â€ Furnished herewith. Â 29 Â Â Signatures Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Date: November 12, 2024 TherapeuticsMD, Inc. Â Â /s/ Marlan D. Walker Â Marlan D. Walker Â Chief Executive Officer (Principal Executive Officer) Â Â /s/ Joseph Ziegler Â Joseph Ziegler Â Principal Financial and Accounting Officer Â 30 Â 561 false --12-31 Q3 0000025743 0000025743 2024-01-01 2024-09-30 0000025743 us-gaap:LicenseAndServiceMember 2024-07-01 2024-09-30 0000025743 us-gaap:LicenseAndServiceMember 2023-07-01 2023-09-30 0000025743 us-gaap:LicenseAndServiceMember 2024-01-01 2024-09-30 0000025743 us-gaap:LicenseAndServiceMember 2023-01-01 2023-09-30 0000025743 2024-07-01 2024-09-30 0000025743 2023-07-01 2023-09-30 0000025743 2023-01-01 2023-09-30 0000025743 us-gaap:CommonStockMember 2023-12-31 0000025743 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000025743 us-gaap:RetainedEarningsMember 2023-12-31 0000025743 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000025743 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000025743 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000025743 2024-01-01 2024-03-31 0000025743 us-gaap:CommonStockMember 2024-03-31 0000025743 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000025743 us-gaap:RetainedEarningsMember 2024-03-31 0000025743 2024-03-31 0000025743 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000025743 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000025743 2024-04-01 2024-06-30 0000025743 us-gaap:CommonStockMember 2024-06-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000025743 us-gaap:RetainedEarningsMember 2024-06-30 0000025743 2024-06-30 0000025743 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000025743 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000025743 us-gaap:CommonStockMember 2024-09-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000025743 us-gaap:RetainedEarningsMember 2024-09-30 0000025743 us-gaap:CommonStockMember 2022-12-31 0000025743 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000025743 us-gaap:RetainedEarningsMember 2022-12-31 0000025743 2022-12-31 0000025743 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000025743 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000025743 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000025743 2023-01-01 2023-03-31 0000025743 us-gaap:CommonStockMember 2023-03-31 0000025743 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000025743 us-gaap:RetainedEarningsMember 2023-03-31 0000025743 2023-03-31 0000025743 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000025743 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000025743 2023-04-01 2023-06-30 0000025743 us-gaap:CommonStockMember 2023-06-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000025743 us-gaap:RetainedEarningsMember 2023-06-30 0000025743 2023-06-30 0000025743 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000025743 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000025743 us-gaap:CommonStockMember 2023-09-30 0000025743 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000025743 us-gaap:RetainedEarningsMember 2023-09-30 0000025743 2023-09-30 0000025743 txmd:MilestonePaymentsOneMember txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743 txmd:MilestonePaymentsThreeMember txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743 txmd:RoyaltyRateOneMember txmd:MaynePharmaMember txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743 txmd:RoyaltyRateTwoMember txmd:MaynePharmaMember

txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743 txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743
txmd:MayneLicenseAgreementMember 2024-09-30 0000025743 txmd:MayneLicenseAgreementMember 2023-08-31 2023-08-31 0000025743 2023-08-31 2023-08-31 0000025743
txmd:RubricCapitalManagementLPMember 2023-05-01 0000025743 txmd:RubricCapitalManagementLPMember 2023-06-29 2023-06-29 0000025743
txmd:RubricCapitalManagementLPMember 2023-06-29 0000025743 txmd:RubricCapitalManagementLPMember 2023-11-15 0000025743
txmd:RubricCapitalManagementLPMember 2023-11-15 2023-11-15 0000025743 us-gaap:SegmentDiscontinuedOperationsMember 2024-07-01 2024-09-30 0000025743 us-gaap:SegmentDiscontinuedOperationsMember 2023-07-01 2023-09-30 0000025743 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-09-30 0000025743 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-09-30 0000025743 us-gaap:PatentsMember 2024-07-01 2024-09-30 0000025743 us-gaap:PatentsMember 2023-07-01 2023-09-30 0000025743 us-gaap:PatentsMember 2024-01-01 2024-09-30 0000025743 us-gaap:PatentsMember 2023-01-01 2023-09-30 0000025743 txmd:HormoneTherapyDrugPatentsMember 2024-09-30 0000025743 txmd:HormoneTherapyDrugPatentsMember 2023-12-31 0000025743 txmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember 2024-09-30 0000025743 txmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember 2023-12-31 0000025743 txmd:IntangibleAssetsSubjectToAmortizationMember 2024-09-30 0000025743 txmd:IntangibleAssetsSubjectToAmortizationMember 2023-12-31 0000025743 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0000025743 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0000025743 txmd:MaynePharmaAgreementMember 2022-01-01 2022-12-30 0000025743 txmd:MaynePharmaAgreementMember 2023-09-30 2023-09-30 0000025743 txmd:MaynePharmaAgreementMember 2023-12-31 0000025743 srt:MaximumMember 2023-12-31 0000025743 srt:MinimumMember 2023-12-31 0000025743 txmd:ParagraphFourCertificationNoticeLetterMember 2024-01-01 2024-09-30 0000025743 srt:ChiefExecutiveOfficerMember 2024-01-01 2024-09-30 0000025743 us-gaap:PhantomShareUnitsPSUsMember 2024-09-30 0000025743 txmd:TwoThousandNineteenStockIncentivePlanMember 2024-09-30 0000025743 us-gaap:PhantomShareUnitsPSUsMember 2022-01-01 2022-12-31 0000025743 txmd:EmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0000025743 txmd:EmployeeStockPurchasePlanMember 2023-07-01 2023-09-30 0000025743 txmd:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0000025743 txmd:EmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0000025743 us-gaap:WarrantMember 2023-12-31 0000025743 us-gaap:WarrantMember 2024-01-01 2024-09-30 0000025743 us-gaap:WarrantMember 2024-09-30 0000025743 2024-01-01 0000025743 2024-01-01 2024-01-01 0000025743 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000025743 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0000025743 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0000025743 us-gaap:PerformanceSharesMember 2023-12-31 0000025743 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0000025743 us-gaap:PerformanceSharesMember 2024-09-30 0000025743 txmd:RoyaltyRateOneMember txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743 txmd:RoyaltyRateTwoMember txmd:MayneLicenseAgreementMember 2024-01-01 2024-09-30 0000025743 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000025743 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000025743 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0000025743 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000025743 us-gaap:PhantomShareUnitsPSUsMember 2024-01-01 2024-09-30 0000025743 us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-09-30 0000025743 us-gaap:WarrantMember 2024-01-01 2024-09-30 0000025743 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000025743 txmd:RubricCapitalManagementLPMember us-gaap:SeriesAPreferredStockMember txmd:SubscriptionAgreementMember 2022-12-30 2022-12-30 0000025743 txmd:RubricCapitalManagementLPMember us-gaap:SeriesAPreferredStockMember txmd:SubscriptionAgreementMember 2022-12-30 0000025743 2022-12-30 2022-12-30 0000025743 txmd:RubricCapitalManagementLPMember 2023-06-29 0000025743 txmd:RubricCapitalManagementLPMember 2023-06-29 0000025743 txmd:RubricCapitalManagementLPMember 2023-11-15 0000025743 txmd:TherameXMember 2024-07-01 2024-09-30 0000025743 txmd:TherameXMember 2024-01-01 2024-09-30 0000025743 txmd:MaynePharmaMember 2024-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure EX-31.1 2 ea021872801ex31-1_therap.htm CERTIFICATION Exhibit 31.1 Â Certification of Chief Executive Officer Â I, Marlan D. Walker, certify that: Â (1)I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; Â (2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â (3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â (4)The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â (5)The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 12, 2024 Â /s/ Marlan D Walker Â Marlan D. Walker Â Chief Executive Officer Â EX-31.2 3 ea021872801ex31-2_therap.htm CERTIFICATION Exhibit 31.2 Â Certification of Principal Financial Officer Â I, Joseph Ziegler, certify that: Â (1)I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; Â (2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â (3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â (4)The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â (5)The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 12,

Disclosure - Licensed Rights and Other Intangible Assets link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Stockholdersâ€™ Equity link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Income (Loss) Per Common Share link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Related Parties link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Business Concentrations link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Prepaid and Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Licensed Rights and Other Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Stockholdersâ€™ Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Income (Loss) Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Discontinued Operations (Details) - Schedule of Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Discontinued Operations (Details) - Schedule of Classes of Assets and Liabilities of Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Licensed Rights and Other Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject to Amortization link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Stockholdersâ€™ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Warrants link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of the Status of Our PSUs and Related Transactions link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Revenue (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted (Loss) Per Common Share link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Business Concentrations (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 txmd-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 txmd-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 txmd-20240930_lab.xml XBRL LABEL FILE Total current assets Total current liabilities Total liabilities Total stockholders' equity Balance Total liabilities and stockholders' equity Product and Service [Axis] Total operating expenses Loss from operations Total other income, net Loss from continuing operations before income taxes Loss from continuing operations, net of income taxes Net loss from continuing operations Loss from continuing operations, net of income taxes (in Dollars) Net loss Net loss (in Dollars) Balance (in Shares) Balance (in Shares) Common stock, shares outstanding Equity Components [Axis] Total adjustments Net cash provided by (used in) continuing operating activities Net cash provided by continuing financing activities Net cash used in discontinued operations Net increase (decrease) in cash Cash and cash equivalents - continuing operations, beginning of period Total cash and cash equivalents, end of period Cash and cash equivalents Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract] Discontinued Operations [Abstract] Total operating expenses Total other income (expense), net Loss from discontinued operations, net of income taxes Loss from discontinued operations, net of income taxes Less: Loss from discontinued operations, net of income taxes Loss from discontinued operations, net of income taxes (in Dollars) Disposal Group Classification [Axis] Prepaid and Other Current Assets [Abstract] Prepaid and other current assets Prepaid and other current assets Licensed Rights and Other Intangible Assets [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Intangible Assets Subject to Amortization [Abstract] Total Accrued Expenses and Other Current Liabilities [Abstract] Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract] Accrued expenses and other current liabilities Commitments and Contingencies [Abstract] Stockholdersâ€™ Equity [Abstract] Class of Warrant or Right [Axis] Beginning Balance Ending Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Ending Balance Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Schedule of Stock Options Activity [Abstract] Options Awards Outstanding, Ending Balance Weighted Average Exercise Price Outstanding, Ending Balance Aggregate Intrinsic Value Outstanding, Ending Balance Options Awards Exercisable, Ending Balance Weighted Average Exercise Price Exercisable, Ending Balance Aggregate Intrinsic Value Exercisable, Ending Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Ending Balance Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Beginning Balance Ending Balance Revenue [Abstract] Income Taxes [Abstract] Income (Loss) Per Common Share [Abstract] Loss per common share, basic and diluted: Schedule of Computation of Basic and Diluted (Loss) Per Common Share [Abstract] Antidilutive Securities [Axis] Related Parties [Abstract] Business Concentrations [Abstract] Assets: Current assets: Royalty receivable, current portion Current assets of discontinued operations License rights and other intangible assets, net Net Right of use assets Royalty receivable, long term Other non-current assets Liabilities and stockholders' equity: Current liabilities: Accounts payable Accrued expenses and other current liabilities Current liabilities of discontinued operations Operating lease liabilities Other non-current liabilities Commitments and contingencies (Note 6) Stockholders' equity: Common stock, par value \$0.001; 32,000 shares authorized, 11,532 issued and outstanding as of September 30, 2024 and December 31, 2023 Common stock, par value (in Dollars per share) Common stock price per share (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock issued (in Shares) Common stock shares Additional paid-in capital Accumulated deficit Revenue, net: License and service revenue Operating expenses: Selling, general and administrative Impairment of long-lived assets (Note 4) Impairment loss Depreciation & amortization Depreciation and amortization Other income (expense): Continuing operations, basic (in Dollars per share) Basic Continuing operations, diluted (in Dollars per share) Diluted Discontinued operations, net basic (in Dollars per share) Basic Discontinued operations, net diluted (in Dollars per share) Diluted Net loss per common share, basic (in Dollars per share) Net loss per common share, diluted (in Dollars per share) Weighted average common shares, basic (in Shares) Weighted average common shares for basic loss per common share (in Shares) Weighted average common shares, diluted (in Shares) Weighted average common shares for diluted loss per common share (in Shares) Share-based compensation Shares issued for vested restricted stock units Shares issued for vested restricted stock units (in Shares) Shares issued for sale of common stock related to private placement sale Shares issued for sale of common stock related to private placement sale (in Shares) Shares issued for exercise of warrants Shares issued for exercise of warrants (in Shares) Cash flows from operating activities: Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities: Write-off of patents and trademarks Share-based compensation Other Changes in operating assets and liabilities: Accounts payable Accrued expenses and other current liabilities Lease liabilities Other non-current liabilities Cash flows from financing activities: Proceeds from sale of common stock, net of costs Discontinued operations: Net cash used in operating activities Interest expense and other financing costs Miscellaneous income Provision for income taxes Provisions for income taxes Other assets Prepaid and other current assets License and service revenue Common Stock Additional Paid in Capital Accumulated Deficit Business, basis of presentation, new accounting standards and summary of significant accounting policies Discontinued Operations Schedule of Discontinued Operations Product revenue, net General and administrative expenses Operating loss from discontinued operations Other income (expense), net Schedule of Classes of Assets and Liabilities of Discontinued Operations Accounts receivable Liabilities: Accrued expenses and other current liabilities Prepaid and other current assets Schedule of Prepaid and Other Current Assets Insurance Capitalized legal Other Licensed rights and other intangible assets Schedule of License Rights and Other Intangible Assets, Net Intangible assets subject to amortization: Gross Carrying Amount Accumulated Amortization Intangible assets not subject to amortization: Schedule of Intangible Assets Subject to Amortization 2024 2025 2026 2027 2028 Thereafter Accrued expenses and other current liabilities Schedule of Other Accrued Expenses and Other Current Liabilities Payroll and related costs Professional fees Operating lease liabilities Other accrued expenses and current liabilities Commitments and contingencies Stockholdersâ€™ equity Schedule of Status of Our Outstanding and Exercisable Warrants Weighted Average Remaining Contractual Life, Beginning Balance Expired, Warrants Expired, Weighted Average Exercise Price Expired, Aggregate Intrinsic Value Expired, Weighted Average Remaining Contractual Life Weighted Average Remaining Contractual Life, Ending Balance Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions Weighted Average Remaining Contractual Life (in Years) Outstanding, Ending Balance Weighted Average Remaining Contractual Life (in Years) Exercisable, Ending Balance Weighted Average Exercise Price Outstanding, Expired Aggregate Intrinsic Value Outstanding, Expired Options Awards Exercisable, Expired Weighted Average Exercise Price Exercisable, Expired Aggregate Intrinsic Value Exercisable, Expired Schedule of the Status of Our RSUs, and Related Transactions Weighted Average Grant Date Fair Value Vested Weighted Average Grant Date Fair Value, Vested Aggregate Intrinsic Value Vested Aggregate Intrinsic Value Schedule of the Status of Our PSUs and Related Transactions Revenue Income taxes Income (Loss) per common share Schedule of Computation of Basic and Diluted (Loss) Per Common Share Numerator: Denominator: Effect of dilutive securities (in Shares) Loss per common share, continuing operations, net of income taxes Loss per common share, discontinued operations, net of income taxes Schedule of Outstanding Securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Related parties Business concentrations Options Awards Outstanding, Expired RSUs, Vested Stock Unit, Vested Discontinued Operations [Member] Hormone therapy drug patents [Member] Hormone therapy drug patents applied and pending approval [Member] Intangible assets subject to amortization [Member] Trademarks/trade name rights [Member] Warrant [Member] Warrants [Member] Restricted Stock Units (RSUs) [Member] RSUs [Member] Performance Shares [Member] Stock options [Member] PSUs [Member] Phantom Share Units (PSUs) [Member] Contingent Consideration by Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related and Nonrelated Parties [Axis] Statistical Measurement [Axis] Legal Proceeding [Axis] Title and Position [Axis] Plan Name [Axis] Counterparty Name [Axis] Class of Stock [Axis] Accounting Policies [Abstract] Milestone payments Net sales amount to determine one-time milestone payment Net sales Royalty rate as percentage on net sales Threshold annual net sales to determine royalty rate Royalties on net sales Period of royalty payments Period of royalty term Decrease in royalty rate on product-by-product basis Decrease in royalty rate Minimal annual royalty payment Period of minimal annual royalty payment Inflation rate adjusted for minimal annual royalty payment Inflation at an annual rate Cash payment Acquisition of net working capital Cash received for prepaid royalties Prepaid Royalties Royalty payment Quarterly royalty payment, interest per annum Royalty payment payable under long term service agreement Royalty payment held Additional fund Sold shares of common stock (in Shares) Price per share (in Dollars per share) Preferred stock at a purchase price Gross proceeds Amortization expense Cash Received For Net Working Capital Incremental accrual for net working capital Working capital amounts Allowance for net working capital allowances remaining Legal costs Executive termination obligations Number of shares

outstanding (in Shares) Remaining shares of common stock available for future issuance (in Shares) Vesting percentage Share based payment compensation expense Total unrecognized share based compensation Unrecognized compensation cost Share-based compensation over a weighted average period Outstanding shares Subscription agreements payment Additional shares of common stock Price per shares Gross proceeds from drawdown before expenses Customer license revenue percentage Royalty receivable short term portion Royalty receivable long term portion General Going concern Basis of presentation New accounting standards Estimates and assumptions Significant accounting policies Milestone Payments One [Member] One-time Milestone Payments [Member] Mayne License Agreement [Member] Milestone Payments Two [Member] Second-time Milestone Payments [Member] Milestone Payments Three [Member] Third-time Milestone Payments [Member] First Royalty Rate [Member] Mayne Pharma [Member] Second Royalty Rate [Member] Rubric Capital Management L P [Member] Rubric [Member] Patents [Member] Mayne Pharma Agreement [Member] Maximum [Member] Minimum [Member] Paragraph IV Certification Notice Letter [Member] Chief Executive Officer [Member] 2019 Stock Incentive Plan [Member] Employee Stock Purchase Plan [Member] Series A Preferred Stock [Member] Subscription Agreement [Member] Theramex [Member] Product and Service [Domain] Statement [Table] Statement [Line Items] Equity Component [Domain] Disposal Group Classification [Domain] Disposal Groups, Including Discontinued Operations [Table] Schedule of Discontinued Operations [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Table] Schedule of License Rights and Other Intangible Assets, Net [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Table] Schedule of Status of Our Outstanding and Exercisable Warrants [Line Items] Award Type [Domain] Stockholdersâ€™ Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stockholdersâ€™ Equity (Details) - Schedule of the Status of Our PSUs and Related Transactions [Table] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Outstanding Securities [Line Items] Contingent Consideration Type [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Related and Nonrelated Parties [Domain] Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) [Table] Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items] Licensed Rights and Other Intangible Assets (Details) [Table] Licensed Rights and Other Intangible Assets [Line Items] Title and Position [Domain] LegalProceedingDomain [Domain] Statistical Measurement [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Plan Name [Domain] Stockholdersâ€™ Equity (Details) [Table] Stockholdersâ€™ Equity [Line Items] Revenue (Details) [Table] Revenue [Line Items] Class of Stock [Domain] Counterparty Name [Domain] Related Parties (Details) [Table] Related Parties [Line Items] Business Concentrations (Details) [Table] Business Concentrations [Line Items] Amount of additional fund paid. Cash received for net working capital. Customer license revenue percentage. Decrease in royalty rate on product-by-product basis. Disposal group including discontinued operation general and administrative income (expense). Disposal group including discontinued operation other income (expense). Disposal group including discontinued operation total other income expense net. General information Going concern. Gross proceeds from drawdown before expenses. Incremental accrual for net working capital. Inflation rate adjusted for minimal annual royalty payment. Minimum annual royalty payment. Miscellaneous income (expense). One-time milestone payments. Payments to acquire net working capital. Period of minimum annual royalty payment. Purchase of transferred assets and grant of licenses cash payment. Quarterly royalty interest. The amount of royalty payment held back. Royalty payment payable under long term service agreement. Royalty rate as percentage on net sales. Royalty receivable, current portion. Royalty receivable, long term. Royalty receivable, long term portion. Royalty receivable short term portion. Tabular disclosure of classes of assets and liabilities of discontinued operations. Tabular disclosure of PSU and related transactions. Expired aggregate intrinsic value. Expired weighted average remaining contractual life. Expired warrants. Expired Weighted average exercise price. Aggregate intrinsic value. Weighted average exercise price. Weighted average remaining contractual life. Weighted average remaining contractual life, Ending balance. Share-Based Compensation Arrangement by Share-Based Payment Award, Option Equity Instruments, Exercised The weighted average exercise price exercisable option expired. The amount of aggregate intrinsic value outstanding expired. The amount of aggregate intrinsic value expired. Term of royalty payments. Threshold annual net sales to determine royalty rate. Threshold net sales amount to determine one-time milestone payment. Working capital amounts. Representation the amount of write-off of patents and trademarks. Legal Proceedings Hormone Therapy Drug Patents Member. Mayne License Agreement. Mayne Pharma Agreement. Mayne Pharma. Milestone payments one. Milestone payments three. Milestone payments two. Royalty rate one. Royalty rate two. Rubric capital management LP. Subscription agreement. Theramex. Two Thousand Nineteen Stock Incentive Plan. Schedule Of The Status Of Our Psus And Related Transactions Abstract Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Remaining Contractual Term Schedule Of The Status Of Our Rsus And Related Transactions Abstract Royalty Rate One Member Use of Estimates, Policy [Policy Text Block] Assets [Abstract] Commitments and Contingencies Series A Preferred Stock [Member] Schedule Of Classes Of Assets And Liabilities Of Discontinued Operations Abstract Nonoperating Income (Expense) [Abstract] Common Stock, Value, Issued Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current Earnings Per Share, Diluted Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Customer License Revenue Percentage Retained Earnings [Member] Other Commitment, to be Paid, Remainder of Fiscal Year Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition License and Service [Member] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Proceeds from Royalties Received Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule Of Outstanding Securities Abstract Weighted Average Number of Shares Outstanding, Basic [Abstract] Weighted Average Number of Shares Outstanding, Basic Accrued Professional Fees, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Finite-Lived Intangible Assets, Net Legal Proceeding Axis Increase (Decrease) in Prepaid Expense and Other Assets Shareholders' Equity and Share-Based Payments [Text Block] Increase (Decrease) in Other Noncurrent Liabilities Writeoff Of Patents And Trademarks Statement of Stockholders' Equity [Abstract] Finite-Lived Intangible Asset, Expected Amortization, after Year Five Royalty Rate Two Member Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash Provided by (Used in) Operating Activities, Discontinued Operations Income Tax Expense (Benefit) Concentration Risk Disclosure [Text Block] Amortization of Intangible Assets Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Income Statement [Abstract] Finite-Lived Intangible Asset, Expected Amortization, Year Two New Accounting Pronouncements, Policy [Policy Text Block] Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expried Phantom Share Units (PSUs) [Member] Minimum Annual Royalty Payment Other Assets, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Theramex Member Royalty Payment Payable Under Long Term Service Agreement Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Additional Paid in Capital Operating Expenses [Abstract] Prepaid Royalties Earnings Per Share, Basic Rubric Capital Management LPMember Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Accounts Payable and Other Accrued Liabilities, Current Net Cash Provided by (Used in) Operating Activities [Abstract] Revenues [Abstract] Assets Liabilities Miscellaneous Incomeexpense Royalty Expense Equity, Attributable to Parent [Abstract] Schedule Of The Status Of Our PSUs And Related Transactions Table Text Block Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Two Thousand Nineteen Stock Incentive Plan Member Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Net Cash Provided by (Used in) Discontinued Operations [Abstract] Purchase Of Transferred Assets And Grant Of Licenses Cash Payment Prepaid Insurance Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Expired Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Milestone Payments Three Member Common Stock, Shares, Outstanding One Time Milestone Payments Royalty Receivable Long Term Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retained Earnings (Accumulated Deficit) Going Concern Policy Text Block Employee Stock Purchase Plan Member Threshold Net Sales Amount To Determine One Time Milestone Payment Working Capital Amounts Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Threshold Annual Net Sales To Determine Royalty Rate Mayne Pharma Agreement Member Prepaid Expense and Other Assets, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Intangible Assets, Gross (Excluding Goodwill) Maximum [Member] Disposal Group, Including Discontinued Operation, Assets, Current Schedule Of License Rights And Other Intangible Assets Net Abstract Common Stock, Shares Authorized Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Employee-related Liabilities, Current Operating Lease, Liability, Noncurrent Other Accrued Liabilities, Current Schedule Of Discontinued Operations Abstract Warrant [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Schedule of Accrued Liabilities [Table Text Block] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Stock Redeemed or Called During Period, Value Disposal Group Including Discontinued Operation Other Income Expense Royalty Receivable Long Term Portion Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Hormone Therapy Drug Patents Applied And Pending Approval Member Operating Income (Loss) Milestone Payments Two Member Performance Shares [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Disposal Group, Including Discontinued Operation, Revenue Income (Loss) from Continuing Operations, Per Basic Share Finite-Lived Intangible Asset, Expected Amortization, Year One Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Stock Issued During Period, Shares, Restricted Stock Award, Gross Intangible Assets Disclosure [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Other Operating Activities, Cash Flow Statement Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Term Of Royalty Payments Depreciation, Depletion and Amortization, Nonproduction Schedule Of Status Of Our Outstanding And Exercisable Warrants Abstract Increase (Decrease) in Other Operating Assets Significant Accounting Policies [Text Block] Sale of Stock, Price Per Share Common Stock [Member] Cash Received For Net Working Capital Incremental Accrual For Net Working Capital Net Cash Provided by (Used in) Operating Activities, Continuing Operations Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expried Weighted Average Exercise Price Statement of Cash Flows [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value Royalty Receivable Current Portion Subscription Agreement Member Other Prepaid Expense, Current Operating Lease, Liability, Current Income Tax Disclosure [Text Block] Proceeds from Related Party Debt Common Stock, Capital Shares Reserved for Future Issuance Income (Loss) from Continuing Operations, Per Diluted Share Financing Interest Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Other Liabilities, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Chief Executive Officer [Member] Related Party Transactions Disclosure [Text Block] Selling, General and Administrative Expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Liabilities, Current [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Intangible Assets Subject To Amortization Abstract Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Intrinsic Value

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term1 Royalty Receivable Short Term Portion Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Severance Costs Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Patents [Member] Legal Fees Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock Issued During Period, Shares, Other Excess Stock, Shares Outstanding Paragraph Four Certification Notice Letter Member Quarterly Royalty Interest Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Equity, Attributable to Parent Revenue from Contract with Customer [Text Block] Earnings Per Share [Text Block] Payments To Acquire Net Working Capital Revenues Stock Issued During Period, Value, Stock Options Exercised Royalty Rate As Percentage On Net Sales Accounts Payable and Accrued Liabilities, Current Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Restricted Stock Units (RSUs) [Member] Period Of Minimum Annual Royalty Payment Hormone Therapy Drug Patents Member Mayne License Agreement Member Royalty Payment Held Back Disposal Group Including Discontinued Operation Total Other Income Expense Net Milestone Payments One Member Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Net Cash Provided by (Used in) Discontinued Operations Common Stock, Par or Stated Value Per Share Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value Expired Common Stock, Shares, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Weighted Average Number of Shares Outstanding, Diluted Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Stock Redeemed or Called During Period, Shares General Information Policy Text Block Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Intangible Assets, Net (Excluding Goodwill) Inflation Rate Adjusted For Minimal Annual Royalty Payment Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Mayne Pharma Member Finite-Lived Intangible Assets, Accumulated Amortization Disposal Group, Including Discontinued Operation, Liabilities, Current Disposal Group, Including Discontinued Operation, Operating Income (Loss) Schedule Of Classes Of Assets And Liabilities Of Discontinued Operations Table Text Block Share-Based Payment Arrangement, Option, Activity [Table Text Block] Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock Issued During Period, Value, Restricted Stock Award, Gross Sale of Stock, Number of Shares Issued in Transaction Gross Proceeds From Drawdown Before Expenses Assets, Current [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Expired Intrinsic Value Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Liabilities, Current Finite-Lived Intangible Asset, Expected Amortization, Year Four Discontinued Operations [Member] Operating Expenses Increase (Decrease) in Accounts Payable Trademarks and Trade Names [Member] Statement of Financial Position [Abstract] Decrease In Royalty Rate On Product By Product Basis Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Expired Disposal Group Including Discontinued Operation General And Administrative Income Expense Other Current Assets [Text Block] Shares Issued, Price Per Share Liabilities and Equity [Abstract] Finite-Lived Intangible Asset, Expected Amortization, Year Three Commitments and Contingencies Disclosure [Text Block] Disposal Group, Including Discontinued Operation, Operating Expense Intangible Assets Not Subject To Amortization Abstract Proceeds from Issuance of Common Stock Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Additional Fund Impairment, Long-Lived Asset, Held-for-Use Weighted Average Number of Shares Outstanding, Diluted, Adjustment Intangible Assets Subject To Amortization Member Liabilities and Equity Liabilities [Abstract] Nonoperating Income (Expense) Share-Based Payment Arrangement, Noncash Expense Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stock Issued During Period, Value, Other Operating Lease, Right-of-Use Asset Assets, Current EX-101.PRE 10 txmd-20240930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover-shares 9 Months Ended Sep. 30, 2024 Nov. 11, 2024 Document Information [Line Items] Å Document Type 10-Q Å Document Quarterly Report true Å Document Transition Report false Å Entity Interactive Data Current Yes Å Amendment Flag false Å Document Period End Date Sep. 30, 2024 Å Document Fiscal Year Focus 2024 Å Document Fiscal Period Focus Q3 Å Entity Information [Line Items] Å Entity Registrant Name TherapeuticsMD, Inc. Å Entity Central Index Key 0000025743 Å Entity File Number 001-00100 Å Entity Tax Identification Number 87-0233535 Å Entity Incorporation, State or Country Code NV Å Current Fiscal Year End Date --12-31 Å Entity Current Reporting Status Yes Å Entity Shell Company false Å Entity Filer Category Non-accelerated Filer Å Entity Small Business true Å Entity Emerging Growth Company false Å Entity Contact Personnel [Line Items] Å Entity Address, Address Line One 951 Yamato Road Å Entity Address, Address Line Two Suite 220 Å Entity Address, City or Town Boca Raton Å Entity Address, State or Province FL Å Entity Address, Postal Zip Code 33431 Å Entity Phone Fax Numbers [Line Items] Å City Area Code 561 Å Local Phone Number 961-1900 Å Entity Listings [Line Items] Å Title of 12(b) Security Common Stock, par value \$0.001 per share Å Trading Symbol TXMD Å Security Exchange Name NASDAQ Å Entity Common Stock, Shares Outstanding Å 11,532,432 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a> + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo

definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: A Cash and cash equivalents \$ 5,047 \$ 4,327 Royalty receivable, current portion 3,323 3,090 Prepaid and other current assets 3,784 4,035 Current assets of discontinued operations 344 Total current assets 12,154 11,796 License rights and other intangible assets, net 4,428 6,098 Right of use assets 6,302 6,873 Royalty receivable, long term 16,610 18,484 Other non-current assets 58 58 Total assets 39,552 43,309 Current liabilities: A Accounts payable 234 27 Accrued expenses and other current liabilities 2,818 3,133 Current liabilities of discontinued operations 2,924 3,694 Total current liabilities 5,976 6,854 Operating lease liabilities 5,777 6,532 Other non-current liabilities 705 636 Total liabilities 12,458 14,022 Commitments and contingencies (Note 6) Stockholders' equity: A Common stock, par value \$0.001; 32,000 shares authorized, 11,532 issued and outstanding as of September 30, 2024 and December 31, 2023 11 11 Additional paid-in capital 979,157 978,917 Accumulated deficit (952,074) (949,641) Total stockholders' equity 27,094 29,287 Total liabilities and stockholders' equity \$ 39,552 \$ 43,309 X - DefinitionRoyalty receivable, current portion. + ReferencesNo definition available. + Details Name: txmd_RoyaltyReceivableCurrentPortion Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty receivable, long term. + ReferencesNo definition available. + Details Name: txmd_RoyaltyReceivableLongTerm Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 12: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12> Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-)

7Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \\(a\\)\\(2\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C\)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 5: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \\(e\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B\)Reference 6: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \\(e\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3\)Reference 7: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8\)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.9-03\\(17\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into \(1\) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and \(2\) is exposed to potential losses or, less frequently, gains, arising from \(a\) possible claims against a company's resources due to future performance under contract terms, and \(b\) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1\)Reference 2: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(25\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 3: \[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.7-03\\(a\\)\\(19\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1\)Reference 4: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(29\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock \(or common stock redeemable solely at the option of the issuer\). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: \[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(a\\)\\(1\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2\)Reference 2: \[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2\]\(http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2\)Reference 3: \[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(22\\)\\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 2: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(20\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 3: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(24\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 4: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(19\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 5: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(25\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 6: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(26\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)Reference 7: \[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(27\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\)](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10)

02(23)) -Publisher FASB -URI

gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1+Details) Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1+Details) Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(17\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details) Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details) Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details) Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(3))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(23)(a)(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1+Details) Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2+Details) Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parentheticals) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Å Å Common stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 Common stock, shares authorized 32,000,000 32,000,000 Common stock, shares issued 11,532,000 11,532,000 Common stock, shares outstanding 11,532,000 11,532,000 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details) Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-05\(4\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-05(4)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1+Details) Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares representing capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details) Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3+Details) Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD (\$) shares in Thousands, \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses: Å Å Å Å Selling, general and administrative \$ 1,310 \$ 1,590 \$ 3,865 \$ 7,427 Impairment of long-lived assets (Note 4) 1,261 Depreciation & amortization 96 130 409 285 Total operating expenses 1,406 1,720 5,535 7,712 Loss from operations (859) (1,773) (4,441) (6,912) Other income (expense): Å Å Å Å Interest expense and other financing costs (3) (20) (8) (115) Miscellaneous income 295 359 2,023 869 Total other income, net 292 339 2,015 754 Loss from continuing operations before income taxes (567) (1,434) (2,426) (6,158) Provision for income taxes Loss from continuing operations, net of income taxes (567) (1,434) (2,426) (6,158) Loss from discontinued operations, net of income taxes (42) (1,944) (7) (3,237) Net loss \$ (609) \$ (3,378) \$ (2,433) \$ (9,395) Loss per common share, basic and diluted: Å Å Å Å Continuing operations, basic (in Dollars per share) \$ (0.05) \$ (0.13) \$ (0.21) \$ (0.6) Continuing operations, diluted (in Dollars per share) (0.05) (0.13) (0.21) (0.6) Discontinued operations, net basic (in Dollars per share) (0.18) (0.32) Discontinued operations, net diluted (in Dollars per share) (0.18) (0.32) Net loss per common share, basic (in Dollars per share) (0.05) (0.32) (0.21) (0.92) Net loss per common share, diluted (in Dollars per share) \$ (0.05) \$ (0.32) \$ (0.21) \$ (0.92) Weighted average common shares, basic (in Shares) 11,532 10,701 11,532 10,241 Weighted average common shares, diluted (in Shares) 11,532 10,701 11,532 10,241 License and service revenue Å Å Å Å Revenue, net: Å Å Å Å License and service revenue \$ 547 \$ (53) \$ 1,094 \$ 800 X - DefinitionMiscellaneous income (expense). +

ReferencesNo definition available. + Details Name: txmd_MiscellaneousIncomeexpense Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThis element represents interest incurred for borrowed money which was used to produce goods or render services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_FinancingInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100](http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)

60BReference 10: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-18> + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 9: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477314/942-235-S99-1>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7>Reference 17: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477349/740-270-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-1>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-3> + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration

- DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income \(loss\) from the day-to-day business activities of the discontinued operation and gain \(loss\) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SAB Topic 5.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5 + Details Name: us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionAmount of current income tax expense \(benefit\) and deferred income tax expense \(benefit\) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6:)

Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37>: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22))) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7))) -Publisher FASB -URI

(3,378) Balance at Sep. 30, 2023 \$ 1,976,799 (948,758) 28,052 Balance (in Shares) at Sep. 30, 2023 10,575,000 \$ \$ Balance at Dec. 31, 2023 \$ 11,978,917 (949,641) \$ 29,287 Balance (in Shares) at Dec. 31, 2023 11,532,000 \$ \$ 11,532,000 Share-based compensation 111 \$ 111 Net loss (734) (734) Balance at Mar. 31, 2024 \$ 11,979,028 (950,375) 28,664 Balance (in Shares) at Mar. 31, 2024 11,532,000 \$ \$ Balance at Dec. 31, 2023 \$ 11,978,917 (949,641) \$ 29,287 Balance (in Shares) at Dec. 31, 2023 11,532,000 \$ \$ 11,532,000 Net loss \$ (2,433) Balance at Sep. 30, 2024 \$ 11,979,157 (952,074) \$ 27,094 Balance (in Shares) at Sep. 30, 2024 11,532,000 \$ \$ 11,532,000 Balance at Mar. 31, 2024 \$ 11,979,028 (950,375) \$ 28,664 Balance (in Shares) at Mar. 31, 2024 11,532,000 \$ \$ Share-based compensation 96 96 Net loss (1,090) (1,090) Balance at Jun. 30, 2024 \$ 11,979,124 (951,465) 27,670 Balance (in Shares) at Jun. 30, 2024 11,532,000 \$ \$ Share-based compensation 33 33 Net loss (609) (609) Balance at Sep. 30, 2024 \$ 11,979,157 \$ (952,074) \$ 27,094 Balance (in Shares) at Sep. 30, 2024 11,532,000 \$ \$ 11,532,000 X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI

gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4>: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5>: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8>: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11>: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12>: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13>: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Δ Δ Net loss \$ (2,433) \$ (9,395) Less: Loss from discontinued operations, net of income taxes (7) (3,237) Net loss from continuing operations (2,426) (6,158) Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities: Δ Δ Depreciation and amortization 409 285 Impairment of long-lived assets (Note 4) 1,261 Write-off of patents and trademarks 59 Share-based compensation 240 1,155 Other 572 525 Changes in operating assets and liabilities: Δ Δ Other assets 1,874 1,185 Prepaid and other current assets 17 (1,241) Accounts payable 207 (1,466) Accrued expenses and other current liabilities (315) (11,918) Lease liabilities (755) (629) Other non-current liabilities 69 82 Total adjustments 3,579 (11,963) Net cash provided by (used in) continuing operating activities 1,153 (18,121) Cash flows from financing activities: Δ Δ Proceeds from sale of common stock, net of costs 1,149 Net cash provided by continuing financing activities 0 1,149 Discontinued operations: Δ Δ Net cash used in operating activities (433) (22,179) Net cash used in discontinued operations (433) (22,179) Net increase (decrease) in cash 720 (39,151) Cash and cash equivalents - continuing operations, beginning of period 4,327 49,317 Total cash and cash equivalents, end of period \$ 5,047 \$ 10,166 X - DefinitionRepresentation the amount of write-off of patents and trademarks. + ReferencesNo definition available. + Details Name: txmd_WriteoffOfPatentsAndTrademarks Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B> + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2>: <http://www.xbrl.org/2003/role/exampleRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:

[Subparagraph \(b\) - Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: [http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: [http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB](#) -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract] A Business, basis of presentation, new accounting standards and summary of significant accounting policies 1. Business, basis of presentation, new accounting standards and summary of significant accounting policies A General A TherapeuticsMD, Inc. (the "Company"), a Nevada corporation, and its condensed consolidated subsidiaries are referred to collectively in this Quarterly Report on Form 10-Q (the "Report") as TherapeuticsMD, a healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the "Closing Date"), we completed a transaction (the "Mayne Transaction") with Mayne Pharma LLC, a Delaware limited liability company ("Mayne Pharma") and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERAA® (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories, and (iii) sold certain other assets to Mayne Pharma in connection therewith. A In a License Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the "Mayne License Agreement"), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories. A Under the Mayne License Agreement, Mayne Pharma will pay us milestone payments of each of (i) \$5.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$100.0 million, (ii) \$10.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$200.0 million and (iii) \$15.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first \$80.0 million in annual net sales and 7.5% on annual net sales above \$80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimal annual royalties of \$3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products. A Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the "Transaction Agreement"), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize the Products in the United States, including, with the Population Council's consent, our exclusive license from the Population Council to commercialize ANNOVERA (the "Transferred Assets"). A The total consideration from Mayne Pharma to TherapeuticsMD for the purchase of the Transferred Assets and the grant of the licenses under the Mayne Transaction Agreement was (i) a cash payment of \$14

and began commercialization efforts in 2024. Â Â—In September 2019, we entered into an exclusive license and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (the “Theramex”) to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries. Â In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive officers were paid in full in January 2023 and severance obligations for terminated executive officers have been paid in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2023 and September 30, 2024, we employed one full-time employee primarily engaged in an executive position. Â We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would serve as our Principal Financial Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan’s resignation. Â Â Â Â Going concern Â Following the transaction with Mayne Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares. Â To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us. Â On May 1, 2023, we entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Rubric”), pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value \$0.001 per share (our “Common Stock”), from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a price per share equal to \$3.6797 pursuant to the Subscription Agreement. We received gross proceeds of \$1.15 million from the draw down, before expenses. On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to \$2.2761. We received gross proceeds of \$2.0 million from the drawdown, before expenses. Â In February 2024, the Company received Mayne Pharma’s calculation of allowance for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement which differed significantly from the Company’s estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. The Company continues to believe its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma’s allowance calculation for payer rebates and wholesale distributor fees. Â In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company’s estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns under the Transaction Agreement, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material. Â If Mayne Pharma’s sales of Licensed Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements. Â The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.Â Â Basis of presentation Â We prepared the condensed consolidated financial statements included in this 10-Q Report following the requirements of the United States (the “U.S.”) Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by accounting principles generally accepted in the U.S. (the “U.S. GAAP”) for complete financial statements can be condensed or omitted. However, except as disclosed herein, there has been no material change in the information disclosed in the notes included in our 2023 Annual Report on Form 10-K (the “2023 10-K Report”). Â As part of the transformation as a result of the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in the condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in the condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of the condensed consolidated financial statements. Â Revenues, expenses, assets, liabilities, and equities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. In our opinion, all adjustments necessary for a fair presentation of the financial statements, which are of a normal and recurring nature, have been made for the interim periods reported. The information included in this 10-Q Report should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 10-K Report. Certain amounts in the consolidated financial statements and accompanying notes may not add due to rounding, and all percentages have been calculated using unrounded amounts. Certain prior period amounts have been reclassified to conform to current-period presentation. Â New accounting standards Â Adoption of new accounting standards Â In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Update 2023-07, the “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” (the “Update 2023-07”). Update 2023-07 applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in Update 2023-07 revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in Update 2023-07 do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. Update 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Update 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting Update 2023-07. Â In December 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-09, the “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures” (the “ASU 2023-09”). ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company’s income tax disclosures and on its consolidated financial statements. Â Estimates and assumptions Â The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. We evaluate our estimates and assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions. Â Significant accounting policies Â The significant accounting policies we use for quarterly financial reporting are disclosed in Note 1 of the notes to the consolidated financial statements included in our 2023 10-K report. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent> Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent> + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations 9 Months Ended Sep. 30, 2024 Discontinued Operations [Abstract] Â Discontinued Operations 2. Discontinued Operations Â As discussed in Note 1, we changed our business in 2022 by licensing our products to receive royalties and future sales related milestone payments, after granting an exclusive license to commercialize our IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma. Â This plan represented a strategic shift having a major effect on our operations and financial results. Upon our conversion from a commercial pharmaceutical company to a licensing only company with the consummation of the Mayne Transaction, we classified all direct revenues, costs and expenses related to commercial operations, within income (loss) from discontinued operations, net of tax, in the condensed consolidated statements of operations for all periods presented. We have not allocated any amounts for shared general and administrative operating support expense to discontinued operations. Â Additionally, the related assets and liabilities have been reported as assets and liabilities of discontinued operations in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. Â As described in Note 1, the acquisition of net working capital by Mayne Pharma was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date. Our estimate of net working capital at closing was determined in accordance with the Transaction Agreement which establishes the process for the determination of final net working capital. Refer to Note 6 for a further discussion of net working capital contingencies. Â The following table presents results of discontinued operations (in thousands): Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Product revenue, netÂ \$ (833)Â \$ (833) General and administrative expensesÂ \$ (39)Â \$ (202)Â Â 296Â Total operating expensesÂ \$ (42)Â \$ (794)Â Â (202)Â Â (1,129) Other income (expense), netÂ \$ (1,150)Â \$ (2,108) Total other income (expense), netÂ \$ (1,150)Â \$ (2,108) Loss from discontinued operations, net of income taxesÂ \$ (42)Â \$ (1,944)Â \$ (7)Â \$ (3,237) Â The following table presents the carrying amounts of the classes of assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023 (in thousands): Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Assets:Â Â Â

A Accounts receivable \$-A \$344A Liabilities A Accrued expenses and other current liabilities \$2,924A \$3,694 X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid and Other Current Assets 9 Months Ended Sep. 30, 2024 Prepaid and Other Current Assets [Abstract] A Prepaid and other current assets 3. Prepaid and other current assets A Our prepaid and other current assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands): A September 30, 2024 A December 31, 2023 A Insurance \$161A \$253A Capitalized legal A 2,334A A 2,334A Other A 1,289A A 1,448A Prepaid and other current assets A \$3,784A A \$4,035A X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Licensed Rights and Other Intangible Assets 9 Months Ended Sep. 30, 2024 Licensed Rights and Other Intangible Assets [Abstract] A Licensed rights and other intangible assets 4. Licensed rights and other intangible assets A The following provides information about our license rights and other intangible assets, net as of September 30, 2024 and December 31, 2023 (in thousands): A September 30, 2024 A December 31, 2023 A Gross Carrying Amount A Accumulated Amortization A Net A Gross Carrying Amount A Accumulated Amortization A Net A Intangible assets subject to amortization: A A A A A A A A A A A A A A A A Hormone therapy drug patents \$5,753A A \$1,957A A \$3,796A A \$6,818A A \$1,871A A \$4,947A Hormone therapy drug patents applied and pending approval A 323A A A A A A A 842A A A A A A 842A Intangible assets subject to amortization A 6,076A A 1,957A A 4,119A A 7,660A A 1,871A A 5,789A Intangible assets not subject to amortization: A A A A A A A A A A A A A A A Trademarks/trade name rights A 309A A A A A A 309A A A 309A A A A 309A License rights and other intangible assets, net A \$6,385A A \$1,957A A \$4,428A A \$7,969A A \$1,871A A \$6,098A A We recorded, in continuing operations, amortization expense related to patents of \$96 thousand and \$110 thousand for the three months ended September 30, 2024 and 2023, respectively, and \$409 thousand and \$227 thousand for the nine months ended September 30, 2024 and 2023, respectively. A The Company conducts regular reviews of the individual patents and portfolios. As a result of this review, also based on input from its licensing partners in the three months ended June 30, 2024, the Company determined it had an indicator of impairment, as it had abandoned the legal right and title to a portion of its granted patent portfolio and had ceased pursuit of a portion of its pending patents based on input from its licensing partners. The Company recognized an impairment loss of \$1,261 thousand related to those abandoned patents and applications, which is classified as an impairment of long-lived assets on the Company's condensed consolidated statements of operations for the nine months ended September 30, 2024. A Our intangible assets subject to amortization are expected to be amortized as follows (in thousands): A Year ending December 31, A 2024 A \$97A 2025 A 384A 2026 A 384A 2027 A 384A 2028 A 384A Thereafter A 2,163A Total A \$3,796A X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities 9 Months Ended Sep. 30, 2024 Accrued Expenses and Other Current Liabilities [Abstract] A Accrued expenses and other current liabilities 5. Accrued expenses and other current liabilities A Other accrued expenses and other current liabilities consisted of the following (in thousands): A September 30, 2024 A December 31, 2023 A Payroll and related costs A \$455A A \$762A Professional fees A 296A A 489A Operating lease liabilities A 1,623A A 1,473A Other accrued expenses and current liabilities A 444A A 409A Accrued expenses and other current liabilities A \$2,818A A \$3,133A X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] A Commitments and contingencies 6. Commitments and contingencies A Mayne Pharma Agreement A Mayne Pharma paid us approximately \$12.1A million at closing on December 30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction Agreement. While the Transaction Agreement calls for much of the net working capital to be true-up shortly after the Closing Date in 2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years following the Closing Date in the case of allowance for returns, net working capital amounts will be adjusted to arrive at final net working capital under the Transaction Agreement. A In September 2023, we increased certain accrual estimates including increasing our working capital adjustment accrual by \$2.0A million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a \$5.5A million payment to Mayne Pharma to settle certain working capital amounts that were required to be true-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees. Of the \$5.5 million, \$2.0 million increased the allowance for net working capital allowances remaining to be true up. A The Company's estimate of the allowance for payer rebates and wholesale distributor fees was determined in accordance with the Transaction Agreement which establishes the process for the determination of net working capital. In February 2024, the Company received Mayne Pharma's calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company's estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. A The Company believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The timing and outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma's allowance calculation for payer rebates and wholesale distributor fees. A In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company's estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material. A Mayne Pharma has also made certain indemnification demands under the Transaction Agreement, which the Company disputes. As of September 30, 2024, the Company believes no additional accrual is required for such claims, as the Company cannot reasonably estimate a range of loss.A Legal proceedings A In February 2020, we received a Paragraph IV certification notice letter (the "IMVEXXY Notice Letter") regarding an Abbreviated New Drug Application ("ANDA") submitted to the FDA by Teva Pharmaceuticals USA, Inc. ("Teva"). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA's Orange Book that claim compositions and methods of IMVEXXY (the "IMVEXXY Patents") are invalid, unenforceable, and/or will not be infringed by Teva's commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva's ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva's ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021, the District Court made available a public version of the order following the parties' agreement to a consent motion to redact information Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. We have incurred and recorded legal costs amounting to \$2,334 thousand in prepaid expenses and other current assets as of September 30, 2024, for the IMVEXXY Paragraph IV legal proceeding since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding, the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying condensed consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in this legal proceeding, then the related capitalized legal costs for this legal proceeding and any unamortized IMVEXXY patent costs that were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding. A In June 2024, Mayne received a Paragraph IV certification notice letter (the "Sun Notice Letter") regarding an ANDA submitted to the FDA by Sun Pharma Inc. ("Sun Pharma"). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the Sun Notice Letter, Sun Pharma alleges that the IMVEXXY Patents are invalid, unenforceable, and/or will not be infringed by Sun Pharma's commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Sun Notice Letter expire in 2032 or 2033. In July 2024, we and Mayne Pharma filed a complaint for patent infringement against Sun Pharma in the United States District Court for the District of New Jersey arising from Sun Pharma's ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Sun Pharma's ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Sun Pharma from infringing the IMVEXXY Patents. A Beginning on December 30, 2022 and per the Mayne License Agreement, Mayne Pharma is responsible for all enforcement of our patents, including the responsibility for and costs of litigation discussed above with respect to Teva and Sun Pharma. A From time to time, we are involved in other litigations and proceedings in the ordinary course of business. We are currently not involved in any other litigations and proceedings that we believe would have a material effect on our condensed consolidated financial condition, results of operations, or cash flows. A Off-balance sheet arrangements A As of September 30, 2024 and

December 31, 2023 there were no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.Â Employment agreements Â In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 30, 2022. Severance obligations for all employees other than executive officers were paid in full in the first quarter of 2023. As of September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. In the aggregate, as of September 30, 2024, we have accrued severance liabilities for executive termination obligations of \$56 thousand. X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1:

[Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7:](#) <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 13:

SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Accounting Policies, by Policy (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A General TherapeuticsMD, Inc. (the “Company”), a Nevada corporation, and its condensed consolidated subsidiaries are referred to collectively in this Quarterly Report on Form 10-Q (the “10-Q Report”) as “TherapeuticsMD,” “we,” “our,” “us,” and “our company.” This 10-Q Report includes trademarks, trade names and service marks, such as TherapeuticsMD®, vitaMedMD®, BocaGreenMD®, IMVEXXYA®, and BIJUVA®, which are protected under applicable intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and service marks referred to in this 10-Q Report may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties. TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the “Closing Date”), we completed a transaction (the “Mayne Transaction”) with Mayne Pharma LLC, a Delaware limited liability company (the “Mayne Pharma”) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the “Licensed Products”) in the United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA® (together with the Licensed Products, collectively, the “Products”) in the United States and its possessions and territories, and (iii) sold certain other assets to Mayne Pharma in connection therewith. In a License Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Mayne License Agreement”), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions and territories. Under the Mayne License Agreement, Mayne Pharma will pay us milestone payments of each of (i) \$5.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$100.0 million, (ii) \$10.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$200.0 million and (iii) \$15.0 million if aggregate net sales of all Products in the United States during a calendar year reach \$300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first \$80.0 million in annual net sales and 7.5% on annual net sales above \$80.0 million, subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimal annual royalties of \$3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for the Licensed Products. A Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Transaction Agreement”), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize the Products in the United States, including, with the Population Council’s consent, our exclusive license from the Population Council to commercialize ANNOVERA (the “Transferred Assets”). The total consideration from Mayne Pharma to TherapeuticsMD for the purchase of the Transferred Assets and the grant of the licenses under the Mayne Transaction Agreement was (i) a cash payment of \$140.0 million at closing, (ii) a cash payment of approximately \$12.1 million at

closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments, (iii) a cash payment of approximately \$1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant estimates which could change materially for a period of up to two years following the Closing Date. On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment No. 1 to the Mayne License Agreement (the “Mayne License Agreement Amendment”). Pursuant to the Mayne License Agreement Amendment, Mayne Pharma agreed to pay us approximately \$1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to \$257 thousand per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty payment was paid to us. We and Mayne Pharma settled the \$1.5 million of consideration due to Mayne Pharma for the assumed obligations under a long-term services agreement, including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023 Mayne Pharma held back our royalty payment of \$0.6 million and we funded an additional \$0.9 million in August 2023 to settle the original \$1.5 million payable. As part of the transformation that included the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in our condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in our condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of our condensed consolidated financial statements. We also have license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S. — In July 2018, we entered into a license and supply agreement (the “Knight License Agreement”) with Knight Therapeutics Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Knight obtained regulatory approval for IMVEXXY and BIJUVA and began commercialization efforts in 2024. — In September 2019, we entered into an exclusive license and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries. In connection with our transformation into a pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive officers were paid in full in January 2023 and severance obligations for terminated executive officers have been paid in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2023 and September 30, 2024, we employed one full-time employee primarily engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would serve as our Principal Financial Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan’s resignation. — — — — — Going concern Going concern Following the transaction with Mayne Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us. On May 1, 2023, we entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (“Rubric”), pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value \$0.001 per share (our “Common Stock”), from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a price per share equal to \$3.6797 pursuant to the Subscription Agreement. We received gross proceeds of \$1.15 million from the draw down, before expenses. On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to \$2.2761. We received gross proceeds of \$2.0 million from the drawdown, before expenses. In February 2024, the Company received Mayne Pharma’s calculation of allowance for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement which differed significantly from the Company’s estimate of the allowances. The Company intends to resolve this matter through the dispute resolution process outlined in the Transaction Agreement. The Company continues to believe its estimated allowances for payer rebates and wholesale distributor fees are reasonable. The outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any additional liability associated with Mayne Pharma’s allowance calculation for payer rebates and wholesale distributor fees. In addition, the Company has received information from Mayne Pharma pertaining to the allowance for returns that differs from the Company’s estimate of the allowance. As of September 30, 2024, the Company believes no additional accrual is required for amounts that may be owed for the allowance for returns under the Transaction Agreement, as the Company cannot reasonably estimate a range of loss. The Company has not recorded any contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material. If Mayne Pharma’s sales of Licensed Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. — — — — — Basis of presentation Basis of presentation We prepared the condensed consolidated financial statements included in this 10-Q Report following the requirements of the United States (“U.S.”) Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by accounting principles generally accepted in the U.S. (“U.S. GAAP”) for complete financial statements can be condensed or omitted. However, except as disclosed herein, there has been no material change in the information disclosed in the notes included in our 2023 Annual Report on Form 10-K (the “2023 10-K Report”). As part of the transformation as a result of the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in the condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in the condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2 of the condensed consolidated financial statements. Revenues, expenses, assets, liabilities, and equities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. In our opinion, all adjustments necessary for a fair presentation of the financial statements, which are of a normal and recurring nature, have been made for the interim periods reported. The information included in this 10-Q Report should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 10-K Report. Certain amounts in the consolidated financial statements and accompanying notes may not add due to rounding, and all percentages have been calculated using unrounded amounts. Certain prior period amounts have been reclassified to conform to current-period presentation. New accounting standards New accounting standards Adoption of new accounting standards In November 2023, the Financial Accounting Standards Board (“FASB”) issued Update 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” (“Update 2023-07”). Update 2023-07 applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in Update 2023-07 revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in Update 2023-07 do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. Update 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Update 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting Update 2023-07. In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company’s income tax disclosures and on its consolidated financial statements. Estimates and assumptions Estimates and assumptions The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. We evaluate our estimates and assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions. Significant accounting policies Significant accounting policies The significant accounting policies we use for quarterly financial reporting are disclosed in Note 1 of the notes to the consolidated financial statements included in our 2023 10-K report. X - Definition General information + References No definition available. + Details Name: txmd_GeneralInformationPolicyTextBlock Namespace Prefix: txmd_Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - Definition Going concern. + References No definition available. + Details Name: txmd_GoingConcernPolicyTextBlock Namespace Prefix: txmd_Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity’s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + References No definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for all significant accounting policies of the reporting entity. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1->

[Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations \(Tables\) 9 Months Ended Sep. 30, 2024 Discontinued Operations \[Abstract\] A Schedule of Discontinued Operations The following table presents results of discontinued operations \(in thousands\): A A Three Months Ended September 30,A A Nine Months Ended September 30,A A 2024A A 2023A A 2024A A 2023A Product revenue, netA \\$â€”A A \\$\(833\)A \\$â€”A A \\$\(833\) General and administrative expensesA 42A A A \(39\)A A 202A A A 296A Total operating expensesA 42A A A \(39\)A A 202A A A 296A Operating loss from discontinued operationsA \(42\)A A A \(794\)A A \(202\)A A \(1,129\) Other income \(expense\), netA 4A A A A \(1,150\)A A 195A A A \(2,108\) Total other income \(expense\), netA 4A A A A \(1,150\)A A 195A A A \(2,108\) Loss from discontinued operations, net of income taxesA \\$\(42\)A A \(\\$1,944\)A \\$\(7\)A A \\$\(3,237\) Schedule of Classes of Assets and Liabilities of Discontinued Operations The following table presents the carrying amounts of the classes of assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023 \(in thousands\): A A SeptemberA 30, 2024A A DecemberA 31, 2023A Assets:A A A A Accounts receivableA \\$-A A \\$344A Liabilities:A A A A Accrued expenses and other current liabilitiesA \\$,924A A \\$3,694A X - DefinitionTabular disclosure of classes of assets and liabilities of discontinued operations. + ReferencesNo definition available. + Details Name: txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTextBlock Namespace Prefix: txmd_ Data Type: dtr-textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AResponse 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AResponse 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BResponse 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AResponse 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BResponse 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CResponse 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DResponse 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AResponse 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid and Other Current Assets \(Tables\) 9 Months Ended Sep. 30, 2024 Prepaid and Other Current Assets \[Abstract\] A Schedule of Prepaid and Other Current Assets Our prepaid and other current assets consisted of the following as of September 30, 2024 and December 31, 2023 \(in thousands\): A A SeptemberA 30, 2024A A DecemberA 31, 2023A InsuranceA \\$161A A \\$253A Capitalized legalA 2,334A A 2,334A OtherA 1,289A A 1,448A Prepaid and other current assetsA \\$3,784A A \\$4,035A X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Licensed Rights and Other Intangible Assets \(Tables\) 9 Months Ended Sep. 30, 2024 Licensed Rights and Other Intangible Assets \[Abstract\] A Schedule of License Rights and Other Intangible Assets, Net The following provides information about our license rights and other intangible assets, net as of September 30, 2024 and December 31, 2023 \(in thousands\): A A SeptemberA 30, 2024A A DecemberA 31, 2023A Gross Carrying AmountA Accumulated AmortizationA NetA Gross Carrying AmountA Accumulated AmortizationA NetA Intangible assets subject to amortization:A A A A A A A A A A A A A A A A Hormone therapy drug patentsA \\$5,753A A \\$3,796A A \\$6,818A A \\$1,871A A \\$4,947A Hormone therapy drug patents applied and pending approvalA 323A A A 323A A A 842A A A 842A Intangible assets subject to amortizationA 6,076A A 1,957A A 4,119A A 7,660A A 1,871A A 5,789A Intangible assets not subject to amortization:A A A A A A A A A A A A A A A A Trademarks/trade name rightsA 309A A A 309A A A 309A A A 309A A A 309A License rights and other intangible assets, netA \\$6,385A A \\$1,957A A \\$4,428A A \\$7,969A A \\$1,871A A \\$6,098A Schedule of Intangible Assets Subject to Amortization Our intangible assets subject to amortization are expected to be amortized as follows \(in thousands\): Year ending December 31, A A 2024A \\$97A 2025A 384A 2026A 384A 2027A 384A 2028A 384A ThereafterA 2,163A TotalA \\$3,796A X - DefinitionTabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration](#)

[illegible]

available. + Details Name: txmd_TermOfRoyaltyPayments Namespace Prefix: txmd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThreshold annual net sales to determine royalty rate. + ReferencesNo definition available. + Details Name: txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThreshold net sales amount to determine one-time milestone payment. + ReferencesNo definition available. + Details Name: txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

-SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 66: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 67: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 68: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 69: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 70: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 71: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 72: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 73: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 74: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 75: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 76: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 93: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 94: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 95: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 96: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 97: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 98: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3Reference 99: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1Reference 100: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap PrepaidRoyalties Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromRelatedPartyDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received for royalties during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap ProceedsFromRoyaltiesReceived Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap RoyaltyExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap SharesIssuedPricePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap TypeOfArrangementAxis=txmd MayneLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=txmd RubricCapitalManagementLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ContingentConsiderationByTypeAxis=txmd MilestonePaymentsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ContingentConsiderationByTypeAxis=txmd MilestonePaymentsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_MaynePharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations (Details) - Schedule of Discontinued Operations - Discontinued Operations [Member] - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Discontinued Operations [Line Items] Á Á Á Á Product revenue, net \$ (833) \$ (833) General and administrative expenses 42 (39) 202 296 Total operating expenses 42 (39) 202 296 Operating loss from discontinued operations (42) (794) (202) (1,129) Other income (expense), net (1,150) 195 (2,108) Total other income (expense), net (1,150) 195 (2,108) Loss from discontinued operations, net of income taxes \$ (42) \$ (1,944) \$ (7) \$ (3,237) X - DefinitionDisposal group including discontinued operation general and administrative income (expense). + ReferencesNo definition available. + Details Name: txmd_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeIncomeExpense Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal group including discontinued operation other income (expense). + ReferencesNo definition available. + Details Name: txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal group including discontinued operation total other income expense net. + ReferencesNo definition available. + Details Name: txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of operating expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B) + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B) + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B) + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1)Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3> + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations (Details) - Schedule of Classes of Assets and Liabilities of Discontinued Operations - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets: Á Á Accounts receivable \$ 344 Liabilities: Á Á Accrued expenses and other current liabilities \$ 2,924 \$ 3,694 X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid and Other Current Assets [Abstract] Á Á Insurance \$ 161 \$ 253 Capitalized legal 2,334 2,334 Other 1,289 1,448 Prepaid and other current assets \$ 3,784 \$ 4,035 X - DefinitionAmount of capitalized acquisition cost excluded from amortization for investment in unproved property and development project in oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 932 -SubTopic 360 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 932 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-10\(c\)\(7\)\(ii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 932 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-10(c)(7)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1) + Details Name: us-gaap_AcquisitionCostsCumulative Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1> + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1>Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5](http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5) + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Licensed Rights and Other Intangible Assets (Details) - Patents [Member] - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Licensed Rights and Other Intangible Assets [Line Items] Á Á Á Amortization expense \$ 96 \$ 110 \$ 409 \$ 227 Impairment loss Á Á \$ 1,261 Á X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used

in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100](http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of License Rights and Other Intangible Assets, Net [Line Items]

Â	Â	Gross Carrying Amount \$ 6,385						
\$ 7,969	Accumulated Amortization 1,957 1,871	Net 4,428 6,098						
Hormone therapy drug patents [Member]	Â	Â						
Schedule of License Rights and Other Intangible Assets, Net [Line Items]	Â	Â						
Gross Carrying Amount 5,753 6,818	Accumulated Amortization 1,957 1,871	Net 3,796 4,947						
Hormone therapy drug patents applied and pending approval [Member]	Â	Â						
Schedule of License Rights and Other Intangible Assets, Net [Line Items]	Â	Â						
Gross Carrying Amount 323 842	Accumulated Amortization Net 323 842	Intangible assets subject to amortization [Member]						
Â	Â	Â						
Schedule of License Rights and Other Intangible Assets, Net [Line Items]	Â	Â						
Gross Carrying Amount 6,076 7,660	Accumulated Amortization 1,957 1,871	Net 4,119 5,789						
Trademarks/trade name rights [Member]	Â	Â						
Schedule of License Rights and Other Intangible Assets, Net [Line Items]	Â	Â						
Gross Carrying Amount 309 309	Accumulated Amortization Net \$ 309 \$ 309	X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_IntangibleAssetsSubjectToAmortizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject to Amortization \$ in Thousands Sep. 30, 2024 USD (\$) Schedule of Intangible Assets Subject to Amortization [Abstract] <table border="1"><tr><td>Â</td><td>Â</td><td>2024 \$ 97 2025 384 2026 384 2027 384 2028 384</td></tr><tr><td>Thereafter 2,163</td><td>Total \$ 3,796</td><td>X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be</td></tr></table>	Â	Â	2024 \$ 97 2025 384 2026 384 2027 384 2028 384	Thereafter 2,163	Total \$ 3,796	X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be
Â	Â	2024 \$ 97 2025 384 2026 384 2027 384 2028 384						
Thereafter 2,163	Total \$ 3,796	X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be						

recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 926-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract] Å Payroll and related costs \$ 455 \$ 762 Professional fees 296 489 Operating lease liabilities 1,623 1,473 Other accrued expenses and current liabilities 444 409 Accrued expenses and other current liabilities \$ 2,818 \$ 3,133 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1:

13Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=txmd_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=txmd_TwoThousandNineteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Warrants - Warrant [Member] shares in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) \$ / shares shares Schedule of Status of Our Outstanding and Exercisable Warrants [Line Items] Å Beginning Balance | shares 99 Weighted Average Exercise Price, Beginning Balance | \$ / shares \$ 66.61 Aggregate Intrinsic Value, Beginning Balance | \$ Weighted Average Remaining Contractual Life, Beginning Balance 6 years 6 months Expired, Warrants | shares (2) Expired, Weighted Average Exercise Price | \$ / shares \$ 281.5 Expired, Aggregate Intrinsic Value | \$ Expired, Weighted Average Remaining Contractual Life Ending Balance | shares 97 Weighted Average Exercise Price, Ending Balance | \$ / shares \$ 63.33 Aggregate Intrinsic Value, Ending Balance | \$ Weighted Average Remaining Contractual Life, Ending Balance 5 years 9 months 18 days X - DefinitionExpired aggregate intrinsic value. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredIntrinsicValue Namespace Prefix: txmd_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExpired weighted average remaining contractual life. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageRemainingContractualTerm Namespace Prefix: txmd_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExpired warrants. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpried Namespace Prefix: txmd_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExpired Weighted average exercise price. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpriedWeightedAverageExercisePrice Namespace Prefix: txmd_Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate intrinsic value. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue Namespace Prefix: txmd_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average exercise price. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice Namespace Prefix: txmd_Data Type: dtr:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual life. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm Namespace Prefix: txmd_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual life, Ending balance. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: txmd_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions - USD (\$) shares in Thousands 9 Months Ended Jan. 01, 2024 Sep. 30, 2024 Schedule of Stock Options Activity [Abstract] Å Options Awards Outstanding, Ending Balance 72 62 Weighted Average Exercise Price Outstanding, Ending Balance \$ 258.55 \$ 264.66 Aggregate Intrinsic Value Outstanding, Ending Balance Weighted Average Remaining Contractual Life (in Years) Outstanding, Ending Balance 3 years 2 years 9 months 18 days Options Awards Exercisable, Ending Balance 72 62 Weighted Average Exercise Price Exercisable, Ending Balance \$ 258.46 \$ 264.54 Aggregate Intrinsic Value Exercisable, Ending Balance Weighted Average Remaining Contractual Life (in Years) Exercisable, Ending Balance 3 years 2 years 9 months 18 days Options Awards Outstanding, Expired Å (10) Weighted Average Exercise Price Outstanding, Expired Å \$ 224.58 Aggregate Intrinsic Value Outstanding, Expired Å Options Awards Exercisable, Expired Å (10) Weighted Average Exercise Price Exercisable, Expired Å Aggregate Intrinsic Value

Exercisable, Expired X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Option Equity Instruments, Exercised + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExpired Namespace Prefix: txmd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average exercise price exercisable option expired. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceExpired Namespace Prefix: txmd_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of aggregate intrinsic value outstanding expired. + ReferencesNo definition available. + Details Name: txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of aggregate intrinsic value expired. + ReferencesNo definition available. + Details Name: txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValueExpired Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions - Restricted Stock Units (RSUs) [Member] 9 Months Ended Sep. 30, 2024 USD (\$) \$ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A Beginning Balance | shares 40,000 Weighted Average Exercise Price, Beginning Balance | \$ / shares \$ 9.67 Aggregate Intrinsic Value, Beginning Balance | \$ \$ 89,600 RSUs, Vested | shares (38,000) Weighted Average Grant Date Fair Value Vested | \$ / shares \$ 9.11 Aggregate Intrinsic Value Vested | \$ Ending Balance | shares 2,000 Weighted Average Exercise Price, Ending Balance | \$ / shares \$ 21.78 Aggregate Intrinsic Value, Ending Balance | \$ \$ 2,880 X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) \(02\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) (02) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference

13:

Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIntrinsic value of vested award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Details) 9 Months Ended Sep. 30, 2024 USD (\$) Revenue [Line Items] Å Period of royalty term 20 years Mayne License Agreement [Member] Å Revenue [Line Items] Å Period of royalty term 20 years Decrease in royalty rate 2.00% Minimal annual royalty payment \$ 3,000,000 Period of minimal annual royalty payment 12 years Inflation at an annual rate 3.00% One-time Milestone Payments [Member] | Mayne License Agreement [Member] Å Revenue [Line Items] Å Milestone payments \$ 5,000,000 Net sales 100,000,000 Second-time Milestone Payments [Member] | Mayne License Agreement [Member] Å Revenue [Line Items] Å Milestone payments 10,000,000 Net sales 200,000,000 Third-time Milestone Payments [Member] | Mayne License Agreement [Member] Å Revenue [Line Items] Å Milestone payments 15,000,000 Net sales \$ 300,000,000 First Royalty Rate [Member] | Mayne License Agreement [Member] Å Revenue [Line Items] Å Royalty rate as percentage on net sales 8.00% Royalties on net sales \$ 80,000,000 Second Royalty Rate [Member] | Mayne License Agreement [Member] Å Revenue [Line Items] Å Net sales \$ 80,000,000 Royalty rate as percentage on net sales 7.50% X - DefinitionDecrease in royalty rate on product-by-product basis. + ReferencesNo definition available. + Details Name: txmd_DecreaseInRoyaltyRateOnProductByProductBasis Namespace Prefix: txmd_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionInflation rate adjusted for minimal annual royalty payment. + ReferencesNo definition available. + Details Name: txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment Namespace Prefix: txmd_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionMinimum annual royalty payment. + ReferencesNo definition available. + Details Name: txmd_MinimumAnnualRoyaltyPayment Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOne-time milestone payments. + ReferencesNo definition available. + Details Name: txmd_OneTimeMilestonePayments Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod of minimum annual royalty payment. + ReferencesNo definition available. + Details Name: txmd_PeriodOfMinimumAnnualRoyaltyPayment Namespace Prefix: txmd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRoyalty rate as percentage on net sales. + ReferencesNo definition available. + Details Name: txmd_RoyaltyRateAsPercentageOnNetSales Namespace Prefix: txmd_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionTerm of royalty payments. + ReferencesNo definition available. + Details Name: txmd_TermOfRoyaltyPayments Namespace Prefix: txmd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThreshold annual net sales to determine royalty rate. + ReferencesNo definition available. + Details Name: txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThreshold net sales amount to determine one-time milestone payment. + ReferencesNo definition available. + Details Name: txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment Namespace Prefix: txmd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EntityWideRevenueMajorCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Taxes [Abstract] Å Å Å Provisions for income taxes X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted (Loss) Per Common Share - USD (\$) \$ / shares in Units, shares in Thousands, \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Å Å Å Å Å Å Loss from continuing operations, net of income taxes (in Dollars) \$ (567) Å Å \$ (1,434) Å Å \$ (2,426) \$ (6,158) Loss from discontinued operations, net of income taxes (in Dollars) (42) Å Å (1,944) Å Å (7) (3,237) Net loss (in Dollars) \$ (609) \$ (1,090) \$ (734) \$ (3,378) \$ (2,414) \$ (3,603) \$ (2,433) \$ (9,395) Denominator: Å Å Å Å Å Å Weighted average common shares for basic loss per common share (in Shares) 11,532 Å Å 10,701 Å Å 11,532 10,241 Effect of dilutive securities (in Shares) Å Å Å Weighted average common shares for diluted loss per common share (in Shares) 11,532 Å Å 10,701 Å Å 11,532 10,241 Loss per common share, continuing operations, net of income taxes Å Å Å Å Å Basic \$ (0.05) Å Å \$ (0.13) Å Å \$ (0.21) \$ (0.6) Diluted (0.05) Å Å (0.13) Å Å (0.21) (0.6) Loss per common share, discontinued operations, net of income taxes Å Å Å Å Å Basic Å Å Å Å Å Basic Å Å (0.18) Å Å (0.32) Diluted Å Å (0.18) Å Å (0.32) X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45->

2Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-18> + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeLossFromContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeLossFromContinuingOperationsAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7>Reference 17: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/214748524/942-220-S99-1> + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 5:

<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479836/810-10-S99-5> + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities - shares shares in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Schedule of Outstanding Securities [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 166 275	Stock options [Member]	Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 62 80	RSUs [Member]	Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2 84	PSUs [Member]	Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5 12	Warrants [Member]
---	------------------------	---	---------------	--	---------------	--	-------------------

 Schedule of Outstanding Securities [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 62 80	RSUs [Member]	Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2 84	PSUs [Member]	Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5 12	Warrants [Member]
---	---------------	--	---------------	--	-------------------

 Schedule of Outstanding Securities [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2 84	PSUs [Member]	Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5 12	Warrants [Member]
--	---------------	--	-------------------

 Schedule of Outstanding Securities [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 97 99	X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
---	--

gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v.23.4.3 Related Parties (Details) - USD (\$) / shares in Units, \$ in Thousands Jun. 29, 2023 Dec. 30, 2022 Sep. 30, 2024 Dec. 31, 2023 Nov. 15, 2023 Related Parties [Line Items] Á Á Á Á Subscription agreements payment Á \$ 3,000 Á Á Á Common stock shares Á Á 11,532,000 11,532,000 Á Rubric [Member] Á Á Á Á Related Parties [Line Items] Á Á Á Á Preferred stock at a purchase price \$ 3.6797 Á Á Á Á Common stock shares 312,525 Á Á Á Gross proceeds \$ 1,150 Á Á Á Additional shares of common stock Á Á Á 877,192 Price per shares Á Á Á \$ 2.2761 Gross proceeds from drawdown before expenses Á Á Á \$ 2,000 Series A Preferred Stock [Member] | Rubric [Member] | Subscription Agreement [Member] Á Á Á Á Related Parties [Line Items] Á Á Á Á Outstanding shares 29,000 Á Á Á Preferred stock at a purchase price Á \$ 1,333 Á Á Á X-DefinitionGross proceeds from drawdown before expenses. + ReferencesNo definition available. + Details Name: txmd_GrossProceedsFromDrawdownBeforeExpenses Namespace Prefix: txmd_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of excess stock held by shareholders. + ReferencesNo definition available. + Details Name: us-gaap_ExcessStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromRelatedPartyDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=txmd_RubricCapitalManagementLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Business Concentrations (Details) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2024 USD (\$) Theramex [Member] Á Á Business Concentrations [Line Items] Á Á Customer license revenue percentage 100.00% 100.00% Mayne Pharma [Member] Á Á Business Concentrations [Line Items] Á Á Royalty receivable short term portion \$ 3,323 \$ 3,323 Royalty receivable long term portion \$ 16,610 \$ 16,610 X - DefinitionCustomer license revenue percentage. + ReferencesNo definition available. + Details Name: txmd_CustomerLicenseRevenuePercentage Namespace Prefix: txmd_Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty receivable, long term portion. + ReferencesNo definition available. + Details Name: txmd_RoyaltyReceivableLongTermPortion Namespace Prefix: txmd_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty receivable short term portion. + ReferencesNo definition available. + Details Name: txmd_RoyaltyReceivableShortTermPortion Namespace Prefix: txmd_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=txmd_TheramexMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=txmd_MaynePharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XCEL 59 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4\$L#!0 (Z,"%D'04UB@0 +\$ 0 9&J'C4')O<.,087!P+GAM M,\$;V,.0/L,1!\$ _EQO=;=1P4B0!2L+ (/>QLOD&1#LD)'<OGC|CVX>;QA&WPIG M*N*1#BV&5 C(I(/ 147BK9.7:=N')=H16-Y #OGDK7A.YNJQ<&4GPZ4A!0W J=0U[R;UEA 6#M!7E!+ P04 M ".@FQ9&BQK NX K @ \$0 &108U!R;WIS+V-O&ULS9+! M.L,P#([9?9?B>*9#R;U96.G@8K.QF;+4UBQUC.R1)'R5>F5*V!])C1TN/ MGT'MB=+T'9J3'S&1PWPW^BYD;=>*G8BB1,CFA%[G<DJ7JGHD]M&,JCU(,_,D\?'!0+L53 Q)8.L\$MRS&Y)%><-0#ZN2FW;@;\+;;O!1U*Q/ MC:~^JH5?==Z&^%!+ P04 ".@FQ9F5R<(Q &")P \$P ^!+W!H M96UE+W!H96UE,2YX;6SM6EMSVC@4N'U'OTAG|FT+QC!;MK03621A -15809R7;9J-NILA!"SI^Y%1^?H.'GS|BYBZ|:(E/X M8-DOV);[MR >X%#BVR]*+ M4B1b%G|@M MNN01.+5)#3(PB=AlA]4P1' DQE|&+&+3&K!|@ \$WVWO@C(WXV)(ZMOFCU7 MH5A)VH3X\$8.S!QSYG/1/L;14!1E6W% .76!4!EQC?>*HU+76>= U/M /!T'3M!Y4"P9!AI@S M&L%&KQMVAVC2/K^! F<-0HACA*FNVB<5@% 9Y>PTG|Z|+>90VX?H;5,VPLCO=U!:=*Y \FIS I C'0% MHY19;'\$5FJ?J,H,L%&D;D>/N5Z> HWEL4*Z">P' T=HWP|JOX@L Y M?RY|SZ7ON?>0]H=>*W-R-J9V'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0([=R2^JVE+ZU)CA* MJ+,<\$X>RPP|9SR2';9WH'TU^ _9==N0C133ET.X&D*^ VVZG=P2,Z8D;D* MTU0>VYZ<5X&N(YV02Y9A7;>?8T=[Y%1L*O/08=QXCRHB^NH8:8S)# MAWE|7YAGE<90-!M1;#PD+!\$W8+Z'2P4X&1@+>.'@Z]1 Q)256 Q6|8#w*Y"B M? \$R,1>APYY=<7"/1DN/;IF6U;J|I=QEM(EYPF8\$V>KRMYL<%S'<]56 *P MOFHJ|MI5.S Y9KF4Q9Z;RWRT,'2Q;B6D2XDU=1=7GFYRN>BjV^!i=V MP6#R 7#1JP E.^=?%U#KQ[VW>/Z;J,|2\$R<><41 71% B.5' 86%\$+D4.Z2 MD 83 >LX=SFWJXP6L UC6'ODRWSEPVSK> U|F M\$RQ#I!|? 8)*@&K8XZKT Y)9P[M^OQ@2";-;/!:=X QU*M.M:I60K\$3]+ M!WP?D@9CC%OT-%&'MIK&MQMHQ#F 6/,,H68XWX=6'FAHSU8NL.8T';T'5 M0.4 VJ0-/-8-- R1!5XQF;8VH^1."CS< N\&+&CN'MB|V4\$L#10 (M Z';%#9R,R#5@8 .PC 8 >=&PO=VJR.W-H965T&UL MM9J|3^LV%.; BM5- TR91&CLM+W=0"0IL;.#E4G:WNVE F,1MHYO\$F>VT,UW MD)2KIS3+"))O-[.4S_VL?USXY.-5% U2@A#GJ,PUJ>#E3')A|%(>RL1<;TO M\$Q'G854\$3=PIJ8CG2C1 3PH"D?>0Y&0 BP?ODOW:OIB9>Y@%Y%#L1&Q;QV3S,J3E%<SDVO =.!)D1)A\$PFP>'?6LQ&L&9*4(Y M2|J|J9E9X|;QJ 15;A|;'\$M9C+V(# ZG1P?""^H? T- J|RLZH#4TR4+& M.J|O-L6SX >=&'DV,BJ#H011\$! ?^7-9=LIM^& E0'LFP#|) EN&>#F1HN2 MY;8NN.'3SR4W1&5/@UIVD=-'@UN@CAKQKE1<#> .#.=R;509\$CTBBNA3T8& M+;,[Z<@/R B64|;F5L5E!&1Y^)]> 0+)=;)<OBN?7|N+&F>VZ|W;|T4M:0Z[CH,UGN 'T#3Y%K(R+&] MCZW\$M^LFQ73+K+!JTPCUQ.H">IX5:B^TA^ _H@?>.SS>[B;UQ/Z|KLW<^<T%#[75(!K6T>!A9? 0+=1E; +S MT1VJZ8 T@V M)|Q9A3XMKG\$|;|8A|T9&M31XU'E0|O|MTAFTH|>WXE7(E9S+>'QCPZ\$A'4T= M5Z:.VV7F05"]+>)(VLYZ|""^U531.,<@<9W|)\$F=>=DIUVCF|'K3'0)%<\$6N MX*)J?L7%FBBS85T|;F\$# 5>=RT9M=HG+??*M'M&@KAY9|9&A&3MKSN\$'E-23O;)>H=C>U|W 4"TB)" MAK YQ\$<>A0 _AU*O|A"/U@Q\$<7 I#3|R9W+M0VL&B K M^B|BjY<|.APZ\$4G|L3JMP|BHC42T99,YD\$|)=;W2-S[,KD8K,9 H9#8DM 7?OOQ=7O/ELM|P% (M"8DBB-B7MOIEB,*;(#8>4#5U?Y=H"-&FB@..Z"= M4NFW8D@7N;-VS#7XHH-P(M=?)3;FAB..>4/N\$Z=S[>D#R M.O@86V> <9+&\$TJ>?<A62|/@N6/UWO=0%L9JB6"N*LM^W\$BK:5QRG@:)Q9 MH&I/|6JWABC6|J|QNJ|L#C146YBJU5<[EQZG#Q \]]9WAP5Z|U/3\$<=[[[U M6j'BO9+K<|L8UK7MU8C?9I3ZRF|);*GBJ|C|U;P,6 @J21AGG;LU KM-FH+Y?2>B=5|J#"R98Z>O?+BG<^H _J|M11^8Y=8Y>X)E?";,R5X M8 _N0@<61L7C^IJJ38I%Z@&EY QY:W?,2=H?<0\$=TF(|@AT|>!OZR4; M:I.M3Z;0&=+FQ8Y^|YOV|I ++=&+!&? KNQ@Q,"\$,@M^V8|)/Y&Y%(%M6^U MC2L!> D8RAM%<>E W2 _+>XC4/4T&^= 8=AY(\$EA|Y=UYK)?116&Y-6"Z.OX^* M^ FJ|B5ZD|5^PZ|/VOK+&[Z@>"WBABAW! &4K4DNG|T5CY>B|3O4'4W9 _+ M,^O;5#RPJ;F|JQ6W|OV|^;Y=+&R,34PW99RUHMOQ,%E250|X\$URM6\$RGI^ MZ<1E8Y>=C--;D=;^R6R5R^C403+ N>K-@Z45VMM|J6*%|H|;X/Y"2O-ZDGU M8%G M^A|02P,.\$% @ #HJL60U7+1X10 IAB @|X;|JW;W)K2|T |J(WOU\$KA^X^H^/E"KPF6*YOY\$S.QR5>;#K MRH#NJOA:W0M^MVB@|RV@N M& <^H|OKOQ=TM<61<.@L F,T0?N4GECO-OYN;WY'H!C2:TEB9\$S< NZ=; MFJ8FDM;QO0FZ;-J|/O7/Z+ 6B6DO|DCDFY^<|+U%Z\$2Y 0O>D3-5G O ; M+1R3+R8I+>Z"QX:6|@ <2D5SOIGK2C|>?V?#8#7T- [H0#;ASP3JM+DZ M<|J\$W6M^0,0;B,TY 5ZR>Y+&J^VS6Q?RJU^U^&Z|5|YNQD>O@SNA\$ M1=Nj=&=52N9|)%5ND7\$5 N2^E2UT\$|2P47I09M>NN@7D^>^XY@5Y P&?"/LW==>UYIFUM=JC^9HTFLUJ^26=&=UH &H^XH\$^<BU\$8.'9] M"84@R N&BG|T011D5D!<>3|/L#M3;S\$WGB|NJ\$==~OW4S7U.<|OSB : M|E1?T><|7F;4Y\$=&S|LJ|JFA&QY4<==YPOB|UFK|;X2|>#F?(>1-:4|4T;N M6,H4HW: HUDLOI3@KQ7M.F.CF@>CQ BF)>V.@3V:96Q;>SA\$H^5N2ARIK(1T?T|SV+>ZD MD6@-QSAT=A,\$A'4TVE@RIZ?'0?#228? T80O3L#M"BLW,A7AB^/CR/OBW/J8RL &H=R-5:1UH'TMR M>_ L75Q3X|ZS"9P. X OT0*0)=M _;L[O-W>?Q@|^./\$VHD+|4>S#9U-JUONZV M _8=^*.U/C,SE-|.<^!- _DO-;D\$T^O/DH(W|J)|JXX> DA|/(&A&)&J8Y< ML'J|L@0(74) R.EZ;T534HE@=S8IH|J=KSCA:'9G>Z2'^<*U2& _I3L'Y M/2YHAMFQ/L"/^6Y61|H[C,QQ\$F8HHLO5;|O6*ZWY073Y6N5.89;U543E| M&J9 JUT8H0FPXP|L^"S8RZQJ|AA.Y9\$P|)%SFD7D81@,"6@U=?"G1K8 MCN%<XGN%U"Y26.K*MO Z@C|/(&KA7KX=2P=L3&SR%V W/#K-QGBP|&YR^V|V^+ MF>W[>|4|1#0GN^2<6"YU(3>:SjX&>CL17TH6M^H7E3GBG= <^9Y5ET~*M&AC MH'>?<|W?FQMSD>=36 ^ U!+ P04 "(@FQ9AOL! IT" I-P & M ^AL+W=OYU M"6#(0V6GGFE,774|W5>0D7U2-8@U;J.HH:#-7&U[4"6CAOQ? TH"!* HDQX M6>KF#B1+96.X\$|01\$=51=7C-7YFWFA|S1QO\$;EL1^EM9T TLP7+N%PLCO M6016=|,J|)>?>.NPNDL? DNx1N#G=X,\$^MD)>6]#3X7,R^P@H!#;BP#Q<<6 MYL^Y)4(9OSI.KU 2 O?>3^RWSCMZ65\$<^F L^4,^~^#1PI8TX.;[G|!V? MB>7+)=?NG^S:W 23VT8;675@5% Q73|I0U>/4 X?>0=&#H6\$<6)GM%67F M^;U00|4R1U1-A09|, #5QJ|1#1-V&XSN&|;J-12AP3Z.^*2LX:(#*XI MIR/LK3SFIPM|)A2C LIUR?D ?D+?&)+G%:I|Y! (9;S|M%|KJ|MQH<674|J (M(G%P0|@&@& YZ _#Z;R;'>C@>2<1 M_J#;"^!CBU^28) SGDQ@YJK^H, M^>5D(35S1^W^U4H;A0?NYY#5EGLS&T_PJFN:0XS# [R;R#6H+7O;N39@\$^X>, M_R>R@S?>1GBU|CQ*%05NL4CE|?>D)H|J|6 7+&!+F1G%.E20VJW?7SH5*T M_J>_W|.;1;.@B|_>V^<QW|E^8@?|^+^)'XAO#R:AC2FE8K^A^%+;>SD[V=-,38 M^<SOF> C\$@/V3WK-D|,U,ZV;8;V3OV2\$X<0I>;WB,0#O4FO-SE=+|X,VE!1


```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

copyright protection. 17 U.S.C. 105. var Show = {}; Show.LastAR = null; Show.showAR = function(a,r,w){if(Show.LastAR)Show.hideAR(e);var e=a;while(e&&e.nodeName!="TABLE")e=e.nextSibling;if(!e||e.nodeName!="TABLE"){var ref=(window)?w.document.document.getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e;Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!="DIV")e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=="none"){d='block';p=''}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}XML 61-report.ess IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.0.24 */ /* DefRef Styles */.report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }.report table.authRefData a { display: block; font-weight: bold; }.report table.authRefData p { margin-top: 0px; }.report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }.report table.authRefData .hide a:hover { background-color: #2F4497; }.report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }.report table.authRefData table { font-size: 1em; }./* Report Styles */.pl a,.pl a:visited { color: black; text-decoration: none; }./* table */.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; }.report hr { border: 1px solid #acf; }./* Top labels */.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; }.report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; }.report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */.report td.pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; }.report td.pl div a { width: 200px; }.report td.pl a:hover { background-color: #ffe; }./* Header rows... */.report tr.rh { background-color: #acf; color: black; font-weight: bold; }./* Calendars... */.report .rc { background-color: #f0f0f0; }./* Even rows... */.report .re,.report .re { background-color: #def; }.report .re td { border-bottom: 1px solid black; }./* Odd rows... */.report .ro,.report .rou { background-color: white; }.report .rou td { border-bottom: 1px solid black; }.report .rou table td,.report .re table td { border-bottom: 0px solid black; }./* styles for footnote marker */.report .fn { white-space: nowrap; }./* styles for numeric types */.report .num,.report .num { text-align: right; white-space: nowrap; }.report .num { padding-left: 2em; }.report .num { padding: 0px 0.4em 0px 2em; }./* styles for text types */.report .text { text-align: left; white-space: normal; }.report .text .big { margin-bottom: 1em; width: 17em; }.report .text .more { display: none; }.report .text .note { font-style: italic; font-weight: bold; }.report .text .small { width: 10em; }.report .sup { font-style: italic; }.report .outerFootnotes { font-size: 1em; }.XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 137 235 1 true 38 0 false 4 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover 1 false false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) Sheet http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.therapeuticsmd.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies Sheet http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies Notes 7 false false R8.htm 995307 - Disclosure - Discontinued Operations Sheet http://www.therapeuticsmd.com/role/DiscontinuedOperations Discontinued Operations Notes 8 false false R9.htm 995308 - Disclosure - Prepaid and Other Current Assets Sheet http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets Prepaid and Other Current Assets Notes 9 false false R10.htm 995309 - Disclosure - Licensed Rights and Other Intangible Assets Sheet http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets Licensed Rights and Other Intangible Assets Notes 10 false false R11.htm 995310 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 11 false false R12.htm 995311 - Disclosure - Commitments and Contingencies Sheet http://www.therapeuticsmd.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 995312 - Disclosure - Stockholders??? Equity Sheet http://www.therapeuticsmd.com/role/StockholdersEquity Stockholders??? Equity Notes 13 false false R14.htm 995313 - Disclosure - Revenue Sheet http://www.therapeuticsmd.com/role/Revenue Revenue Notes 14 false false R15.htm 995314 - Disclosure - Income Taxes Sheet http://www.therapeuticsmd.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 995315 - Disclosure - Income (Loss) Per Common Share Sheet http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare Income (Loss) Per Common Share Notes 16 false false R17.htm 995316 - Disclosure - Related Parties Sheet http://www.therapeuticsmd.com/role/RelatedParties Related Parties Notes 17 false false R18.htm 995317 - Disclosure - Business Concentrations Sheet http://www.therapeuticsmd.com/role/BusinessConcentrations Business Concentrations Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies 21 false false R22.htm 996001 - Disclosure - Discontinued Operations (Tables) Sheet http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.therapeuticsmd.com/role/DiscontinuedOperations 22 false false R23.htm 996002 - Disclosure - Prepaid and Other Current Assets (Tables) Sheet http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables Prepaid and Other Current Assets (Tables) Tables http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets 23 false false R24.htm 996003 - Disclosure - Licensed Rights and Other Intangible Assets (Tables) Sheet http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables Licensed Rights and Other Intangible Assets (Tables) Tables http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets 24 false false R25.htm 996004 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities 25 false false R26.htm 996005 - Disclosure - Stockholders??? Equity (Tables) Sheet http://www.therapeuticsmd.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://www.therapeuticsmd.com/role/StockholdersEquity 26 false false R27.htm 996006 - Disclosure - Income (Loss) Per Common Share (Tables) Sheet http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables Income (Loss) Per Common Share (Tables) Tables http://www.therapeuticsmd.com/role/IncomeTaxes 27 false false R28.htm 996007 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) Sheet http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) Details 28 false false R29.htm 996008 - Disclosure - Discontinued Operations (Details) - Schedule of Discontinued Operations Sheet http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable Discontinued Operations (Details) - Schedule of Discontinued Operations Details http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables 29 false false R30.htm 996009 - Disclosure - Discontinued Operations (Details) - Schedule of Classes of Assets and Liabilities of Discontinued Operations Sheet http://www.therapeuticsmd.com/role/ScheduleofClassesofAssetsandLiabilitiesofDiscontinuedOperationsTable Discontinued Operations (Details) - Schedule of Classes of Assets and Liabilities of Discontinued Operations Details http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables 30 false false R31.htm 996010 - Disclosure - Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets Sheet http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets Details http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables 31 false false R32.htm 996011 - Disclosure - Licensed Rights and Other Intangible Assets (Details) Sheet http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails Licensed Rights and Other Intangible Assets (Details) Details http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables 32 false false R33.htm 996012 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net Sheet http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net Details http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables 33 false false R34.htm 996013 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject to Amortization Sheet http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject to Amortization Details http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables 34 false false R35.htm 996014 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities Sheet http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities Details http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables 35 false false R36.htm 996015 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.therapeuticsmd.com/role/CommitmentsandContingencies 36 false false R37.htm 996016 - Disclosure - Stockholders??? Equity (Details) Sheet http://www.therapeuticsmd.com/role/StockholdersEquityDetails Stockholders??? Equity (Details) Details http://www.therapeuticsmd.com/role/StockholdersEquityTables 37 false false R38.htm 996017 - Disclosure - Stockholders??? Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Warrants Sheet http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable Stockholders??? Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Warrants Details http://www.therapeuticsmd.com/role/StockholdersEquityTables 38 false false R39.htm 996018 - Disclosure - Stockholders??? Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions Sheet http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable Stockholders??? Equity (Details) - Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions Details http://www.therapeuticsmd.com/role/StockholdersEquityTables 39 false false R40.htm 996019 - Disclosure - Stockholders??? Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions Sheet http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable Stockholders??? Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions Details http://www.therapeuticsmd.com/role/StockholdersEquityTables 40 false false R41.htm 996020 - Disclosure - Stockholders??? Equity (Details) - Schedule of the Status of Our PSUs and Related Transactions Details http://www.therapeuticsmd.com/role/StockholdersEquityTables 41 false false R42.htm 996021 - Disclosure - Revenue (Details) Sheet http://www.therapeuticsmd.com/role/RevenueDetails Revenue (Details) Details http://www.therapeuticsmd.com/role/Revenue 42 false false R43.htm

996022 – Disclosure – Income Taxes (Details) Sheet <http://www.therapeuticsmd.com/role/IncomeTaxes> 43 false false R44.htm 996023 – Disclosure – Income (Loss) Per Common Share (Details) – Schedule of Computation of Basic and Diluted (Loss) Per Common Share Sheet <http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTable> Income (Loss) Per Common Share (Details) – Schedule of Computation of Basic and Diluted (Loss) Per Common Share Details <http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables> 44 false false R45.htm 996024 – Disclosure – Income (Loss) Per Common Share (Details) – Schedule of Outstanding Securities Sheet <http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables> 45 false false R46.htm 996025 – Disclosure – Related Parties (Details) Sheet <http://www.therapeuticsmd.com/role/RelatedPartiesDetails> Related Parties (Details) Details <http://www.therapeuticsmd.com/role/RelatedParties> 46 false false R47.htm 996026 – Disclosure – Business Concentrations (Details) Sheet <http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails> Business Concentrations (Details) Details <http://www.therapeuticsmd.com/role/BusinessConcentrations> 47 false false All Reports Book All Reports ea0218728-10q_therapeutics.htm txmd-20240930.xsd txmd-20240930_cal.xml txmd-20240930_def.xml txmd-20240930_lab.xml txmd-20240930_pre.xml <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/doi/2024> true true JSON-66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0218728-10q_therapeutics.htm" }, { "nsprefix": "txmd", "nsuri": "http://www.therapeuticsmd.com/role/20240930", "dts": { "inline": { "local": { "ea0218728-10q_therapeutics.htm" } }, "schema": { "local": { "txmd-20240930.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/irr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/doi/2024/doi-2024.xsd", "https://xbrl.sec.gov/doi/2024/doi-2024_def.xsd", "https://xbrl.sec.gov/doi/2024/doi-2024_lab.xsd", "https://xbrl.sec.gov/doi/2024/doi-2024_pre.xsd", "https://xbrl.sec.gov/doi/2024/doi-sub-2024.xsd", "https://xbrl.sec.gov/eed/2024/eed-2024.xsd", "https://xbrl.sec.gov/eed/2024/eed-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" }, "calculationLink": { "local": { "txmd-20240930_cal.xml" } }, "definitionLink": { "local": { "txmd-20240930_def.xml" } }, "labelLink": { "local": { "txmd-20240930_lab.xml" } }, "presentationLink": { "local": { "txmd-20240930_pre.xml" } }, "keyStandard": 190, "keyCustom": 45, "axisStandard": 15, "axisCustom": 1, "memberStandard": 16, "memberCustom": 17, "hidden": { "total": 88, "http://fasb.org/us-gaap/2024": 73, "http://xbrl.sec.gov/doi/2024": 5, "http://www.therapeuticsmd.com/20240930": 10 }, "contextCount": 137, "entityCount": 1, "segmentCount": 38, "elementCount": 597, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 515, "http://xbrl.sec.gov/doi/2024": 30, "http://xbrl.sec.gov/eed/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/doi/role/document/Cover", "longName": "995100 – Document – Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "b", "p", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "b", "p", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R2": { "role": "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "longName": "995301 – Statement – Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "txmd:RoyaltyReceivableCurrentPortion", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "unique": true }, "R3": { "role": "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 – Statement – Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "unique": true }, "R4": { "role": "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "longName": "995303 – Statement – Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R5": { "role": "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3", "longName": "995304 – Statement – Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c36", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true }, "uniqueAnchor": { "contextRef": "c40", "name": "us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "unique": true }, "R6": { "role": "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "longName": "995305 – Statement – Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true }, "uniqueAnchor": { "contextRef": "c10", "name": "txmd:WriteoffOfPatentsAndTrademarks", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "unique": true }, "R7": { "role": "http://www.therapeuticsmd.com/role/BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies", "longName": "995306 – Disclosure – Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies", "shortName": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R8": { "role": "http://www.therapeuticsmd.com/role/DiscontinuedOperations", "longName": "995307 – Disclosure – Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R9": { "role": "http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets", "longName": "995308 – Disclosure – Prepaid and Other Current Assets", "shortName": "Prepaid and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R10": { "role": "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets", "longName": "995309 – Disclosure – Licensed Rights and Other Intangible Assets", "shortName": "Licensed Rights and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R11": { "role": "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities", "longName": "995310 – Disclosure – Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "R12": { "role": "http://www.therapeuticsmd.com/role/CommitmentsandContingencies", "longName": "995311 – Disclosure – Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q_therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false",

"lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.therapeuticsmd.com/role/StockholdersEquity", "longName": "995312 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.therapeuticsmd.com/role/Revenue", "longName": "995313 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.therapeuticsmd.com/role/IncomeTaxes", "longName": "995314 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare", "longName": "995315 - Disclosure - Income (Loss) Per Common Share", "shortName": "Income (Loss) Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.therapeuticsmd.com/role/RelatedParties", "longName": "995316 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.therapeuticsmd.com/role/BusinessConcentrations", "longName": "995317 - Disclosure - Business Concentrations", "shortName": "Business Concentrations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "txmd:GeneralInformationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "txmd:GeneralInformationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables", "longName": "996001 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.therapeuticsmd.com/role/PrepaidAndOtherCurrentAssetsTables", "longName": "996002 - Disclosure - Prepaid and Other Current Assets (Tables)", "shortName": "Prepaid and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables", "longName": "996003 - Disclosure - Licensed Rights and Other Intangible Assets (Tables)", "shortName": "Licensed Rights and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "longName": "996004 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.therapeuticsmd.com/role/StockholdersEquityTables", "longName": "996005 - Disclosure - Stockholders\u2019 Equity (Tables)", "shortName": "Stockholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables", "longName": "996006 - Disclosure - Income (Loss) Per Common Share (Tables)", "shortName": "Income (Loss) Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "longName": "996007 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)", "shortName": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "txmd:TermOfRoyaltyPayments", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "ix:continuation", "us-

gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "txmd:PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p", "ix:continuation", "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "unique": true } }, "R29": { "role": "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable", "longName": "996008 – Disclosure – Discontinued Operations (Details) – Schedule of Discontinued Operations", "shortName": "Discontinued Operations (Details) – Schedule of Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c78", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c78", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.therapeuticsmd.com/role/ScheduleofClassesofAssetsandLiabilitiesofDiscontinuedOperationsTable", "longName": "996009 – Disclosure – Discontinued Operations (Details) – Schedule of Classes of Assets and Liabilities of Discontinued Operations", "shortName": "Discontinued Operations (Details) – Schedule of Classes of Assets and Liabilities of Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable", "longName": "996010 – Disclosure – Prepaid and Other Current Assets (Details) – Schedule of Prepaid and Other Current Assets", "shortName": "Prepaid and Other Current Assets (Details) – Schedule of Prepaid and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails", "longName": "996011 – Disclosure – Licensed Rights and Other Intangible Assets (Details)", "shortName": "Licensed Rights and Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c81", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c81", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable", "longName": "996012 – Disclosure – Licensed Rights and Other Intangible Assets (Details) – Schedule of License Rights and Other Intangible Assets, Net", "shortName": "Licensed Rights and Other Intangible Assets (Details) – Schedule of License Rights and Other Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable", "longName": "996013 – Disclosure – Licensed Rights and Other Intangible Assets (Details) – Schedule of Intangible Assets Subject to Amortization", "shortName": "Licensed Rights and Other Intangible Assets (Details) – Schedule of Intangible Assets Subject to Amortization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable", "longName": "996014 – Disclosure – Accrued Expenses and Other Current Liabilities (Details) – Schedule of Other Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities (Details) – Schedule of Other Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "longName": "996015 – Disclosure – Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c93", "name": "txmd:CashReceivedForNetWorkingCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c93", "name": "txmd:CashReceivedForNetWorkingCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "longName": "996016 – Disclosure – Stockholders\u2019 Equity (Details)", "shortName": "Stockholders\u2019 Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "unique": true } }, "R38": { "role": "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable", "longName": "996017 – Disclosure – Stockholders\u2019 Equity (Details) – Schedule of Status of Our Outstanding and Exercisable Warrants", "shortName": "Stockholders\u2019 Equity (Details) – Schedule of Status of Our Outstanding and Exercisable Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c107", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c107", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable", "longName": "996018 – Disclosure – Stockholders\u2019 Equity (Details) – Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions", "shortName": "Stockholders\u2019 Equity (Details) – Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c110", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c110", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable", "longName": "996019 – Disclosure – Stockholders\u2019 Equity (Details) – Schedule of the Status of Our RSUs, and Related Transactions", "shortName": "Stockholders\u2019 Equity (Details) – Schedule of the Status of Our RSUs, and Related Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c112", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",

"unitRef": "shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "td": "tr", "table": { "ix:continuation": "ix:continuation", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c112", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "td": "tr", "table": { "ix:continuation": "ix:continuation", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "R41": { "role": "http://www.therapeuticsmd.com/role/ScheduleoftheStatusOfOurPSUsandRelatedTransactionsTable", "longName": "996020 Disclosure Stockholders\u2019 Equity (Details) Schedule of the Status of Our PSUs and Related Transactions", "shortName": "Stockholders\u2019 Equity (Details) Schedule of the Status of Our PSUs and Related Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c115", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "td": "tr", "table": { "ix:continuation": "ix:continuation", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c115", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "td": "tr", "table": { "ix:continuation": "ix:continuation", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "R42": { "role": "http://www.therapeuticsmd.com/role/RevenueDetails", "longName": "996021 Disclosure Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "txmd:TermOfRoyaltyPayments", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": { "ix:continuation": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.therapeuticsmd.com/role/IncomeTaxesDetails", "longName": "996022 Disclosure Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": null, "uniqueAnchor": null }, "R44": { "role": "http://www.therapeuticsmd.com/role/ScheduleofComputationOfBasicandDilutedLossPerCommonShareTable", "longName": "996023 Disclosure Income (Loss) Per Common Share (Details) Schedule of Computation of Basic and Diluted (Loss) Per Common Share", "shortName": "Income (Loss) Per Common Share (Details) Schedule of Computation of Basic and Diluted (Loss) Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "td": "tr", "table": { "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable", "longName": "996024 Disclosure Income (Loss) Per Common Share (Details) Schedule of Outstanding Securities", "shortName": "Income (Loss) Per Common Share (Details) Schedule of Outstanding Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "td": "tr", "table": { "ix:continuation": "ix:continuation", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "td": "tr", "table": { "ix:continuation": "ix:continuation", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "R46": { "role": "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "longName": "996025 Disclosure Related Parties (Details)", "shortName": "Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c130", "name": "us-gaap:StockRedeemedOrCalledDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "p": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c130", "name": "us-gaap:StockRedeemedOrCalledDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "p": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "R47": { "role": "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails", "longName": "996026 Disclosure Business Concentrations (Details)", "shortName": "Business Concentrations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c134", "name": "txmd:CustomerLicenseRevenuePercentage", "unitRef": "pure", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "p": "us-gaap:ConcentrationRiskDisclosureTextBlock", "div": "body", "html": }, "reportCount": 1, "baseRef": "ea0218728-10q-therapeutics.htm", "first": true, "unique": true }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [], "us-gaap:AccountsPayableAndAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": { "r291" }, "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable", "lang": { "en-us": { "role": { "totalLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": { "r48", "r49" }, "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [], "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r47", "r556" }, "us-gaap:AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": [], "us-gaap:AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": [], "us-gaap:AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable", "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r49" }, "us-gaap:AcquisitionCostsCumulative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionCostsCumulative", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": { "parentTag": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable", "lang": { "en-us": { "role": { "terseLabel": "Capitalized legal", "label": "Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost", "documentation": "Amount of capitalized acquisition cost excluded from amortization for investment in unproved property and development project in oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest." } } }, "auth_ref": { "r394", "r395" }, "us-gaap:Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": { "r629" }, "txmd:AdditionalFund": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "AdditionalFund", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Additional fund", "documentation": "Amount of additional fund paid.", "label": "Additional Fund" } } }, "auth_ref": [], "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r57", "r556", "r811" }, "us-gaap:AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital",

"label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r445", "r703", "r704", "r705", "r706", "r766", "r812" } }, "doi": "AdditionalSecurities462b", { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": { "r685" } }, "dei": "AdditionalSecurities462bFileNumber", { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b), File Number" } } }, "auth_ref": { "r685" } }, "dei": "AdditionalSecuritiesEffective413b", { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Additional Securities Effective. 413(b)" } } }, "auth_ref": { "r683" } }, "dei": "AddressTypeDomain", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Address Type [Domain]" } } }, "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": { "r642" } }, "ecd": "AdjToCompAmt", { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation. Amount" } } }, "auth_ref": { "r642" } }, "ecd": "AdjToCompAxis", { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation." } } }, "auth_ref": { "r642" } }, "ecd": "AdjToNonPecCompFnTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPecCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO-NEO Compensation Footnote" } } }, "auth_ref": { "r642" } }, "ecd": "AdjToPecCompFnTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPecCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation. Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation. Footnote" } } }, "auth_ref": { "r642" } }, "us-gaap": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": { "r642" } }, "us-gaap": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method." } } }, "auth_ref": { "r74" } }, "us-gaap": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "r642" } }, "ecd": "AggtChngPnsnValInSummaryCompstnTblForApblYrMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": { "r676" } }, "ecd": "AggtErrCompAmt", { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r592", "r603", "r619", "r654" } }, "ecd": "AggtErrCompNotYetDeterminedTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": { "r595", "r606", "r622", "r657" } }, "ecd": "AggtPnsnAdjsSvcCstMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": { "r677" } }, "ecd": "AllAdjToCompMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": { "r642" } }, "ecd": "AllExecutiveCategoriesMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": { "r649" } }, "ecd": "AllIndividualsMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": { "r596", "r607", "r623", "r649", "r658", "r662", "r670" } }, "ecd": "AllTradingArrangementsMember", { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": { "r668" } }, "us-gaap": "AllocatedShareBasedCompensationExpense", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based payment compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r287", "r289" } }, "dei": "AmendmentDescription", { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": { "r642" } }, "dei": "AmendmentFlag", { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { "r642" } }, "us-gaap": "AmortizationOfIntangibleAssets", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": { "r5", "r207", "r213", "r546" } }, "dei": "AnnualInformationForm", { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": { "r599" } }, "us-gaap": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfOutstandingSecuritiesTable", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r172" } }, "us-gaap": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfOutstandingSecuritiesTable", "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r15"

"ArrangementsAndNonarrangementTransactionsMember", "presentation": {
"http://www.therapeuticsmd.com/role/BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
"http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "http://www.therapeuticsmd.com/role/RelatedPartiesDetails",
"http://www.therapeuticsmd.com/role/RevenueDetails" }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." } } },
"auth_ref": { "r328" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit",
"calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation":
"Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r95", "r104", "r126", "r141", "r176", "r180", "r185", "r186", "r193", "r229",
"r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r329", "r331", "r358", "r399", "r479", "r541", "r542", "r556", "r571", "r733", "r734", "r771" } }, "us-
gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": {
"http://www.therapeuticsmd.com/role/ScheduleofClassesofAssetsandLiabilitiesofDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Assets:",
"label": "Assets [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrent", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0,
"order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "totalLabel": "Total current
assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": {
"r121", "r130", "r141", "r193", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r329", "r331", "r358", "r556", "r733", "r734", "r771" } }, "us-
gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": {
"http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]"
} } }, "auth_ref": { } }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": {
"http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Current assets of discontinued operations", "label":
"Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or
disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1", "r26", "r42", "r80", "r82", "r119", "r120" } },
"dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements",
"presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation":
"Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": { "r599" } }, "dei_AuditorFirmId": {
"xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": {
"http://xbrl.sec.gov/dei/role/document/AuditInformation" }, "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm
Identifier" } } }, "auth_ref": { "r584", "r587", "r599" } }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": { } }, "dei_AuditorLocation": { "xbrltype":
"internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": {
"http://xbrl.sec.gov/dei/role/document/AuditInformation" }, "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": { "r584", "r587", "r599" } },
"dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": {
"http://xbrl.sec.gov/dei/role/document/AuditInformation" }, "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": { "r584", "r587", "r599" } },
"dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": {
"http://xbrl.sec.gov/dei/role/document/AuditInformation" }, "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": { "r681" } },
"dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": {
"http://xbrl.sec.gov/dei/role/document/AuditInformation" }, "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": { } }, "ecd_AwardExrcPrice": {
"xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": {
"r665" } }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair
Value as of Grant Date" } } }, "auth_ref": { "r666" } }, "ecd_AwardTmgDisclLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgDisclLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } },
"auth_ref": { "r661" } }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing,
How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": { "r661" } }, "ecd_AwardTmgMethodTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing
Method" } } }, "auth_ref": { "r661" } }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI
Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": { "r661" } }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award
Timing MNPI Disclosure" } } }, "auth_ref": { "r661" } }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award
Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": { "r661" } }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {
"http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUsandRelatedTransactionsTable",
"http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable",
"http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label":
"Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": {
"r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281",
"r282", "r283", "r284", "r285", "r286" } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Underlying
Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": { "r664" } }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" },
"lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r663" } },
"ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]",
"terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": { "r662" } }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
"terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": { "r662" } }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": {
"http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting,
Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial
statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { } },
"txmd_BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.therapeuticsmd.com/20240930", "localname":
"BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable", "presentation": {
"http://www.therapeuticsmd.com/role/BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us":
{ "role": { "label": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": { } },
"txmd_BusinessConcentrationsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname":
"BusinessConcentrationsDetailsTable", "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails" }, "lang": { "en-us": { "role": { "label":
"Business Concentrations (Details) [Table]" } } }, "auth_ref": { } }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": {
"label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": { "r587", "r599" } }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": {
"http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
"periodStarLabel": "Cash and cash equivalents—continuing operations, beginning of period", "periodEndLabel": "Total cash and cash equivalents, end of period",
"terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash
and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash
includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand
deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r14", "r70", "r139" } }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":

"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r70" } }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash Provided By Used In Operating Activities Discontinued Operations", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Net cash used in operating activities", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } }, "auth_ref": { "r41", "r70" } }, "txmd_CashReceivedForNetWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "Cash Received For Net Working Capital", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash Received For Net Working Capital", "documentation": "Cash received for net working capital.", "label": "Cash Received For Net Working Capital" } } } }, "auth_ref": { } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } } }, "auth_ref": { "r640" } }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer [Member]", "label": "Chief Executive Officer [Member]" } } } }, "auth_ref": { "r714" } }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } } }, "auth_ref": { "r637" } }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } } }, "auth_ref": { "r635" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } } }, "auth_ref": { } }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } } }, "auth_ref": { "r112", "r127", "r128", "r129", "r141", "r166", "r167", "r169", "r171", "r178", "r179", "r193", "r229", "r231", "r232", "r233", "r236", "r237", "r239", "r240", "r242", "r243", "r245", "r358", "r436", "r437", "r438", "r439", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r467", "r488", "r510", "r521", "r522", "r523", "r524", "r525", "r693", "r701", "r707" } }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Stockholders'2019 Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { "r127", "r128", "r129", "r178", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r436", "r437", "r438", "r439", "r547", "r693", "r701" } }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } } }, "auth_ref": { "r21" } }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable", "lang": { "en-us": { "role": { "label": "Schedule of Status of Our Outstanding and Exercisable Warrants [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } } }, "auth_ref": { "r21" } }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } } }, "auth_ref": { "r641" } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } } }, "auth_ref": { "r641" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } } }, "auth_ref": { "r53", "r96", "r401", "r466" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]", "auth_ref": { } }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingencies", "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } } }, "auth_ref": { "r84", "r223", "r224", "r527", "r728", "r730" } }, "txmd_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]", "auth_ref": { } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Remaining shares of common stock available for future issuance (in Shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } } }, "auth_ref": { "r56" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } } }, "auth_ref": { "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r703", "r704", "r706", "r766", "r810", "r812" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals", "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock price per share (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } } }, "auth_ref": { "r56" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals", "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } }, "auth_ref": { "r56", "r467" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock issued (in Shares)", "netLabel": "Common stock shares", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } }, "auth_ref": { "r56" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel":

"Balance (in Shares)", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r7", "r56", "r467", "r485", "r812", "r813" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "en-us": { "role": { "terseLabel": "Common stock, par value \$0.001; 32,000 shares authorized, 11,532 issued and outstanding as of September 30, 2024 and December 31, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r56", "r402", "r556" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": { "r646" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": { "r645" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": { "r647" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": { "r644" } }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrations": { "lang": { "en-us": { "role": { "terseLabel": "Business concentrations", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": { "r77" } }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails": { "lang": { "en-us": { "role": { "label": "Business Concentrations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r526" } }, "us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRisksTypesNoConcentrationPercentageAbstract", "lang": { "en-us": { "role": { "label": "Business Concentrations [Abstract]" } } }, "auth_ref": { } }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": { } }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": { "r587" } }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": { } }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": { } }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": { } }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": { } }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)" } } }, "auth_ref": { } }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails": { "http://www.therapeuticsmd.com/role/RevenueDetails": { "lang": { "en-us": { "role": { "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": { } }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails": { "http://www.therapeuticsmd.com/role/RevenueDetails": { "lang": { "en-us": { "role": { "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": { } }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": { "r143", "r144", "r238", "r241", "r382", "r386", "r398", "r535", "r537" } }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": { } }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { } }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format MM-DD." } } }, "auth_ref": { } }, "txmd_CustomerLicenseRevenuePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "CustomerLicenseRevenuePercentage", "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer license revenue percentage", "documentation": "Customer license revenue percentage", "label": "Customer License Revenue Percentage" } } }, "auth_ref": { } }, "txmd_DecreaseInRoyaltyRateOnProductByProductBasis": { "xbrltype": "percentItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "DecreaseInRoyaltyRateOnProductByProductBasis", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails": { "http://www.therapeuticsmd.com/role/RevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Decrease in royalty rate", "documentation": "Decrease in royalty rate on product-by-product basis.", "label": "Decrease In Royalty Rate On Product By Product Basis" } } }, "auth_ref": { } }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/PrepaidAndOtherCurrentAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet, and other deferred costs." } } }, "auth_ref": { } }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": { "r611", "r612", "r626" } }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation & amortization", "documentation": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": { "r5", "r20" } }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": { "r119" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofClassesofAssetsandLiabilitiesofDiscontinuedOperationsTable": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r1", "r26", "r42", "r82" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth-ref": { "r1", "r26", "r42", "r80", "r82" } }, "txmd_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeIncomeExpense", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "Disposal group including discontinued operation general and administrative income (expense)", "documentation": "Disposal group including discontinued operation general and administrative income (expense)" } } }, "auth-ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth-ref": { "r40" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "terseLabel": "Operating loss from discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth-ref": { "r40" } }, "txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Disposal group including discontinued operation other income (expense)", "documentation": "Disposal group including discontinued operation other income (expense)" } } }, "auth-ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth-ref": { "r40", "r120" } }, "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable", "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Disposal group including discontinued operation total other income expense net", "documentation": "Disposal Group Including Discontinued Operation Total Other Income Expense Net" } } }, "auth-ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/DiscontinuedOperations", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth-ref": { "r25", "r79" } }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth-ref": { "r611", "r612", "r626" } }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.'" } } }, "auth-ref": { "r587" } }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth-ref": { "r584", "r587", "r599" } }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth-ref": { } }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth-ref": { } }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth-ref": { } }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Domain", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth-ref": { } }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth-ref": { } }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction Flag", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth-ref": { "r584", "r587", "r599", "r650" } }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to u00a7240.10D-1(b)." } } }, "auth-ref": { "r584", "r587", "r599", "r650" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q and 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth-ref": { } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth-ref": { } }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth-ref": { } }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { } }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth-ref": { } }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth-ref": { } }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as htm 25911.htm, exhibit1.htm, v105727-8k.txt." } } }, "auth-ref": { } }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is

```

"MM-DD-YYYY", "auth_ref": [], "documentPeriodStartDate": { "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [], "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "r585" } }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": { "r573" } }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": { "r587" } }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": { "r587" } }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth.'" } } }, "auth_ref": [], "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period.'" } } }, "auth_ref": [], "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report.'" } } }, "auth_ref": [], "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r627" } }, "dei_DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [], "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [], "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": { "r576" } }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrRwRfctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrRwRfctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "auth_ref": { "r630" } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "label": "Income (Loss) Per Common Share [Abstract]", "terseLabel": "Loss per common share, basic and diluted." } } }, "auth_ref": [], "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r137", "r153", "r154", "r155", "r156", "r157", "r158", "r164", "r166", "r169", "r170", "r171", "r175", "r318", "r327", "r353", "r354", "r396", "r410", "r538" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r137", "r153", "r154", "r155", "r156", "r157", "r158", "r166", "r169", "r170", "r171", "r175", "r318", "r327", "r353", "r354", "r396", "r410", "r538" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r163", "r172", "r173", "r174" } }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)", "auth_ref": { "r689" } } }, "dei_EffectiveOnDate486a": { "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)", "auth_ref": { "r689" } } }, "dei_EffectiveOnDate486b": { "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)", "auth_ref": { "r690" } } }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)", "auth_ref": { "r689" } } }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)", "auth_ref": { "r690" } } }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)", "auth_ref": { "r688" } } }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)", "auth_ref": { "r690" } } }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)", "auth_ref": { "r692" } } }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesTable", "lang": { "en-us": { "role": { "label": "Payroll and related costs", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r49" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": { "r288" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Share-based compensation over a weighted average period", "documentation": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYmMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days
```

"Employee Stock Purchase Plan Member" } } }, "auth_ref": { } }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": { } }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": { } }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": { } }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": { "r575" } }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": { "r579" } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r575" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { } }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r575" } }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": { "r691" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r575" } }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": { } }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated." } } }, "auth_ref": { } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { } }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": { } }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r680" } }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": { "r679" } }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": { } }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType",

"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5.' } } }, "auth_ref": { } }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": { } }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": { } }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01.'" } } }, "auth_ref": { } }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": { } }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": { } }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": { } }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": { } }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": { } }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": { "r599" } }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "credit": "credit", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": { } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r575" } }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD.'" } } }, "auth_ref": { } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r575" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r575" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r575" } }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": { } }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { } }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": { "r682" } }, "us-gaap-EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": { "http://www.therapeuticsmd.com/role/RevenueDetails": { "lang": { "en-us": { "role": { "label": "Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "ecd-EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": { "r633" } }, "ecd-EqtyAwrdsAdjsExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": { "r675" } }, "ecd-EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": { "r675" } }, "ecd-EqtyAwrdsInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": { "r675" } }, "us-gaap-EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders'u2019 Equity [Abstract]" } } }, "auth_ref": { } }, "us-gaap-EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r7", "r115", "r133", "r134", "r135", "r145", "r146", "r147", "r150", "r157", "r159", "r161", "r177", "r197", "r203", "r221", "r246", "r300", "r301", "r314", "r315", "r316", "r319", "r326", "r327", "r336", "r338", "r339", "r340", "r341", "r343", "r352", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r368", "r376", "r409", "r423", "r424", "r425", "r445", "r510" } } }, "ecd-EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": { "r643" } }, "ecd-ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": { "r592", "r603", "r619", "r654" } }, "ecd-ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": { "r589", "r600", "r616", "r651" } }, "us-gaap-ExcessStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesOutstanding", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional shares of common stock", "label": "Excess Stock, Shares Outstanding", "documentation": "Number of shares of excess stock held by shareholders." } } }, "auth_ref": { } }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": { } }, "ecd-ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } } }, "auth_ref": { "r649" } }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": { "r687" } },

"dei-ExhibitsOnly462dFileNumber": { "xbrltype": "fileNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": { "r687" } }, "dei-Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": { "us-gaap-FinancingInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingInterestExpense", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "en-us": { "role": { "negatedLabel": "Interest expense and other financing costs", "label": "Financing Interest Expense", "documentation": "This element represents interest incurred for borrowed money which was used to produce goods or render services." } } }, "auth_ref": { "r65" } } }, "us-gaap-FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r124", "r204", "r212", "r546" } } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r724", "r814" } } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r214", "r531", "r546" } } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": { "r814" } } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables": { "en-us": { "role": { "terseLabel": "Schedule of License Rights and Other Intangible Assets, Net", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": { "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r214", "r531", "r546" } } } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r214", "r531", "r546" } } } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r214", "r531", "r546" } } } }, "us-gaap-FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": { "r206", "r208", "r209", "r210", "r211", "r212", "r215", "r216", "r389", "r393", "r531" } } }, "us-gaap-FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets Subject to Amortization [Abstract]" } } }, "auth_ref": { "us-gaap-FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails": { "en-us": { "role": { "label": "Schedule of License Rights and Other Intangible Assets, Net [Line Items]", "terseLabel": "Licensed Rights and Other Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r206", "r212", "r215", "r216", "r389", "r531", "r546" } } }, "us-gaap-FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": { "r206", "r208", "r209", "r210", "r211", "r212", "r215", "r216", "r531" } } }, "us-gaap-FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjecttoAmortizationTable": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r389", "r723" } } }, "us-gaap-FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Licensed Rights and Other Intangible Assets [Abstract]" } } }, "auth_ref": { "eed-ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": { "r596", "r607", "r623", "r658" } } }, "eed-ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": { "r596", "r607", "r623", "r658" } } }, "eed-ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": { "r596", "r607", "r623", "r658" } } }, "eed-ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": { "r596", "r607", "r623", "r658" } } }, "eed-ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r596", "r607", "r623", "r658" } } }, "dei-FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"FormerAddressMember", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": { "r586", "r610" } }, "doi_FoermerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": { } }, "eecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": { "r638" } }, "txmd_GeneralInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "GeneralInformationPolicyTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "General", "documentation": "General information", "label": "General Information Policy Text Block" } } }, "auth_ref": { } }, "txmd_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "GoingConcernPolicyTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Going concern", "documentation": "Going concern", "label": "Going Concern Policy Text Block" } } }, "auth_ref": { } }, "txmd_GrossProceedsFromDrawdownBeforeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "GrossProceedsFromDrawdownBeforeExpenses", "erdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from drawdown before expenses", "documentation": "Gross proceeds from drawdown before expenses", "label": "Gross Proceeds From Drawdown Before Expenses" } } }, "auth_ref": { } }, "txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfLicenseRightsandOtherIntangibleAssetsNetTable" }, "lang": { "en-us": { "role": { "terseLabel": "Hormone therapy drug patents applied and pending approval [Member]", "label": "Hormone Therapy Drug Patents Applied And Pending Approval Member" } } }, "auth_ref": { } }, "txmd_HormoneTherapyDrugPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "HormoneTherapyDrugPatentsMember", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfLicenseRightsandOtherIntangibleAssetsNetTable" }, "lang": { "en-us": { "role": { "terseLabel": "Hormone therapy drug patents [Member]", "documentation": "Hormone Therapy Drug Patents Member", "label": "Hormone Therapy Drug Patents Member" } } }, "auth_ref": { } }, "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": { "r584", "r587", "r599" } }, "us_gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "erdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets (Note 4)", "verboseLabel": "Impairment loss", "label": "Impairment, Long-Lived Asset, Held for Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": { "r5", "r19", "r81", "r551" } }, "us_gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "erdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 }, "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable" }, "lang": { "en-us": { "role": { "totalLabel": "Loss from continuing operations, net of income taxes", "terseLabel": "Net loss from continuing operations", "verboseLabel": "Loss from continuing operations, net of income taxes (in Dollars)", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": { "r24", "r63", "r74", "r153", "r154", "r155", "r156", "r157", "r168", "r171", "r327" } }, "us_gaap_IncomeLossFromContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": { } }, "us_gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "erdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Loss from continuing operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r62", "r98", "r103", "r397", "r406", "r540", "r541", "r709", "r710", "r711", "r712", "r713" } }, "us_gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Continuing operations, basic (in Dollars per share)", "verboseLabel": "Basic", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r63", "r99", "r137", "r149", "r153", "r154", "r155", "r156", "r157", "r166", "r169", "r170", "r318", "r327", "r354", "r396", "r780" } }, "us_gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Continuing operations, diluted (in Dollars per share)", "verboseLabel": "Diluted", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r63", "r137", "r149", "r153", "r154", "r155", "r156", "r157", "r166", "r169", "r170", "r171", "r327", "r354", "r396", "r780" } }, "us_gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "erdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable", "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": { "totalLabel": "Loss from discontinued operations, net of income taxes", "terseLabel": "Loss from discontinued operations, net of income taxes", "verboseLabel": "Less: Loss from discontinued operations, net of income taxes", "netLabel": "Loss from discontinued operations, net of income taxes (in Dollars)", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r30", "r31", "r32", "r33", "r34", "r44", "r120", "r308", "r407" } }, "us_gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Loss per common share, discontinued operations, net of income taxes", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": { } }, "us_gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/ScheduleOfComputationOfBasicandDilutedLossPerCommonShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, net basic (in Dollars per share)", "verboseLabel": "Basic", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r64", "r137", "r167", "r169", "r170", "r770", "r780" } }, "us_gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",

"http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedLossPerCommonShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, net diluted (in dollars per share)", "verboseLabel": "Diluted", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r94", "r167", "r169", "r170" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": {} }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {} }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held for sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r6", "r10", "r12", "r26", "r35", "r36", "r37", "r38", "r39", "r43", "r45", "r46", "r83" } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": {} }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": { "r142", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r305", "r307", "r309", "r310", "r441", "r550" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Provision for income taxes", "terseLabel": "Provisions for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r105", "r110", "r160", "r161", "r176", "r183", "r186", "r293", "r294", "r306", "r411", "r550" } }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": { "r700" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": {} }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": { "r694", "r700" } }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": {} }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r4" } }, "txmd_IncrementalAccrualForNetWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "IncrementalAccrualForNetWorkingCapital", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Incremental accrual for net working capital", "documentation": "Incremental accrual for net working capital", "label": "Incremental Accrual For Net Working Capital" } } }, "auth_ref": {} }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual" } } }, "auth_ref": { "r596", "r607", "r623", "r649", "r659", "r662", "r670" } }, "txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment": { "xbrltype": "percentItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "InflationRateAdjustedForMinimalAnnualRoyaltyPayment", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inflation rate adjusted for minimal annual royalty payment", "verboseLabel": "Inflation at an annual rate", "documentation": "Inflation rate adjusted for minimal annual royalty payment", "label": "Inflation Rate Adjusted For Minimal Annual Royalty Payment" } } }, "auth_ref": {} }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements" } } }, "auth_ref": { "r588", "r674" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": { "r588", "r674" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": { "r588", "r674" } }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "Licensed rights and other intangible assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": { "r205", "r217", "r219", "r530", "r531" } }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": { "r123" } }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"], "lang": { "en-us": { "role": { "terseLabel": "License rights and other intangible assets, net", "verboseLabel": "Net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r206", "r723", "r725" } }, "txmd_IntangibleAssetsSubjectToAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "IntangibleAssetsSubjectToAmortizationMember", "presentation": {

```

http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable", "lang": { "en-us": { "role": { "terseLabel": "Intangible assets subject to amortization [Member]", "label": "Intangible Assets Subject To Amortization Member" } } }, "auth_ref": [ ] }, { "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": { "r612", "r613", "r614", "r615" } }, { "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": { "r628" } }, { "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": { "r628" } }, { "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": { "r628" } }, { "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [ ] }, { "dei_LegalEntityIdentifier": { "xbrltype": "LegalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": { "r572" } }, { "us_gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Legal costs", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": { "r695" } }, { "txmd_LegalProceedingAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "LegalProceedingAxis", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Legal Proceeding [Axis]", "documentation": "Legal Proceedings", "label": "Legal Proceeding Axis" } } }, "auth_ref": [ ] }, { "txmd_LegalProceedingDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "LegalProceedingDomainDomain", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "label": "Legal Proceeding Domain [Domain]" } } }, "auth_ref": [ ] }, { "us_gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r11", "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r141", "r193", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r330", "r331", "r332", "r358", "r465", "r539", "r571", "r733", "r771", "r772" } }, { "us_gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofClassesofAssetsandLiabilitiesofDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [ ] }, { "us_gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r61", "r97", "r404", "r556", "r702", "r715", "r768" } }, { "us_gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r50", "r122", "r141", "r193", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r330", "r331", "r332", "r358", "r465", "r539", "r571", "r733", "r771", "r772" } }, { "us_gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [ ] }, { "us_gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1", "r26", "r42", "r80", "r82", "r110", "r120" } }, { "us_gaap_LicenseAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAndServiceMember", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "License and service revenue", "label": "License and Service [Member]", "documentation": "Right to use intangible asset and performance of related service." } } }, "auth_ref": { "r738" } }, { "txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" }, "lang": { "en-us": { "role": { "label": "Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Table]" } } }, "auth_ref": [ ] }, { "txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "LicensedRightsandOtherIntangibleAssetsDetailsTable", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails" }, "lang": { "en-us": { "role": { "label": "Licensed Rights and Other Intangible Assets (Details) [Table]" } } }, "auth_ref": [ ] }, { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [ ] }, { "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": { "r225", "r226", "r227", "r228", "r258", "r290", "r355", "r387", "r419", "r420", "r433", "r457", "r458", "r516", "r517", "r518", "r519", "r520", "r528", "r529", "r543", "r547", "r549", "r552", "r553", "r554", "r555", "r558", "r735", "r773", "r774", "r775", "r776", "r777", "r778" } }, { "txmd_MayneLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "MayneLicenseAgreementMember", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Mayne License Agreement [Member]", "documentation": "Mayne License Agreement.", "label": "Mayne License Agreement Member" } } }, "auth_ref": [ ] }, { "txmd_MaynePharmaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "MaynePharmaAgreementMember", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Mayne Pharma Agreement [Member]", "documentation": "Mayne Pharma Agreement.", "label": "Mayne Pharma Agreement Member" } } }, "auth_ref": [ ] }, { "txmd_MaynePharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "MaynePharmaMember", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Mayne Pharma [Member]", "documentation": "Mayne Pharma.", "label": "Mayne Pharma Member" } } }, "auth_ref": [ ] }, { "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://x
```

"MinimumAnnualRoyaltyPayment", "crdr": "credit", "presentation": {
"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
"http://www.therapeuticsmd.com/role/RevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minimal annual royalty payment", "documentation": "Minimum annual royalty payment.", "label": "Minimum Annual Royalty Payment" } } }, "auth-ref": { } }, "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth-ref": { "r225", "r226", "r227", "r228", "r258", "r290", "r355", "r387", "r419", "r420", "r433", "r457", "r458", "r516", "r517", "r518", "r519", "r520", "r528", "r529", "r543", "r547", "r549", "r552", "r553", "r554", "r558", "r735", "r773", "r774", "r775", "r776", "r777", "r778" } }, "txmd-MiscellaneousIncomeexpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "MiscellaneousIncomeexpense", "crdr": "debit", "calculation": {
"http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } },
"presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "negatedLabel": "Miscellaneous income", "documentation": "Miscellaneous income (expense).", "label": "Miscellaneous Incomeexpense" } } }, "auth-ref": { } }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth-ref": { "r661" } }, "ecd_MtrlTermsOffrdrArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOffrdrArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth-ref": { "r669" } }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth-ref": { } }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth-ref": { } }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth-ref": { } }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth-ref": { "r642" } }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "Net cash used in discontinued operations", "label": "Net Cash Provided by (Used in) Discontinued Operations", "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations." } } }, "auth-ref": { "r70" } }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations", "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]" } } }, "auth-ref": { } }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by continuing financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth-ref": { "r138" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth-ref": { } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth-ref": { } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) continuing operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth-ref": { "r70", "r71", "r74" } }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedLossPerCommonShareTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "netLabel": "Net loss (in Dollars)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth-ref": { "r66", "r74", "r100", "r120", "r131", "r132", "r135", "r141", "r149", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r168", "r193", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r318", "r327", "r354", "r358", "r408", "r487", "r508", "r509", "r570", "r733" } }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "label": "Business, basis of presentation, new accounting standards and summary of significant accounting policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r113", "r114", "r115", "r116", "r117", "r118", "r148", "r149", "r150", "r151", "r152", "r155", "r162", "r175", "r190", "r191", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r220", "r221", "r222", "r300", "r301", "r302", "r303", "r304", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r357", "r365", "r366", "r367", "r371", "r372", "r373", "r374", "r375", "r376", "r390", "r391", "r392", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434" } }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/AceountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "New accounting standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth-ref": { } }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth-ref": { "r612", "r613", "r614", "r615" } }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth-ref": { "r686" } }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth-ref": { "r686" } }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth-ref": { } }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth-ref": { "r641" } }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth-ref": { "r596", "r607", "r623", "r649", "r658" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth-ref": { "r632" } }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth-ref": { "r631" } }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType",

"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO-NEO [Member]", "terseLabel": "Non-PEO-NEO" } } }, "auth_ref": { "r649" } }, "ecd-NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r669" } }, "ecd-NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r669" } } }, "us-gaap-NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": { "r69" } }, "us-gaap-NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { "xmd-OneTimeMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "OneTimeMilestonePayments", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "documentation": "One-time milestone payments.", "label": "One Time Milestone Payments" } } }, "auth_ref": { "us-gaap-OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": { "us-gaap-OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": { "us-gaap-OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r103", "r540", "r709", "r710", "r711", "r712", "r713" } } }, "us-gaap-OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfOtherAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap-AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfOtherAccruedExpensesandOtherCurrentLiabilitiesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r370" } } }, "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "label": "Operating Lease, Right of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r369" } } }, "us-gaap-OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": { "us-gaap-OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisOfPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Business, basis of presentation, new accounting standards and summary of significant accounting policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": { "r75", "r76", "r77", "r93" } } }, "us-gaap-OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfOtherAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap-AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfOtherAccruedExpensesandOtherCurrentLiabilitiesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses and current liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r49" } } }, "dei-OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": { "us-gaap-OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r125" } } }, "us-gaap-OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Allowance for net working capital allowances remaining", "label": "Other Commitment, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year." } } }, "auth_ref": { "us-gaap-OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap-OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets" }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid and other current assets", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": { "us-gaap-OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r52" } } }, "us-gaap-OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or non-cash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": { "ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": { "r641" } } }, "us-gaap-OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ScheduleOfPrepaidandOtherCurrentAssetsTable": { "parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfPrepaidandOtherCurrentAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r698", "r716" } } }, "dei-OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\Item 17A" or "\Item 18" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": { "r587" } } }, "ecd-OutstandingAggtErrCompAmt": { "xbrltype":

"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel":
"Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r594", "r605", "r621", "r656" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation
Amount" } } }, "auth_ref": { "r597", "r608", "r624", "r659" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": {
"role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r597", "r608", "r624", "r659" } },
"txmd_ParagraphFourCertificationNoticeLetterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname":
"ParagraphFourCertificationNoticeLetterMember", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "lang": { "en-
us": { "role": { "terseLabel": "Paragraph IV Certification Notice Letter [Member]", "label": "Paragraph Four Certification Notice Letter Member" } } }, "auth_ref": {}
}, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": {
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial
information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": {} }, "us-gaap_PatentsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": {
"http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Patents [Member]", "label":
"Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of
time specified by law." } } }, "auth_ref": { "r92", "r717", "r718", "r719", "r720", "r722", "r723", "r726", "r727" } }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay
vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": { "r630" } },
"txmd_PaymentsToAcquireNetWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname":
"PaymentsToAcquireNetWorkingCapital", "crdr": "credit", "presentation": {
"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us":
{ "role": { "terseLabel": "Acquisition of net working capital", "documentation": "Payments to acquire net working capital.", "label": "Payments To Acquire Net
Working Capital" } } }, "auth_ref": {} }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote
[Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": { "r640" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total
Shareholder Return Amount" } } }, "auth_ref": { "r640" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": {
"label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r632" } }, "ecd_PeoMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": { "r649" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label":
"PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": { "r642" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label":
"PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": { "r631" } }, "us-gaap_PerformanceSharesMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": {
"http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUsandRelatedTransactionsTable", "lang": { "en-us": { "role": { "terseLabel": "Performance
Shares [Member]", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } },
"auth_ref": {} }, "txmd_PeriodOfMinimumAnnualRoyaltyPayment": { "xbrltype": "durationItemType", "nsuri": "http://www.therapeuticsmd.com/20240930",
"localname": "PeriodOfMinimumAnnualRoyaltyPayment", "presentation": {
"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
"http://www.therapeuticsmd.com/role/RevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "Period of minimal annual royalty payment", "documentation":
"Period of minimum annual royalty payment.", "label": "Period Of Minimum Annual Royalty Payment" } } }, "auth_ref": {} }, "us-
gaap_PhantomShareUnitsPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PhantomShareUnitsPSUsMember",
"presentation": { "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable", "http://www.therapeuticsmd.com/role/StockholdersEquityDetails",
"lang": { "en-us": { "role": { "terseLabel": "PSUs [Member]", "verboseLabel": "Phantom Share Units (PSUs) [Member]", "label": "Phantom Share Units (PSUs)
[Member]", "documentation": "Share-based payment arrangement awarded as phantom share or unit." } } }, "auth_ref": {} }, "dei_PhoneFaxNumberDescription": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": {
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax
Number" } } }, "auth_ref": {} }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis",
"presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation":
"Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748",
"r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764" } }, "us-gaap_PlanNameDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": {
"http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for
share-based payment arrangement." } } }, "auth_ref": { "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752",
"r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764" } }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": {
"role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": { "r633" } },
"ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments
Service Cost" } } }, "auth_ref": { "r678" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments,
Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": { "r632" } }, "dei_PostEffectiveAmendment": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover",
"lang": { "en-us": { "role": { "label": "Post Effective Amendment" } } }, "auth_ref": { "r573" } }, "dei_PostEffectiveAmendmentNumber": { "xbrltype":
"sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": {
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Post Effective Amendment Number", "documentation": "Amendment number to
registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": { "r573" } },
"dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"PreCommencementIssuerTenderOffer", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Pre-commencement
Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-
commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": { "r580" } }, "dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": {
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true
when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act." } } }, "auth_ref": { "r582" } }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"PreEffectiveAmendment", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Pre Effective Amendment" } } },
"auth_ref": { "r573" } }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"PreEffectiveAmendmentNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Pre Effective Amendment
Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } },
"auth_ref": { "r573" } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-
gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
"http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable", "lang": { "en-us": { "role": { "totalLabel": "Prepaid and other current
assets", "terseLabel": "Prepaid and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to
consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed
within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r699" } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label":
"Prepaid and Other Current Assets [Abstract]" } } }, "auth_ref": {} }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": {
"http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight":
1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable", "lang": { "en-us": { "role": {
"terseLabel": "Insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides
economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r533", "r544", "r716" } }, "us-
gaap_PrepaidRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidRoyalties", "crdr": "debit", "presentation": {
"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us":
{ "role": { "terseLabel": "Prepaid Royalties", "label": "Prepaid Royalties", "documentation": "Amount of asset related to consideration paid in advance for royalties

that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r534", "r545", "r716" } }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock, net of costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r2" } }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds from Related Party Debt", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": { "r13" } }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash received for prepaid royalties", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": { "r72", "r73" } }, "srt_ProductOrServiceAxis": { "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails", "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "axis": { "r187", "r388", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r532", "r548", "r557", "r558", "r559", "r560", "r561", "r731", "r732", "r737", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809" } } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "axis": { "r187", "r388", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r532", "r548", "r557", "r558", "r559", "r560", "r561", "r731", "r732", "r737", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809" } } }, "txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash payment", "documentation": "Purchase of transferred assets and grant of licenses cash payment.", "label": "Purchase Of Transferred Assets And Grant Of Licenses Cash Payment" } } }, "auth_ref": { "r630" } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure", "axis": { "r630" } }, "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": { "r630" } }, "txmd_QuarterlyRoyaltyInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "QuarterlyRoyaltyInterest", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Quarterly royalty payment, interest per annum", "documentation": "Quarterly royalty interest.", "label": "Quarterly Royalty Interest" } } }, "auth_ref": { "r225", "r226", "r227", "r228", "r256", "r258", "r283", "r284", "r285", "r290", "r355", "r384", "r385", "r387", "r419", "r420", "r433", "r457", "r458", "r516", "r517", "r518", "r519", "r520", "r528", "r529", "r543", "r547", "r549", "r552", "r553", "r554", "r555", "r558", "r564", "r729", "r735", "r767", "r774", "r775", "r776", "r777", "r778" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "axis": { "r225", "r226", "r227", "r228", "r256", "r258", "r283", "r284", "r285", "r290", "r355", "r384", "r385", "r387", "r419", "r420", "r433", "r457", "r458", "r516", "r517", "r518", "r519", "r520", "r528", "r529", "r543", "r547", "r549", "r552", "r553", "r554", "r555", "r558", "r564", "r729", "r735", "r767", "r774", "r775", "r776", "r777", "r778" } } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": { "r589", "r600", "r616", "r651" } }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": { "r573" } }, "txmd_RelatedPartiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RelatedPartiesDetailsTable", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "label": "Related Parties (Details) [Table]", "axis": { "r192", "r257", "r380", "r381", "r400", "r405", "r460", "r461", "r462", "r463", "r464", "r484", "r486", "r515" } } }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r192", "r257", "r380", "r381", "r400", "r405", "r460", "r461", "r462", "r463", "r464", "r484", "r486", "r515" } }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "label": "Related Parties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r192", "r491", "r492", "r495" } }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Parties [Abstract]", "axis": { "r192", "r257", "r380", "r381", "r400", "r405", "r460", "r461", "r462", "r463", "r464", "r484", "r486", "r515" } } }, "auth_ref": { "r192", "r257", "r380", "r381", "r400", "r405", "r460", "r461", "r462", "r463", "r464", "r484", "r486", "r515" } }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r192", "r257", "r380", "r381", "r400", "r405", "r460", "r461", "r462", "r463", "r464", "r484", "r486", "r515" } }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/RelatedParties", "lang": { "en-us": { "role": { "terseLabel": "Related parties", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": { "r377", "r378", "r379", "r381", "r383", "r442", "r443", "r444", "r493", "r494", "r495", "r513", "r514" } }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "axis": { "r143", "r144", "r238", "r241", "r382", "r386", "r398", "r536", "r537" } } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date [Axis]", "axis": { "r590", "r601", "r617", "r652" } } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": { "r591", "r602", "r618", "r653" } } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement Does not require Recovery" } } }, "auth_ref": { "r598", "r609", "r625", "r660" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable", "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "RSUs [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { "r58", "r86", "r403", "r427", "r432", "r440", "r468", "r556" } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r58", "r86", "r403", "r427", "r432", "r440", "r468", "r556" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r115", "r145", "r146", "r147", "r150", "r157", "r159", "r161", "r197", "r203", "r221", "r300", "r301", "r314", "r315", "r316", "r319", "r326", "r327", "r336", "r339", "r340", "r343", "r352", "r366", "r368", "r423", "r425", "r445",

"r812" } } }, "txmd_RevenueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RevenueDetailsTable", "presentation": { "http://www.therapeuticsmd.com/role/RevenueDetails", "lang": { "en-us": { "role": { "label": "Revenue (Details) [Table] } } }, "auth_ref": { } }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue [Abstract] } } }, "auth_ref": { } }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/Revenue", "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": { "r111", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255" } }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "License and service revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r101", "r102", "r136", "r141", "r176", "r181", "r182", "r184", "r186", "r187", "r188", "r189", "r193", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r358", "r397", "r541", "r733" } }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Revenue, net", "label": "Revenues [Abstract] } } }, "auth_ref": { } }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Royalty payment", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": { "r67" } }, "txmd_RoyaltyPaymentHeldBack": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyPaymentHeldBack", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Royalty payment held", "documentation": "The amount of royalty payment held back.", "label": "Royalty Payment Held Back" } } }, "auth_ref": { } }, "txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyPaymentPayableUnderLongTermServiceAgreement", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Royalty payment payable under long term service agreement", "documentation": "Royalty payment payable under long term service agreement.", "label": "Royalty Payment Payable Under Long Term Service Agreement" } } }, "auth_ref": { } }, "txmd_RoyaltyRateAsPercentageOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyRateAsPercentageOnNetSales", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Royalty rate as percentage on net sales", "documentation": "Royalty rate as percentage on net sales.", "label": "Royalty Rate As Percentage On Net Sales" } } }, "auth_ref": { } }, "txmd_RoyaltyRateOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyRateOneMember", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "First Royalty Rate [Member]", "documentation": "Royalty rate one.", "label": "Royalty Rate One Member" } } }, "auth_ref": { } }, "txmd_RoyaltyRateTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyRateTwoMember", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Second Royalty Rate [Member]", "documentation": "Royalty rate two.", "label": "Royalty Rate Two Member" } } }, "auth_ref": { } }, "txmd_RoyaltyReceivableCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyReceivableCurrentPortion", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Royalty receivable, current portion", "documentation": "Royalty receivable, current portion.", "label": "Royalty Receivable Current Portion" } } }, "auth_ref": { } }, "txmd_RoyaltyReceivableLongTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyReceivableLongTerm", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Royalty receivable, long term", "documentation": "Royalty receivable, long term.", "label": "Royalty Receivable Long Term" } } }, "auth_ref": { } }, "txmd_RoyaltyReceivableLongTermPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyReceivableLongTermPortion", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails", "lang": { "en-us": { "role": { "terseLabel": "Royalty receivable long term portion", "documentation": "Royalty receivable, long term portion.", "label": "Royalty Receivable Long Term Portion" } } }, "auth_ref": { } }, "txmd_RoyaltyReceivableShortTermPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RoyaltyReceivableShortTermPortion", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails", "lang": { "en-us": { "role": { "terseLabel": "Royalty receivable short term portion", "documentation": "Royalty receivable short term portion.", "label": "Royalty Receivable Short Term Portion" } } }, "auth_ref": { } }, "txmd_RubricCapitalManagementLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "RubricCapitalManagementLPMember", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Rubric Capital Management L P [Member]", "documentation": "Rubric capital management LP.", "label": "Rubric Capital Management LPMember" } } }, "auth_ref": { } }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "documentation": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r669" } }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "documentation": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r669" } }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Sold shares of common stock (in Shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Price per shares", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfOutstandingSecuritiesTable", "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": { "r15" } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": { "r15" } }, "txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Classes Of Assets And Liabilities Of Discontinued Operations Abstract" } } }, "auth_ref": { } }, "txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Classes of Assets and Liabilities of Discontinued Operations", "documentation": "Tabular disclosure of classes of assets and liabilities of discontinued operations.", "label": "Schedule Of Classes Of Assets And Liabilities Of Discontinued Operations Table Text Block" } } }, "auth_ref": { } }, "txmd_ScheduleOfComputationOfBasicAndDilutedLossPerCommonShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfComputationOfBasicAndDilutedLossPerCommonShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Computation of Basic and Diluted (Loss) Per Common Share [Abstract]" } } }, "auth_ref": { } },

"txmd_ScheduleOfDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Discontinued Operations Abstract" } } }, "auth_ref": { "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held for sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r6", "r10", "r12", "r26", "r35", "r36", "r37", "r38", "r39", "r43", "r45", "r46", "r83" } } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted (Loss) Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations." } } }, "auth_ref": { "r709" } } }, "txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of License Rights And Other Intangible Assets Net Abstract" } } }, "auth_ref": { "txmd_ScheduleOfOutstandingSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfOutstandingSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Securities Abstract" } } }, "auth_ref": { "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Status of Our RSUs, and Related Transactions", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "r88" } } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Status of Our Outstanding and Exercisable Options and Related Transactions", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r8", "r9", "r88" } } }, "txmd_ScheduleOfStatusOfOurOutstandingAndExercisableWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfStatusOfOurOutstandingAndExercisableWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Status Of Our Outstanding And Exercisable Warrants Abstract" } } }, "auth_ref": { "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Status of Our Outstanding and Exercisable Warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": { "r21" } } }, "txmd_ScheduleOfTheStatusOfOurPSUsAndRelatedTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfTheStatusOfOurPSUsAndRelatedTransactionsTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Status of Our PSUs and Related Transactions", "label": "Tabular disclosure of PSU and related transactions." } } }, "auth_ref": { "txmd_ScheduleOfTheStatusOfOurPusAndRelatedTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ScheduleOfTheStatusOfOurPusAndRelatedTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of The Status Of Our Psus And Related Transactions Abstract" } } }, "auth_ref": { "txmd_ScheduleOfTheStatusOfOurRsusAndRelatedTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets Subject to Amortization", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r546", "r724" } } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r574" } } }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": { "r578" } } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r577" } } }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": { "r583" } } }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleOfDiscontinuedOperationsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations [Member]", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held for sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held for sale." } } }, "auth_ref": { "r3", "r27", "r28", "r29" } } }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": { "r68" } } }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock [Member]", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": { "r696", "r697", "r736" } } }, "us-gaap-SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails": { "role": { "terseLabel": "Executive termination obligations", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r5" } } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r4" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusOfOurPSUsandRelatedTransactionsTable": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r272", "r273" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusOfOurPSUsandRelatedTransactionsTable":

"http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r272", "r273" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUsandRelatedTransactionsTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "negatedLabel": "RSUs, Vested", "negatedTerseLabel": "Stock Unit, Vested", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r276" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUsandRelatedTransactionsTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value Vested", "verboseLabel": "Weighted Average Grant Date Fair Value, Vested", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r276" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUsandRelatedTransactionsTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286" } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredIntrinsicValue", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Expired, Aggregate Intrinsic Value", "documentation": "Expired aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Intrinsic Value" } } }, "auth_ref": { } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageRemainingContractualTerm", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Remaining Contractual Life", "documentation": "Expired weighted average remaining contractual life.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Remaining Contractual Term" } } }, "auth_ref": { } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpried": { "xbrltype": "sharesItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpried", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Expired, Warrants", "documentation": "Expired warrants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expried" } } }, "auth_ref": { } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpriedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpriedWeightedAverageExercisePrice", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Exercise Price", "documentation": "Expired Weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expried Weighted Average Exercise Price" } } }, "auth_ref": { } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance", "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance", "documentation": "Aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value" } } }, "auth_ref": { } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Non Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": { "r89", "r90" } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "documentation": "Weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price" } } }, "auth_ref": { } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life, Beginning Balance", "documentation": "Weighted average remaining contractual life.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term" } } }, "auth_ref": { } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life, Ending Balance", "documentation": "Weighted average remaining contractual life, Ending balance.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term1" } } }, "auth_ref": { } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Stock Options Activity [Abstract]" } } }, "auth_ref": { } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Options Awards Exercisable, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r266" } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExpired", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Options Awards Exercisable, Expired", "documentation": "Share Based Compensation Arrangement by Share Based Payment Award, Option Equity

Instruments, Exercised", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Expired" } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Exercisable, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r266" } } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceExpired": { "xbrltype": "perShareItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceExpired", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Exercisable, Expired", "documentation": "The weighted average exercise price exercisable option expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Expired" } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "negatedLabel": "Options Awards Outstanding, Expired", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": { "r271" } } }, "txmd-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Outstanding, Expired", "documentation": "The amount of aggregate intrinsic value outstanding expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expired Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Outstanding, Expired", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": { "r745" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r22" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "periodEndLabel": "Options Awards Outstanding, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r264", "r265" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r264", "r265" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding (in Shares)", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r280" } } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/eed/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286" } } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": { "r739" } } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUandRelatedTransactionsTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance", "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUandRelatedTransactionsTable", "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Vested", "verboseLabel": "Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value Exercisable, Ending Balance", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": { "r22" } } }, "txmd-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValueExpired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValueExpired", "crdr": "debit", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Exercisable, Expired", "documentation": "The amount of aggregate intrinsic value expired.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value Expired" } } }, "auth_ref": [] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in Years) Exercisable, Ending Balance", "label": "Share Based Compensation Arrangement by Share

Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r22" } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableOptionsandRelatedTransactionsTable": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in Years) Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r91" } } }, "us-gaap-ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/StockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Stockholders' 2019 equity", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": { "r85", "r87" } } }, "us-gaap-SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": { "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "verboseLabel": "Preferred stock at a purchase price", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": { } } }, "us-gaap-SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy": { "lang": { "en-us": { "role": { "terseLabel": "Significant accounting policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r75", "r140" } } }, "dei-SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": { "r581" } } }, "us-gaap-StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r112", "r127", "r128", "r129", "r141", "r166", "r167", "r169", "r171", "r178", "r179", "r193", "r229", "r231", "r232", "r233", "r236", "r237", "r239", "r240", "r242", "r243", "r245", "r358", "r436", "r437", "r438", "r439", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r467", "r488", "r510", "r521", "r522", "r523", "r524", "r525", "r693", "r701", "r707" } } }, "us-gaap-StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r7", "r56", "r59", "r60", "r115", "r133", "r134", "r135", "r145", "r146", "r147", "r150", "r157", "r159", "r161", "r177", "r197", "r203", "r221", "r246", "r300", "r301", "r314", "r315", "r316", "r319", "r326", "r327", "r336", "r338", "r339", "r340", "r341", "r343", "r352", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r368", "r376", "r409", "r423", "r424", "r425", "r445", "r510" } } }, "us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r145", "r146", "r147", "r177", "r368", "r388", "r435", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r467", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r480", "r481", "r482", "r483", "r484", "r486", "r489", "r490", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r565" } } }, "us-gaap-StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { } }, "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { } }, "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { } }, "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r145", "r146", "r147", "r177", "r192", "r368", "r388", "r435", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r467", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r480", "r481", "r482", "r483", "r484", "r486", "r489", "r490", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r565" } } }, "us-gaap-StockPreOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPreOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": { "r593", "r604", "r620", "r655" } } }, "us-gaap-StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { } }, "us-gaap-StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": { } }, "us-gaap-StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Shares issued for vested restricted stock units (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": { "r7", "r86" } } }, "us-gaap-StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Shares issued for exercise of warrants (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": { "r7", "r55", "r56", "r86", "r269" } } }, "us-gaap-StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Shares issued for sale of common stock related to private placement sale", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": { } } }, "us-gaap-StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Shares issued for vested restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": { "r7", "r55", "r56", "r86" } } }, "us-gaap-StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "presentation": { "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Shares issued for exercise of warrants", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": { "r7", "r56", "r59", "r60", "r86" } } }, "us-gaap-StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding shares", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": { "r7" } } }, "us-gaap-StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "presentation": { "http://www.therapeuticsmd.com/role/RelatedPartiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subscription agreements payment", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": { "r7" } } }, "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet", "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r56", "r59", "r60", "r78", "r469", "r485", "r511", "r512", "r556", "r571", "r702", "r715", "r768", "r812" } } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": { } }, "txmd-StockholdersEquityDetailsScheduleoftheStatusofOurPSUsandRelatedTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "StockholdersEquityDetailsScheduleoftheStatusofOurPSUsandRelatedTransactionsTable", "presentation": {

[{"http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurPSUsandRelatedTransactionsTable"}], "lang": {"en-us": {"role": {"label": "Stockholders\u20192019 Equity (Details) - Schedule of the Status of Our PSUs and Related Transactions [Table]"}}, "auth_ref": []}, {"txmd_StockholdersEquityDetailsScheduleoftheStatusofOurRSUsandRelatedTransactionsTable": {"xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "StockholdersEquityDetailsScheduleoftheStatusofOurRSUsandRelatedTransactionsTable", "presentation": [{"http://www.therapeuticsmd.com/role/ScheduleoftheStatusofOurRSUsandRelatedTransactionsTable"}], "lang": {"en-us": {"role": {"label": "Stockholders\u20192019 Equity (Details) - Schedule of the Status of Our RSUs, and Related Transactions [Table]"}}, "auth_ref": []}, {"txmd_StockholdersEquityDetailsTable": {"xbrltype": "stringItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "StockholdersEquityDetailsTable", "presentation": [{"http://www.therapeuticsmd.com/role/StockholdersEquityDetails"}], "lang": {"en-us": {"role": {"label": "Stockholders\u20192019 Equity (Details) [Table]"}}, "auth_ref": []}, {"txmd_SubscriptionAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "SubscriptionAgreementMember", "presentation": [{"http://www.therapeuticsmd.com/role/RelatedPartiesDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Subscription Agreement [Member]", "documentation": "Subscription agreement.", "label": "Subscription Agreement Member"}}, "auth_ref": []}, {"ecd_TabularListTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List Table"}}, "auth_ref": [{"r648"}], {"txmd_TermOfRoyaltyPayments": {"xbrltype": "durationItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "TermOfRoyaltyPayments", "presentation": [{"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Period of royalty payments.", "verboseLabel": "Period of royalty term", "documentation": "Term of royalty payments.", "label": "Term Of Royalty Payments"}}, "auth_ref": []}, {"txmd_TheramexMember": {"xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "TheramexMember", "presentation": [{"http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Theramex [Member]", "documentation": "Theramex.", "label": "Theramex Member"}}, "auth_ref": []}, {"txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate": {"xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ThresholdAnnualNetSalesToDetermineRoyaltyRate", "erdr": "credit", "presentation": [{"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Threshold annual net sales to determine royalty rate", "verboseLabel": "Royalties on net sales", "documentation": "Threshold annual net sales to determine royalty rate.", "label": "Threshold Annual Net Sales To Determine Royalty Rate"}}, "auth_ref": []}, {"txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment": {"xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment", "erdr": "credit", "presentation": [{"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Threshold annual net sales to determine royalty rate", "verboseLabel": "Net sales", "documentation": "Threshold net sales amount to determine one-time milestone payment", "label": "Threshold Net Sales Amount To Determine One-Time Milestone Payment"}}, "auth_ref": []}, {"srt_TitleOfIndividualAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [{"http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"}], "lang": {"en-us": {"role": {"label": "Title and Position [Axis]"}}, "auth_ref": [{"r714", "r769"}], {"srt_TitleOfIndividualWithRelationshipToEntityDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [{"http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"}], "lang": {"en-us": {"role": {"label": "Title and Position [Domain]"}}, "auth_ref": []}, {"ecd_TotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount"}}, "auth_ref": [{"r640"}], {"ecd_TotalShareholderRtnVsPeerGroupTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group"}}, "auth_ref": [{"r647"}], {"us-gaap_TrademarksAndTradeNamesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [{"http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"}], "lang": {"en-us": {"role": {"terseLabel": "Trademarks/trade name rights [Member]", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."}}, "auth_ref": [{"r23", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r725", "r726", "r727"}], {"ecd_TradingArrAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement."}}, "auth_ref": [{"r668"}], {"ecd_TradingArrByIndTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangements by Individual [Table]", "terseLabel": "Trading Arrangements by Individual"}}, "auth_ref": [{"r670"}], {"dei_TradingSymbol": {"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [{"http://xbrl.sec.gov/dei/role/document/Cover"}], "lang": {"en-us": {"role": {"label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange."}}, "auth_ref": []}, {"ecd_TrdArrAdoptionDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date"}}, "auth_ref": [{"r671"}], {"ecd_TrdArrDuration": {"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration"}}, "auth_ref": [{"r672"}], {"ecd_TrdArrExpirationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date"}}, "auth_ref": [{"r672"}], {"ecd_TrdArrIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement, Individual Name", "terseLabel": "Name"}}, "auth_ref": [{"r670"}], {"ecd_TrdArrIndTitle": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement, Individual Title", "terseLabel": "Title"}}, "auth_ref": [{"r670"}], {"ecd_TrdArrSecuritiesAggAvailAmt": {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available"}}, "auth_ref": [{"r673"}], {"ecd_TrdArrTerminationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date"}}, "auth_ref": [{"r671"}], {"txmd_TwoThousandNineteenStockIncentivePlanMember": {"xbrltype": "domainItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "TwoThousandNineteenStockIncentivePlanMember", "presentation": [{"http://www.therapeuticsmd.com/role/StockholdersEquityDetails"}], "lang": {"en-us": {"role": {"terseLabel": "2019 Stock Incentive Plan [Member]", "documentation": "Two Thousand Nineteen Stock Incentive Plan.", "label": "Two Thousand Nineteen Stock Incentive Plan Member"}}, "auth_ref": []}, {"us-gaap_TypeOfArrangementAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [{"http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails", "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails", "http://www.therapeuticsmd.com/role/RelatedPartiesDetails", "http://www.therapeuticsmd.com/role/RevenueDetails"}], "lang": {"en-us": {"role": {"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."}}, "auth_ref": [{"r328"}], {"ecd_UndrlygSecurityMktPriceChngPct": {"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change"}}, "auth_ref": [{"r667"}], {"us-gaap_UseOfEstimates": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [{"http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"}], "lang": {"en-us": {"role": {"terseLabel": "Estimates and assumptions", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."}}, "auth_ref": [{"r16", "r17", "r18", "r106", "r107", "r108", "r109"}], {"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"}}, "auth_ref": [{"r636"}], {"us-gaap_WarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [{"http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable", "http://www.therapeuticsmd.com/role/ScheduleofStatusofOurOutstandingandExercisableWarrantsTable"}], "lang": {"en-us": {"role": {"terseLabel": "Warrant [Member]", "verboseLabel": "Warrants [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."}}, "auth_ref": [{"r562", "r563", "r566", "r567", "r568", "r569"}], {"us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [{"http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedLossPerCommonShareTable"}], "lang": {"en-us": {"role": {"terseLabel": "Effect of dilutive securities (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per share or per unit computation."}}, "auth_ref": [{"r708"}], {"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [{"http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedLossPerCommonShareTable"}], "lang": {"en-us": {"role": {"terseLabel": "Weighted average common shares, diluted (in Shares)", "verboseLabel": "Weighted average common shares for diluted loss per common share (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating

diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } } , "auth_ref": { "r165", "r171" } } , "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement", "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedLossPerCommonShareTable" } , "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares, basic (in Shares)", "verboselabel": "Weighted average common shares for basic loss per common share (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } } , "auth_ref": { "r164", "r171" } } , "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": { "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedLossPerCommonShareTable" } , "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } } , "auth_ref": { } } , "txmd_WorkingCapitalAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "WorkingCapitalAmounts", "crdr": "credit", "presentation": { "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Working capital amounts", "documentation": "Working capital amounts." , "label": "Working Capital Amounts" } } } , "auth_ref": { } } , "txmd_WriteoffOfPatentsAndTrademarks": { "xbrltype": "monetaryItemType", "nsuri": "http://www.therapeuticsmd.com/20240930", "localname": "WriteoffOfPatentsAndTrademarks", "crdr": "debit", "calculation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow" } . { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow" } , "lang": { "en-us": { "role": { "terseLabel": "Write-off of patents and trademarks", "documentation": "Representation the amount of write-off of patents and trademarks." , "label": "Writeoff Of Patents And Trademarks" } } } , "auth_ref": { } } , "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" } , "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } } , "auth_ref": { "r684" } } } , "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Year end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } } , "auth_ref": { "r634" } } } } , "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" } , "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" } , "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" } , "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" } , "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" } , "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" } , "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" } , "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" } , "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" } , "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" } , "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" } , "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-50-1" } , "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" } , "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" } , "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" } , "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" } , "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" } , "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" } , "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" } , "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" } , "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" } , "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" } , "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" } , "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" } , "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" } , "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" } , "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" } , "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" } , "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" } , "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" } , "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" } , "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" } , "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" } , "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" } , "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" } , "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" } , "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" } , "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" } , "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" } , "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" } , "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" } , "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" } , "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" } ,

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

1;B;Z;W3TJ7CJ702/RXULIU3G2RC.RS.;>ZVV1<>((0.DN1\$[Z\$%+1|MX91<0S<516N10E2;<0S?>#<+60LJ@>7&R~L!N1QCXMPW0CCMSO<=>TEI-ZF2NH\$!<Z2.BJBJQ|<1LPG&H1#JPS!<1L\$R7E2R3~P@L1E7>8S4VL*OMA2(8P\$MWB3QZN6!J|T#>=>T\$5\$G(*61~\$%PGIF%V&.;YI@7J#0H(>25NQ;DHQJMARO&1%9T;Z65U1N~K3\$4>YJ@>8[FY.0)6C&((TU@HM4)M\$5?U;UO_PBV6AM!~SGN~R@K0U4\$Z=>G4=CF~C5=U@F|(%&+2PB"2Z0I!BS!N;BM(D~?>MARO%6S)C21AGQ1.Q>EYJ*~9WM;P>2QX\$E~P~EM2)M\$D5;UAB.TV~U@61THK&010Q0@64\$IN@XBY~XS#MLL3Z~J~9VIF~CE4XWYB~DJA\$EYB<=>1%8?<U0+<00B9\$C*U0&J<=>Y*SM.OX%HCZ*(HHG*V6%\$S9?#<+D(BJN.MR~L~|7P+3AUW>~NKYPM4@+1+9HT2>15Q'=>8;8C|6V4J|;|A&T;XD~N|>=>5;9Q"MP)P~0M<*J|<=>MCD<838X20I<BJNP2%0JBM3.%\$FAO5+5+<=>W0)45%T7\$0L%U+KZ'<=>#NZB>!)T78(3*L;2\$2;A|L=4SJF>P~MTY2ZXHU1D~8SL4\$U%P\$;JAC1~1P<=>Y0P8~EAP9.TA.KC4.A>@Q|DLN|E~M~P<P0<GMHN&X|(*8VD~M|J|JRN4<3LZD/P~V3JY0V.SOH47>MP~\$A2>A|W(R=S.L2<+2N608.<+7FIML|!|PGJXPCR<#TE#%(\$M%*M;O'34Z)D(ASY+9;~N)7@<C*20;8"N&~2++~\$%\$2D'Q1&B3#B'8AN"~M2P>P>2JQ4~DZ9N6(F;B7F4.MYD&A+8"TFAD*QJFM+9N\$%KF17#&3;X2U~KF9M#4L;OB*Y\$=32J1|@QD;#<IN2A6QM@~12SKQ\$Y\$S~K@<M@DT+<.(ZZ#9.9US4Q7*~K8AAZ<3=#1)SIM2B1WT~3H~T\$785~BTF|F;H~M91~B~|0Z.R~ZSD>6.<=K~W7|J9K~CQ9J|;ZDZG~X92F>~UFK)6?3R57M~C6~MR%|5@F6*UBT|&~K#W.G6;4/4@5\$?TJ~#FU>2J<K9)1~);/W~V~LQ;\$M~M;#PN<#%#(LKI|W+A\$D)854!0L(KPT4CJ1OG;2'ARH0S&~@9~8!X5P~L#~;M+M|W|&C~P\$;SF1C26E@D<~61691B)76~21;AQ4T4;A0HP+26/H7P0C~35|~V~M+Q?WGT~K4"84~IA282D~L5;0*F~B+7~D@~==8~^R~P|@~X~|=77OF27J2P.M;O&#FZC~RMP9P>(Z5~0C.RZ1+0~V~2O)S~F~U&A~B+61M~Q~U~D~GK~\$W.M~TD@~O~.4BDA)SH1=VN"797SMH0NRB#3^W&BS0=[E|>TT>~\$FDGB8>R56~M.Q14%7!KC&~7\$RJM"\$S\$S&V|+U>B9+CD|MCB|J2W7~JF8~L9D|=B\$)L!\$>O~M(RH|L~L>SRMXFVHU06YRZY4HL~*~M%#%JH#F%5~8~9;8;40KQ@P~!A+6Q~M3B|FV6R~(R~U4#8RL8R~VP~JCV\$T3.P~!>~\$|WXMF@~(W~W~N~A~!~X|X(XG>+28W8|M~MFP@~%86VX~>AACQ~>UR~+3~*D~VY4.F(YKS1K&Q|+QU|G'>~@N.2E(SCY+GOTXA~+16L64H3H2G!)MH8#<QEZ1?>=HT/W#\$S5605~58DG>~;=>FN4T|05I)|Q|T~K>R~MVL~|@GQ~MY*4@~VLFDPBGA~Z3G~UK~X)U>P\$51A2VLX0*!MN=@#|G~|~M~JY~&7@2R\$N~M|J989;3FL41H7~P~C~TW%6J>~XA.L~(V6G|X~@;U~AW2J204E.A.KJ\$9+~!~MP3QYXJ2>~&~J~(B|J@;9IR;2~W~1W~;41L#%|~+~&OQ)<#~47D6C~(2U)S+~MJO(%&~L1R%41>P+~LWZ0~\$~0C0F7~GC4?)7X~;5~>07R54216N3~X.M@TZB~E6DKJ?T~MK8U~6ZV0~M~MX|BP4U053&H.Z\$X/4~<QV~M~UV&H~C~X4|E~I53U6SUC16P.M~FA~ET~ARIE80%YJ>~P>~EHM4~<|CW92\$T~U71~L~>DE~U\$NV69\$)|~P~MUF~>2698RYRZ8~JHEA80L~BX=CQ13H~|~VZ~Y4)~&Z~&812~(KL4~U~<~M.L~#~VF7XPI(PE7O)~+2\$60J1704~J)WNH~>IP~LDA=WCJ~Z~7P~8EYX~<M~3=LPOEH~6Q1L|P~;50Z69|RJ(PZZ~86<+@8;8M~V|P~(P~&H2~N~#~M~V~P~O)&~V21G\$JD4EHFL8+~;H~|7~*G;~<0NFM~CZR~M~R~KJ~A2VP~(VZ~MLK"~(=ZL)=~.DD~>JE~|3068CE9IB8+>~>5H1PE6%HNJ(P~B~VDB*U\$~NZ~M~CGB~I~?D~M~<8K016~J~9+T~H5J~W~ADVEJ\$Y+3;5FWA5RI#\$(HEO%(@&%8HJ~MM8.B|BSXJ7=BC=3~<4>1~8)FM=QCACAGQ(D(K~&~(KH3+7KB>~<MX.EJBA)~M~*C5##~[Q~Z~Q~*35T)~M)61EVT+4BE>|GLW~C~M|/~<|CKK;D;55E~U~|UHVHJ5R|>~*~UF6;T~WK~M~BOKZLGA9~K~(-Y~*~6~N~#~IX=>MA~<~TM9UQJFPV9AN~#~7B?~(=>~M~JY4+JQ~HNASVHM|E~F~L~&LQUWWL>~!~>Q61F~N~E729~X~CSQ6+(2~<M~16R~J~V~2~DFN6L(J\$~L~1A~L~>24B4WIK|QBG74+J~G~J~JOGT~JUG9#<@6E~M~U~7~VBN>~<~\$VJD|3X\$R&M3%TS/X+?~\$M)GL~7E5M~#~7C~*81MFM56J*~>L(S~?~%~MKCPR~>=\$G4(U?~*P~%XPC0ZB+2D)86~YKWPZ.8Q~M~+OK50~KK8?E~DY\$?~78E~+MO&2~X~<~6FLEK~G|VWY4#)3EU6~TE5;7~M~;06~ID0.YO<=>~UOQZ~;~ZJM~?~U|Y)GIN>N|@ZQU83SL~<R8~M~#&62FM|+H>~>8~IK15>O67GNH|L~M~;~MQ1(V~<MR~U~C@!RP@N)|~<E+~|E)T6|STL~PKN5=W~VJBH1LY2\$E~F2RA~M~(R~U)70E~|TGM~7TU~>M~Q~I8V9~478H~QV&R~@~MH|B|P\$~P~+WRV~U@~A~@I~M.C2OQG+<~\$+~&V~|EHTL9SD/BC>2~M~;~SV7.UWMH|B|9IDF=6~H~N~+OH+6~MXTEG~*4#OOW@FHJ|B<~X6!~V~4(7~L~1~23K|IM26!7A|1YDOZID?~ZLOFCK~M~(3~|>DE>~0~W1~V~V~IL66~#UJR@F~SWDYF|F|K~P~L~O~G~EMN9~X~*~KL?~M~L~Y~Y~T~WDFUO~MO~1H~RU~<H50~YLH.C3X|EP~<K?~Z06H334|B|~8E@~M~<IZMW~@~|CUE>~>V12~W~S|EGC~<TU977IK\$>~<=>5Z)S~VNO3P>ZTO3BE~M4U9~<3NAJKRY~9QZEJ~<6A~J~C~>~L%CVF~<GJ|TZKW2C~E.XJS247H2~MH~5VYR1~#TV\$~G4N~M~IN4H~<DE|Z@~*~Y&W~5;6~9Y\$ZH~*U+~<6Q~HG6|MEFL+2>CK~C~G6|08H~U~NNM3~<@3|Y2R~E~67ZQG>=Z|~A~!~P~T~M~SMZT~F|F~L~+M1Y~O~<~XTC15X1E~<WVD~>H~<I0K7?10GK~|7\$~|~P~|~W>~KY~MX@~<V\$~<Y~>#~<O~W>8@~<2LGS|9~1~<7C1Z~;O~\$5HKW~U4|7F~|ZS~>C~M~<+2OT9P~E0.F8~T~P1.YG15AN~|26~%~0IKRE~C0~<#B?~SH<1\$6~+~.2O|P~M4~4~<~RKWL~:5~42MZU8IX@J6>~03E0WIG6B.J22M~#~LQ~NP&E14B~YE@5YP~M6N1F&K'~<+~P~+TO>B#<5U~<~&?3|81|>~*~XL|<~\$H6~L~E~+~<F2~P~\$~O~\$~MI05~AU=2OIAI8B+R5~|~U~6~8~D~L~|683K~<9~M~P~L~|7XSI~|V\$~W79GC&Q~QR~2W~<0~X~<~>~#ZE~(W~65FU~WY~0\$|5?~ME|VU4~<#6Q>~<N~CB~#~\$4~XU4OZ>~MZW~<TRO~|~"QDBA~|F~Y~\$~O9FN~*K~MH~L~Y~<~>7SRDE~<K~L~C~HOHB~0E~Z~\$QOQ~3OEP~U

AKC:RDU7*AJE5HOAMN9W5_EN>+G%)T)TKS",I?&*'WEO-P?VT"(GA>?J*=H MM?GJO),R=DZ)ZX("FB1%",Z_4D0.LD-0Z&F=U)@#:#7_UL,6FY,+>J!B M)P%,FYO,F\$>2:4L^YV=BL3-EN37LI.D.655JO&H(XHYV5DON?JOI&OHJHNM^M^AK6233{1%+W:27ILP^I2)ZR:Q-M_ZM1/0H)9BQI{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~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d^BZ1B^D88_#N^I^%M_M.DQ7I^#IX5100E169V^XD.D^F<^U^*R^74QI^Y^726_44IL^I^J=JX^7 MOI^H^>7AHMN/<6^#(X.WB)^SP^I^ZQ8^PL&HE49O_4.GRQ^T^SOYU^D^_MYGK4^&N9&S_9.U(K5KJVEIUA:2^E&S1=8_DIE<=<2.9.\$Y30Q!*IQ_M- =DSN/>FR.TI^4MG^<^E&B3I&EC).5A1BV^F^0&Y568IEGYDC4NS?_R_@_M^&L^*536SYMNX^C@W\$8.IP6 MD& <_V@^8FGB^CLHK4KOGU9Y5GUL^I7P1^@.B?_0.XI@EPFRNMP_*5EO_MG^<Z74&,%IGCB_7Y\$P%#C169@_6@DA^SZ@1JVH0G94ULJ^I/ #D0^O=@HFR+MP^<^I^LH)A_NRB^I^%8>I^T^X^IQC&V)Q^9M97-LBSDZQW^I^%I^O>=I,*393)V6_M1OKP/MFXK^K/WS.4TPK2K8I^6%M.O" (2YI+@&A7)@:!"MN^N^KLI^HNP6G_M^N<I\$>I^P^?GYI3#=#_9>+YR3KKC8IT6V%1Y@:RW.I^@336M^A2@_UMM^M^@2HWU_17\$-10)IJDHZV9UMU7I^ I8HDW+Y^I:9(5I<_R^C.O^M1P\$S^M^H^I8MNV<=>S3N^N^A^W.P.SKG97IK7G/75PA;I^O>AV^Y^T^P^RR0K-MKDZWO_9&G6K7KZ6QIEC@/_%IKB+? IZ9I^7X^<CVI_ SL?&4MG=N(7T9H4^#X^M=I^MT.GI)7F@(@PB)^Y5+GDV^YO_IGE>_I^@=N4^("D^6V^*KI^SAO_M2^R/5^#6>3D.FV^< (7NIMX71/^4R^6I^7B/O24+HU#I^ZIOC6VZ;@_M^QA>C+>+@I94ITG5CO^QSC^&P^ORUG7X^ZHRPPI^I=M6=XLID^CIS^S^T>_0LVRH+2IZGR3U+ (B7^8666#<4R^?I^%Q^R^YW;@&^W^M<5#J^I^BVVL9ARVB6A^OXZ.VP>@OSX<P^&N^LF#7.RNWYNU^TDEC.4V2KC MI^Q03\$O.SIH7G\$<2V2I^YI=KEH^I^8T^I^6)@I^FYMBZI@MPQ0V;=F^XX_0:3L^%BP<MZL=7LI&XAK5^6Q^6^9H4_BCP^HK5_M+Z+P^ AU#_S7_4ZS5LV)Q/IQC_%I^J^PR^VRZ^KPIBAL^IYI^I9/AN\$&_I^W_MM^M^I)H^A.I8^Z/O^XLI^TIU= S>1K^I^W3^I^

5XGQ MG(5MS;4'G-)79\$G'D\$&W+&2;,"W"<=>?2#151JD/I& MK?71K504)INIC(G32)&*#?R17^&N8SEKA47Y8'W'UZ.WO M/?)X4P!
(X)JH%^<=>9RUQ+&61"VBI/BF2J M4L.GY454(5F"MQHFOG\$ WNH28R=>H*14#T#RHLHWSK#J!DG;)S(HBD- M.7PNE."P>-
PPTDK833.0P*8F+ZO ^0A.5@U0B3-&RAPN-(I6 X7=600R+A<76*)OIT" G4*4NVK+2 JAZ)1K9?5
M_33^Y1*(\$YK<=>Y1^VDL.14/CPT>&&L8H6S5W0)Y26^ AY 1/=-JMX.<-(MJPBH+*G.\$*U.93R9JPN)6S\$=-'9TCCJVRKIR C/ K243 /X>|<)RD-72> MC(>
(H+SOAAZ(9,2)HELFHO^C-H.9C_N)E\$6Y0DMNR.=5D;J-A)5)T)M-M^TZ\$NNA\$+&.WIMWY?1?F1@+49P59S,M^IKE,TW#W L\$%LCTJV8?(>3)H3J;B-
H2>Y/15);W)EUPRT5HN^<+<174QLW<9J^KGBK02ND MQ^VF9^NU_=(XR)G;NT6MYZF9^YS9Q.=UPPM0Q^Y1@H?JE.FD\$5"KVZTJ
M8/++70\$Y.+1@>-DW4*1A=4H15IZ%O%\$NNG6.*6&*1=HHE'EJO\$25 MBEXC9K/0U#G?<IE,5&P#G#=1.9(=W 1@U&KPSW.59Y+R\$ *INV Y?/PI>JF
M.W7IH?NMS<2%=>PN20D.HSIR*Q.OICS %6Q9*#&H!#@S&1^Q%2%IF^0%<CVXRHF(X%)OJBZ3. M"#9.Q@S*72A6W5/182 M8@JF-
(QV)RD;DW(93&L)/(NGF+FT2P220V>9=3X.GP.M#>MG 10 QGM4B;B5?BTJRHJF2F?<1.Q<S\$+4TVI.U>K>6W>25"MT9-
QE0LZKRWNIN8;0LMV7+/Y6./9M.6JVL1W4>.Z7G8=GR9IB9=I79=TPM/4 M%P(T-CM@NJD=;#A)%A&UHF/U/%>DE>@JMWY?7UI7IF27>YO M(Z.;#Z?
60TG-HRB)3;M4E.G9@>@PYS^R>H5L1<2LPDB.<<^J10^B2?EK M.2H;JT2?Z>?<7+T^S?>QOA-21>D+MMG<^&J)=<+WD^JH<H3V)=TWB-
MARJY^61\$B4D1DMFHKS">^ISJBLGCVW?I2)S)WLA=M22;VUMLI@?9JGM? MUI?7IVP^YG.@4QI/B9VGM04Y&X?Y7+N;Y:R27XJ_@2^4HO^U-
QMWNUH=//AFI,*MO"3/D\$N X^B;AP\$AV BD:KT-M3JZVR;FH^L^L^!FO?>1=1>I5@-4F?Q>I#XQ;YA>?#WNH;^JU9J?>Z%J
MK<.;N=T&. ^V 19F839PJ.JHVSW>3%VJEL(DMSH.ZLT+31R5W1JYVYF<=>MQ%Q.O-SMO-Y+T^G1/O^WKOQU+WSJWV7B8#&3XB)5C;HF\$H+8?
\$EFNB?>@N.MO2"KOK!F!G01RVQMS;6JVF!E:D#8#0R+&C\$S.R2CW)5"FAH6%8&+G,"OTIHV.MZ4 I((PV#PWF3H=-'W=<=>LJS^(+<+E+K/^8@?
H739=YMS^10+Q?>=615IK M16L5C2W550*U"J\$#QRVY^5DWU70W^YVKECJ2ZBM1*E.C<5-29<=1H?ZY M/Q8HPOKMC\$J_1(,++9&)FRT
QFV5_9Q@ZE"/@6PNE(>TFEZ?5ZVE)9%=@F& MW7*2KRRD)I.N.F)=<7"Y%MZ.7G.UW(@# M>3NRI.F<+*QEV5;F.OD1MDARV4FIK7=
(V)=>K2Y6 ^L9T5MA3RJ-3G?>M<^<X2M#OMI?9E;4J6QWD7)V1^9QB/ ^UZUFITZ21*#(^B YQBNB<8>(V1;M=I=)5>U6_37><@<
10296NMS=>#N6_1^#14#9JQGR+J-O M_S1^@>S^Z.UF#W%\$CG;F'W0^E.MW;^BJ^O-E+Y:HV6/U0B=I""2\$CGI0W02^X5=Q-(MIT)3>JG
>M% /D6.<26I>.>0?)P'E7K&O>.H8D.^LWR87R&IB4N,%1/480*0 MI- P\$DXREV.)SCVB+RB)F/A=-WJ6_FP^82*.ARL:7 M@?140LW_9XXG/Z8R;CC:9Y-R-
/61+R\$1W=-V^>Z18.)ZBWJ_5YI-8RG.*M)1\$M7#E% MZV6I00@.P^V=ODI@?W+^?GR%MSZFCKZ.XSF05U35)=75S2^KHJZ@VYN?
MN4DE(MB(G:9@QKDG>4.K.1.1^>1F5.V6>#027K.0."GJ?TW:K68C M24@CDW;G14WKDZM>L>L4&FB@JVS-R\$JA25ZWIE)F_655?
(Y.%JTAI^AKIE< MLHHF15(R?3/O^Y?4JOMW9KVB* C>>X?Y8M=I/Y<I.QDTKA39RWYGIQ?7 M=IMV5_="<IQ3W7>Q-GVJ^SI5?
2^KGS8JF5Z&N\$M1^=VM93+45HJW?SIA=54 M^+ INU^MCJHD?2^6*22K^<OX/LRI^<2KUM% 0GI^<OHB.W-9>G7#WW9.%Z M=S?U0:?
JHVPT^JT&A^3JM3Z1B1^0\$J^+AM7?S4JSF1+M+RDCNEWI;4&G MI_KOXFSFY=9_9U^NCU\$8ZQ@-9T^P+>5"JKN@N?L6K1;9I^P\$N)J#5+\$IX
M1;3.6U>_O6BBL#KE68I\$&K^#173J;J03@K^04QCG<^DM>K C 92S.0I_=>#+Z^1.366&FS/L^15YVDLIU5Y\$KPO0I63 K">=8KPI2" @FH.D\$XSY^<3?
3B?B:HF1<8IOUO4B(O=U M- M+96^W6A7NVKEGM?PEHYWE;KR107MS;+FH8;T.KI:IQFMNCG5?C
M5-.5F@X#^300TOQ+@)E31 M^EXX>Q.C.5+4#N16ZGE>O>#Q?>7DVPDU^>O. M#5YDIWE-ACI0V9P&H?
TI+R(#>#&BNHJ2D1\$TN?>HJ6(U8^A8)TMIJ+ M9TSI^5M.DJ>-EZEPEB=B;80=JHJ.4V>Q6;LE0D9/D^?V;CMK;YI Z1\$NUE M-VC6>NNA?>KCE&?
*75K-JJM;+<ZG2P9>#>#>CB19#;@JX%E(^R4;#2N18 MG7AD^Y)3SX-U^L?SZ478ES+KQG^X_""5>.=5E.2K1H28L8IG (DD1<5UJ2
MK0GN;6(H9;NE&S)>RIY K4A/B413A/(<40N%)4YHYQG(CH;2^I MP?<7MB=M2W1@)D15IM\$;DWIL M^2*QH\$@ (MKAR6)76-
ZER=>GSPA(A.3).XDB@BF=JU;JA806I(^M&Q9(^N" GF^Y0^Y%K%>@KRWEI+P2^YI6?+XSEH^W:851A30H+2-M<
MS)/^R1J@OEMGEO<86YH.NS<^T|^B*=-,RP?/HKK^FN?7U0?2Q@9F.\$*="K _MC%|WBGPJHU96I=912\$T?(Q9LWT^\$K>RI-I,0%D^7NNAY@8D\$C.@0-
DE.7892C+>W1SP35/O^>Z^OP^J/S8H@-ORS;LB.4_8P3 M1#2<0>#Y>.*ZLV A6^X=ACFVR M=4HIYJ+0_1ZC%/CR _P+7S/TL.Y\$2\$G.<+IYMX
MJCNA4)NAPIG41^71ZZY/P^N^YMGFCF;WDX^K@P37EX.O.9H11PM%RI^G _M75S;I^F^0&Q7C.Q4V+!"+<IP;I\$UNXO
M^FJH)X@YIXRHBG;T.2I35Z19JU;T>VXY">_0P\$K(9^AITU^C%M2X1; MU^F>@NX N-SI0?H%>-2I<((MI@XM%M@6H&S5\$9@A1-7HJ@>MK"
I)US_5Y72 M#77H0Z)Q18KVES)<(<HK7F5M^D+\$.W<=>SP-R^70D#>+Q^I>D2YB;BZ.CXMU\$AG1O.(A)>0?HLZ>)_MS.6CYB^F4\$V4D4^W#\$;B)H8
#10#PB7^R6J^<@V4.SP3B1^B(^<^YN M^7ZI(<1<.<9&@4YHE\$D=>3;+NC=>#&#>@>X-MJ#&_ ?18U7^+08_@G4H@ MUFMG ((U^
(F5^>@YEPNB(THU^AP68.A9CXYT&WA^CG?7H2SP5^M2H7P-WE4@HPI?>_W^?K^+Q.L7P,ET5>1HFGPA1/L#>HVEN^8A.<1<-
Z\$9C#KVAOL.HJ?P IBS_K+2JUWZ1\$4I&&^ED MI+;I/XMF=G"TWEM3%XC.S.DIGH2^LD9@/OS;#17IW%:UX6I+C(23(T<-
MHUHU5MS^Q@<GN^"AH^>0I>E200.IJ3=Z77(@1C^T^HC.R.G8ON2MGN&JF
M8KD3YTM+@JMHBBY59HMS=>BH7T%VDN%MM.011#R^?9.BU210M^VZG4I%Z-4W M\$F16N^TC;JYV^1U18I#Z^I/1<=>\$7.4>3P%FA7-
CD1TOSOZO>?JBB(5I)T MJ.^MTT882^JG_?0;A34@N:.#2N=%M5^RIE50:"0H3^TNH-0WSGM(OEA(E9^< MGGVYO_ _9Y06Z;^SZN* OGSI^Y&O
6@<H12AXMECP32I)Z^>GW/(KDK2P-MGT^XMI^A3Y2CAEXRIW.5\$^>6.T?QXK%G1+X0OZYUHH)H@I3^519@<8S)6A?@ M(\$;14>)E#NK^R/M#O=<M-0X7?
C#QIHI^L&(^FW?AL M^;B;DR:29S@62^4O1\$>M3.CPO;O.;+3C=FDDF^I02X^I\$V6I4+NCO_-ML&#^I^C.<1D1).XXI^EXO2EPE42?44"&4FC)>O<)!
I@I@#2AJ^Y;1D M0^BX^1K#6^45\$S^<=<=<BQ/WDH6BYI.TOBLIB M^1^K^);.8?T1>AE/0L2A M.F^#V01M^%=>13^
<6AZ+53^R8B1FK1V1B+A^N^O^OHEB>"I^F".E+K\$LD8ST8>7YX1FJ3DC%\$I3^QCO04_\$.6%BD5/A.4&(1P.M)TD4>U\$ _Q^X>RI9#259Q>>@IR-
\$%>4LFLB=0BAZ9O G-L12Q@IPYI_-M%IHB_<X_9@A^VZ^PM<(<C^*R R6_>=>UHI E7PR.O_\$.D Y@Z9Z1^3YA_X
MNI%TME/2B^<2W71^Q5WR^<YWG;R5\$=8<X@ELV3V^+I02%KQ.FA9P@+;Z MF^K(PYM^Y^T^T8I MTUXS1
I:6B92P)C)0LMHO4NWMONP""F8.V96B8UV.3W&+YV7FEK1/R@K _M.YYSFY@Z509NWFSQL^UBXD+ _S^<JU87^9_E;2J6=FI^1L??V9T4HYM&
M#23NTK141^T^PDV^W^>R^R6F>M5XN240C1Y2Z^<I3Q6G1+FE52L6;6K/A MSJH&O=>HY.LGY62=>@LU4R0;IHE>I=Y3;0-
Q=DE>>E/LU^IV4&4AH;JQC I47^M3)5?D2.N>7<HU3R>^DHXBD1@I71RG(%."KL62P=?ZE(6.8)^Y.S&EV.W^DP@R6-
4^XFT3.D_^(E.S9ZAH7^7DTL)^T5VCD8CMVH;.\$(@15_)9DEIB@=-,^3E875-MGD;MI=-I%GH>(A+&V.DL<0QT&-DJ^0IS^>U\$T4^PE^?
KAED1^5@JZ9@I M;3#1@6%>@P\$P2K).V43G6R-2HU?<0L.SQE(8G;JTG F^>G^I^T4XZI9@<=>V12SF%I^BM%FFYGXHG4.2WI.BZ>) ^<CRYB+3JGXGZ1-
_U@ M.Q6H10PG\$T1I<#;#ROXU@50<+L.T+=,78?0D&E.Y^>@Y;Y+B1 I97G)I; MJF.W&I\$<=>?@_I3?_E8I^U23^Y%>SDSCG*_@*_I\$O.5
UR702IPY0_0E^?2 MEY;0I^J HHMOQI-OWGM.COINEITW^+G6;Y5U9?>@G21UJG;I^23#33^O M^O12@;%0P>_7T?
M1G1S@+^H762J88ZAI^T^I^QO&XMA+7^H8Q2=%>CG M (CGS2RID<^T^I#09/TT3IRT/BO/I\$19C.UYK=@+H3S2@_I6IKW\$>_M
I_0M^44V;ZE49M.)KH2^C QO08^NW^7-Q*1^LH(+%OYG9-V+&E20<+>M^>C 8SR2Z+>B+42G^UO^F?! _H^I\$+ZO.3;E)3I5N(D?Q4.FY.T4>>
M@-78 MBAMW9@;(H1KKS^C.6)P2JIR^@01-1RS^&#;5I;=4%L1 V&#%I0F(I^2)A^SP^3_ MQC^M^4Z/A EJR6;=>B^8I.SOE66G^<ZAGC#Q.24FI&*&
(M?/I25+YD.O)^T^MM>%)3. 72HKS;O+L.D2IFKJ99HYIX_\$.4 B.\$4Q2#DOMK4^T=M.V^".(C9(Z9GXZ;W@G4LXJ904#8'S?MQ15;1.OOS(FP^5D58D)HVA.QJ6
M^"AIW0_0P=1Q4F^J_5>^>^D17?S44HU02&I&S;+5/RKHM.ND%70;X M-X4?PH^PTD;^M@I^JYUA%YI^T4;6AB1-2^TW^C-I54BE^R2F=^P.U19G4
M&1^0HL(HZ9%;6X1^>RH1=514@<Q3(.5;D^+>HJCG6M+Z^L^I^#IM;@AF.M9TY04PH.OY%&?#H=9U_ M2NK^9?62)WRDY
MU%IQR^<XI;CDW;MD^Q2W7)V#ZCZG;UO^<^OJ3J_60C.WS7.Z.O(3OH%+%+HUP MM=\$3<_#;+K P4OXN6!^YP^EI^V BI^EV1+V\$PID.%<^".#...O)
(^PQJ+5 MN@<YV04^7<#%>L&S1^7PVSN10^=W%#00WCDPB&70S1#1ZC_>=>BE5Z18^ MG6%0^M13_5>N6 BXD7;2H#BHIZS7C#WN(2M1%HU>L?2
N\$V1+0=7(E^6I.M). (5O1PQ>_>M.W/DFI626WD.VPJV^Q;S6?J.YH^= ?Z. M#IFHR@&HA.FW;0517WBWDH+@;1F;EF)I=N^OJ?
C@85N54I@B8I7&64^?5 MLBK\$=JE^A@.@.FDL I^?>I3D0^C30QHL#MK^IZXW2^S B+7^DA#1+76
M<7REU^XU^N4^4^VKS^0K1@0@<9(ZYIVY=62)YHY.)\$#I\$ 5 A^=FW>@&A M\$Y^W@=#A.X1C1<^<NC2)Y5Pl.0ZES9YF^*SW+^XPAEQ9I^E9+7^Y2+
(CP^9U>?>?>C*."7=>SKD;#?;#>@&\$%+4O1EMOD M1?J^58Q91G?>I>^4=ZSBF@ZJ^IH.^M#^D1;I^C4!OTD\$3H6V^>D6^>G0WT MM?
I)YV.Z=9;PDVJ+@L^>H&+P\$JSH.IFYIYB2@-OF)SAG2YBMPP3GL^I6Y<@BI9CG1^I2C5^<+65+#+&J> MPP(1Q?P.PSSB/AHL^OU7R+H2P\$
>.;JOH)<_IPG\$9EH1%)<2#I=NYXXT)2MD^859F^2^9H MW\$C?X5V+Q!<ICRJ;S^L^JYS8P10JZM+@XL(4-AG;H1F/X34= M9<X 8\$K^<^U
A+88Z^UR^E1J/53T^R@LH1^8C386MY_#1+W12(U5^B7 M13N=2V2Y^I^<4C)&(A.M;J3Y.5U1FRLE\$&+I5-EEBY^<I^Z1%GB)MX)^#&
M.GS9/39Y30I_5_>B.1#4^>Y-M54H@G^>2.4D Q>-Y 2 M547^HJ34HC9P)RYT(O.&A^R+BK).F1((QO6ID0I;R(D^9I^27L5FI^CJ\$> M#_5RT<^E6-
H)^<^CS^71E^F=IJS-(+M+I@I^?^I=)HKK1O(K13ZY^A2. MFZ(GDF6-BR58+WZ1_\$.5% 4IK^UZ(A2<^Z^G(<+C0I50^3 MJR2%>D@ZH4>
<#&)9(PPEPETS2D_?E^0_AZ^?>2H&C&F7Q08J1ODFW+9(C A MX^T_X^3ELGH&L^>ADIC F+^>9HUZ&NK^S;RG.MV1^M2=2KVT^I7Y/OZ>
C)DAI0^N.X2+<^R&IKO#H)2HKD.WE8>?E M+AGYKA>W19WBMG/CMU3W^8-RIV)ADIC6K_;;6/H!^7MUI9_I0&KI2A^K
M1PIPS0^BOI P^MPI 3.IG^C(+W7H+1_5VFEV@W<23N6^>9C<=>5<^AC7^?E MHJK^HA&\$/C+I+^<
=N5806)E.S18H9#^Q9UHI.136^AIQ1GT\$9DB^2RPS^ MV8Z.FSS<^73XKM+HFO1RIHJ^K\$<Z^U(YV^)^SN&(3HPRWT+D?@<-(DL\$6I
MH2DYK^<IA+>HDMOCID6\$3^BG E6N?C 7?AJ^FN\$A?P^I MBKLIJ8B3JGYB&K+@<C>S^Y0417RYGRZL^&83DJN-5V(IFSP@UD 4V7N
M50@-YTR8^HR.O%>@HSH^Z9A^C^E=V0T6CA.14^HBI4&^9R51RCHI& FJG M0/WBR;^TF6)<I>Y^*Y(S.O8SR^O^<PI8&^<CYT3.<-HFGMB-/6I_ILKYT^B
MH;F<220FN28#7 EEPG)9LXH5X=BG9+7.7AS^7TLY.B7&1D: M5H0A(0\$H)P4VTGHI^MIY&8QH#AZ85&/FW;B KP;=5SHGAOH93^<@X;V
M\$H^AB883ZHUOS^T=C>@<CVD MW^W76F6AJHMSDW_TIOJ2^YI^/HZ V/GYO EC_<SNJK^KX^>MTZ15@&R2F_2 M^*
*KUZ849P8I_P=>@012.50V&#&^T301^7H10>^HGC^3&I^MFHJXG^>2CG0.M0(\$+>_VLD/IRAD)X^<+8=I.OEYI@Q@WLOQ@_N%>X\$G_ZE4Y
MIJA^T^<V.LT^<55CC+^_+L.W@<6C^6?I 3HSIW5D3?)8DEG^FP^<O_W MO+<COT^?#>JD>L^>B1.^CV@58 MW_&@6>IH@D^"3-
K=>_I7=K1GMJ&S^&2L.Z_?2543B_>496-IG09C80>=>=MSEB^OSJ.O^W&S3IP1^<#<#%2UQ(RK%YA\$WGQCB1R B2)^< <O.ZPIIF KRH MHKX-
52U(I\$YIUH458_YU7.BL^I.MJ.T)495-7Y6^G6@^*2^+&EG^>T.M^R^86<^H3_1BUYXFZ.UN_W3^2B2^=U69\$ V M+1^QF7) V<V\$X14R^=J0S0
C5^<10PQ3N)=^KEHH\$CHHDG^IVPUS.OT M@<I^N3HJF62=2R^IV3;D2=>4L\$^TMW4^I^H+I^3#C Y M&3L\$GRB@81P(\$*(?<_1H44AE5<^<^<)E3_7E=I
I^?>W=^70M@<26W)3J_B M&S98T5Y^F0.*LHY=S/EJZZ+Q+Y(^EX^OPO:5H255B9U)20IAY>^B(H5T9 &MRS-
#;14Y.ITAHX@<A+CC7^Q^<LX^3W5\$XJCKP4Q^K3\$HKRMJUO^U2DG^MZ^<6= A5T6\$IE..HVE6&^<ASMOOY1L8^U?(&7SZ P>4.JH826O.U\$V!>HUQ
ME7N_5_T0_>_7T^70>AJOIN.M_14Y\$+BXW/M^T= M+&RIZ4IY9^X430N.126KF+DI\$Q5P6>3^FHDH94/5>3#^G.OXX516%>^V>U M_1SZ
H61O%LH.)8TFI448D3IW#DA;FG^NZ1K_9EL5<^<NIM+P.SZWC^YIA M1<5932;D6K/#)%YT94D04ITL8MEIM(ZO#R/G-K3WLY^U M=>I);3%?D^?
S^>?>#>G>IYC;INE#06CI^O.M9TMO@&^<C0R3 MY^M_IH(RYESF+PE09P9@90F/>=>#>S.WJG1XYNTRRX^+ \$<5F.E^K&IYD4P5_9=QI/H;DS;NGC0
M^<V< MXV0Q77F.DX>=C+P (DEH;0>+MG(6S4M^2L.SU.E.S^B-(BKYR^NGIS^ZP3E_MGC^=\$6.
DHD<^<J>D4HI7K21PIKK&0%3&L0UA^7D43E.4X>=C+2.M0L MFI\$1.UZTF;=HAO.3^<^P=ZW^*RXY\$E^?N^\$.OX5:GPJ8M^TI?>^MI)YO^H
M\$B.ACK6Y^H1KR3@<W6C0D)D#SN^24N2O.04V+8858V;^G6GXC^PISW^RL+OCU;KDI^HIF.LVG>7PZ5_MV6C^B>=ZQ0^6S\$K^Y_&UK0?24^I-
QQ>#V.Y.4(1Y1^L^PH^*FIC_24S#M1.U0%#SORIVRD?CWSR^R@TIW.TFAU^&@;11^>#&3+1MB^13EYL_L#1^<M
M&BU4E2SOIY(F^7W2P3VMKIBN3ML;K#;QXPR>PV@2WI(^<AE6^A.^Q4Y^<=>MV.H8+^IGST3FC8.N^JISONYD\$VPZ8_V;
(Y9UY8:F>V_#ZIOY720#VB)I& MV^W+W.E.;D6SG^L)5AY^25B1^I6MG6/WAMY\$#=>V;IG_P1FU^>)JU7/7 M-EJ7N4@ZA;V7)H<^<M3NP

[illegible]

S%#K=SY\$!>7>AWUVS.332;*99*5Y006836SE-MIK*8R&FBN%V1%6G**89J4-1%(2C0J0Y\$&-&#?)WZJT@9J6\$3&3Q05V1YMLTPF4!>5G
 S%A@|=7."Q:3G@=12,E%2OE M02B16-2.%Q1313JIWRDOVO)^2 M0>EN/19SG(JF3"F^|K@.H7M8=VAZ>5'=(8-AJ\$X?YC6.8.2-9*R(F.P14O MNW\$M,B
 j2PV%SL8E.OH*H13.9HF8E#<|A81.-8W>TC|:OV.B-Z+B MW*.*YM#G.%FBNXW)2L3N2|DMTEH>0?G|+ICRU1 9TM
 |O1%2^+V.~@6KER6CZ&I~9D2B37-AKO4UW66ONC>G1)?D\$KJ(O|P|MOBT7.CN:W3 M>G/H6W|Q<1*~>W*1*%ZC+R. Z8?|=XL-
 (H:GL4.69PLK+D M8KJ(O9%8A8EP<.%A9>!<@V+>R# HWUQ|>~2@V1P9%|X8^H95G6M1M VMYQX71XWCIFD RIV +CZHYB/W%KP".T.:W800Y?
 W_~@.NIS MCB?%*VHR&I%TOD5H XK8? (2BR<|&414OHU)R|Y| M5E)=|<Q2C+PGDTE@:|>QRT|MA+*CF543\$) E&O2C>Q:8RJB"94:6BBDVN
 M_95-KN61Q<|<1"8~9A) FJGLIQTN2)~D?DEUK\$Y\$|OX^S|J|@H|B|@M-MS|O.\$9WR3M\$%HL5V.VZN?_5PWWQ|(/#Y<2VD.9Y+Z'-BC J83IZ1N-N6
 MUNU(SOV765D9\$CP- M*A\$A+>D- W+4=.%@+%|J~8EC-@RJ9M.OD^89=WM2<B5B|N1ZU>#6-#M.M0L-C:DQ|C|E(XH|D^XL\$*0<(>1U Z
 H|B1K:2+8FB^>=.%2D3XG& 9)%X8RZ5MM5=@@#B85 M.WAW\$S-O:4R4|&U.~|EW(DW?P-U|&|BV6%.QE@ZG'PG".B-~60@9'!TR*4(?
 HXQ4&4QW%OV5 M03HKJY.GUI+YS>4G2EO.LN:2E|H|K|L>|URY:D~.E7HN 1GK.4VV|*T^ M^I WGI=NAB16EU0Z.
 NZ\$.S9M#CX|O|H~D6PH>AWYR".S:X8~NL<+2 M^H|K8G05Y^FB<@P41.NLA^")JMZO-4%"88OX M?L-12S|+28&0FLMVX840N3T%|_K_

 /X.@B2JY|TVAUSK>_RD##>>LZ27-MV1C4"G2F1T0OF-W*3\$<0H X|PMS ?DG-QJZO:78.T?>7#-8U569f3>
 MH21\$NY*WSC"SU#)=+|PE|5>+B>295.SOCN.(BE3@F5Q.1F#|70A~.B\$M M2DVZ?M7?#_Z0QE!#C\$%UOLNWHOC|3PSYI
 M01"94!MKX|K06U&C0U.3ZO.TS|!>|X|HN#""ORUMPS|AL:R&J9@>2L24 M78#0F7OP&ZA^D.P*(U|HAB7W.L7D".#G/AV=1&4=HN=.O!A~<+

 MP.#.E%N&(<|N0-.18SHF?|OT|8X7=.#K|+EY 6X3PA750\$(61#Z1C+771\$ MO\$5Q?P.=E2&?/431)KJC4G |INTN&9E66E@Q9K17LJ188S&UUE^F-
 4EEF M3^(<S& R%<|LB-W%|LSZ\$&|H0M| MZ>9O?|=M.R5F5O~)U@<>^H|>YZM|*1.1298A.F#%O%6%GE\$R*.HSR|U|
 MA(>S^CO*RSSOLDJ@Q.O.QE7289R!6-52ZC|)I+>O.W1FPK.^/PME4U M.BADYQ P.H:\$1%ROA|CAI6- PRB|ROMT MRDCE\$#")-54\$*/MTOXA.4!FEB>Z
 M(APTM?B=B.E.YN|AM.60EW7W=RO|CG:3J6G;Y>W=R4^&PAX|Y*~2XW@X|P.O M&G6|H237FF7|X131L3|<XZQO L|L7A/U4JE9+WOL
 *0HD#~|521~ MWESK26B#(G(H XN1%|T3|T0FU@|S\$.R5B|M|GOK^+TL+XJKBU7=S9>C^B M1F&^FZ9|MB^+6AJGN;|R.RP6\$|E\$E%|^ZQ-
 H438R\$?~L%R9:SP2W3JFWM@|O0R.#I8DE+P|K0^KUOX^:V.LQ:5(4%.9KN|\$. M3A&B.G88-D34J#^<7<%8\$#P)RC\$NA6|TEA)-9 MH12R;V|G
 |D:OR<B&TXV?T\$&1 AKW=A^@SABNV|E|P|S|EFC TA0P|<^M9E77?>|X|\$. M342|BR~21A1B~V1A.(VK^?>O.BOCL@18;|X|BG2NOO&R
 M7#Z^FYC2^ZX0MFWM/LN P\$R=3B-JKM.ZL37|G|>Y%WT.RID9(L\$ 13AB\$"-M@X@S\$W\$Y9 OK@8B6%ZO9 CG^X: @LWAIM05'-
 ^U5WW/KM(S)|XRRPHY\$58~YVGDH|M| MZTN1&PXP|>8P>Z Y|<6*~.8H1FCM2>+2|& 1A(8K.@|P+P>3010MPMF M@+YHZ|?
 15H|H|TQ9NP7D|V?P|H|.#>205)ACN1R TE(QE<49\$H4^<@>YJ M30H;|G|V|L7I.E%<C7>9.T.V|TB|O.AB|B37|H8J7?<1.EWG?K?T943T^

 MWWK|H13VG@+SG^|79T|<\$Y7.&|D(O'S4TCQ*G.K\$VK2H1!<4>5=>Q MRV=45V|E_K+S@|A=1#.5R|(B (H(R1P.ON)ZM@R@UJ9?&Y916I MF\$&L
 J|R|HESI&S"RJK<Z\$&1 A14^B.%|L\$7X#K;#69 M7X|L#69 M2 PC8?2=..B*\$9+1A#P BPG-O3:2|1RC.GR^E=H\$75.J1SED0F5OXV M\$6\$)T9.<3|H|
 8\$ZFN#|C62N2%ORABLD005^EB(576J35-1 H^H^53E|36;~XW12Q?ZDWT.O (8|N<@<@92143U23+YSNUCFYNT|HJK78Z.8KDS'D%&)<S@>=BE
 M\$X5@&1=2)|2HK*E.BF&|B|ZT:W(HN^60<8WUOQYK D4%ASEB\$|ZDV=IKD.OAHH|(T\$|P%<CZ6SA M.#P|ER>~462P0WZNU#Y|<@TIR105I
 JM0<~>2K?M29#|FLW|>1TG|). M0FX(\$MB7Z|3|ET|@|VID3\$=K5U094L0GBR<^/Y2 M.XTN1THI8DQHG~.M52?C+0|&697UA7?7X|1ZQ^H|T?

 7#19\$|<UNO=U|@<S=U|L%|A71013E M(YOY|B0GZ5159VAH8KJ+;FHQO OY? OXIU ? M18\$|NG.^5(SG06^O.NS<+E7|WDLG V 7#3&5-
 K;Z@_EZU35FM>|/M_X MVM\$K^Q?KV^WSTK#T6'MKGPVJ2K-W= F|^P.Z|KEBM>V^=;G L.K#X%._M=IX53VSK7=7NHV>:'S30I?

 73?|J|=0%5CJ74|Z|Z2|/OOXYBT| M.MV&<80>5^<|THOK5NW23|<5J^O7O&U^BWWYHW30?~M|P^X^S|K3?>2>=K|

 F7G8|HUMN#PKEN|G|W3QZ|O|C7@|L42 MK^|X\$K4X;UYNEON\$|L|^<=OYMU=HM<K+R^X=MX;|G|H7 M|9-
 R|@Z|!C0!N1O(0)\$+##%~)W?KD|SA+|=HLG<QB^VHF..A<0\$7@ MBA#RDX^|&@5G\$P+T6B."KZ|B|9|OQ(KXGV|230+14L.&G/P)5TGC(?

 8H.2COX(B)QX<35|S6RUD\$96=EJN3|^L M/QC)9|H3LRRZH\$S817E.A(E|Z<."RO IY/^25%8|SMY1C.KW#M&G- MFB=8QH|D

 14UHSZ8GZB\$FB.AT#P/P@?7H<57ZUR?2!H\$K|EX@<K3^2W5Y1Z#RYA|>.P69Y14&E|8.^K F29A.P-S|H|HE^M1<|".<009R6RGJ5A">1#SOG4(#

 <|&2ZXOK<2W/N4^GD/L7+RSWG69W0 MX%69L8&K.3)2JF51QWTHYADA~WX25CLU|+G+K|D6^B.QE06KTS.P/R.+& M6|O\$86.PT9|

 <|H@H|X1@|S|X|)0E|F+L&E|HXRX>K015MQG1E X 7.M."RHH5\$RYM47Q~>XT|&O-35\$="|>YB|D*|RAMGB239=609-5HUR

 M7D6G#<C*#E@TO>|644.B76C>P4>~)NW|L(X|Q|D\$= T5?QO Z|O|L|UXFT M|-1T8+>|B|<+>Y:~S3|JBCFH&^1-1;Y<9;CDN2JSR\$EFL.SOU|C|FT#MB

 M\$ (6)LFV%~LFTU40W/^<3W|H(YO|PU3X|K#L|R|ZFEBCG|<IDYG& MPCU V6F0>D|7-8TN<^W|/\$%K~|YDMF70?V949FEW|Q>@R UA6^K^2-L2\$

 MOA0(|=3&/_ M3(E|JPK7P?<Z|A3A>L8YE630>+H(G|HFT63GYO|<=27\$|4=>?Q<|+3 MA:6ZN=,N.9.N=&LKB^FR^|M?PE?|+=;|X_M@87'D&?

 XWFL=E^6P)Y|^>|=66Q^2P|XLTH=63^9<+R3HOR.A+<=|QJ^8@SFXJ6|<+ M>+<@Q4\$1=|P|RUI>^>)GK^KZ|E+MF+7L.O.U&=>?B+55\$F

```

%22@#)KERLYU:7YF"8-VX8-R-M-4PL67AOEH@D:1H6>IP3D2A=&B%124(>+FL01(T):G0GC*MA+G1-IV812,MKI:W0X-X
1+~P130V*W~(J)/K)~U8R+JZXP*GAC=>+U5UJL&MK$N+~1752M3W2P7*HN8T21H2C(=OTY 0.45I:G RO>X$01*1~)=EL&#EP90
M"LLH1B=WELHW."H=3W=-X'@/B-3VO*8A(AY=&G6715E0K-ZHK&K:MB-N:O&Y:(IRI6*:XYOZV$6470(INPCD5+1HM+^2DIVTD:06:
IDD13:C-M=ES%396+!#J+J30~)~)5$)H0"<Q$8BI+M68XNW2);7F2D*7.M+!MDYNZ(*=B/OA3X$?GC?HBM:A)GGJS7IN(#EQIDQ-MOK1W^A
8U9:AH12THR-8K-F:L1ECG2GR78A)-GJOXI@/l9*XYL:CV-MU&I3~.L1:K5JWS*2$G1?~1-1<3/S?~L7D:G-SOW$S2WHFGL^M17GT/XM?Q?
VH->?J=KXKU=V=>I>K>K)~$$.?MI9NOXZ-LZ-?EXIO+UY?P-M3U:IV>?7JZ<~ZSKJ|>~H>K1SE:GMW=>H?~JK$T7Z17?~8Z&OR^M-
Z1^05N*WL7L^L-SJOQ?3MVAW~>EQ?2C@TIN1V323_QQ-OW?#1~17Z-MKIR/P7I-QM8-?00L28PFIU?Q?2WWY1=W@#COW6?Z^<Q?YW?
Q4I7G$~^>WM-M:V12?OYLLIX@+~1FZX8-7:WYRHH=6GNW2HZIVW~Y69R^~WJ-MI^2K^Q?@A^~^Q?A?
Z/ROJ?>?JXOI-77Y*UGKXY^AL>K7WU=O)LEI~R=F1Y5GT?2.MJZP6I@-D/GY|QAI+~P.WO1P"A$JH-M20D^X6^&"(EKP21%@( <8D;/&"7@>~
+CNB^A^A$5B17R"(H8W@~1)103ZQ-MD&SDI^(-R1YXJLDAU@/(<~(323V0&5C%39*EFNYCQ%432K(MC:9N:10:~#
%:OX804"RLM)M#~+G$JF34N/B#&VP-11B5~.116$>15S=9>+MH7AQA*Z80"HAZB@9KGK@ZBH7)8G&IYH1TEZIP.7):*6"+JB$A:4H$)@:30
M^L1L:GL2LX?E?P-MRJ?&~3-2G*FVTT$T9V-#9-7N*ND3Q9EV8(OHB#E~BHDH$870G:4WB0
M~/NH5|H>:0.98IHDFI&XIH6DN8:RU,YUHL4L/OM/RIHJZ<(<NXPJU.%3-MT13FI4*E:7FE-63I*W2WY-1"RUS'D66-25XT0$M%:7TH|RX-IX^~J@MQ>/
M2~PBOY0R9N1H8ON:HR#0D:Y3>M-%8T^$M>>^HPG?)Y8NU-55=&~<1=0&Z^<M&8YA)W0M3)W+OB=T6I.FI527Y4$@)1%~
~"KFBI0KJISR7DU?6625LMA51UXLL@V3B1&U31><4G$1A7X&2ECWQ?~E1P-9:0"MH@~N4L<1&M+BKY|:TH6%U1+DJ-87IOFX1D:~#
H1=TLT7W7K15"Y1M#00(EI)W+>Z2-M-G:GOMOG=>YK9-MAR0A8S=2G^4YZB579LZA=+2E&1AU<3MJPX~P=:~
PFX+4UFMDM$&3LV8?TLW??URAI|A|9.YTR)-M?0X/9D-5D4'2'4Q>OG@&7+~#6"8LUK3>H-X&9S>89|LCF|X89=VTL6R*:
M=E.D-BD-~W6$A"Z+(&AKG*)V1U72.H2ZIG6?R9"/<G&1~DY~>W11M201FN?>F19*0-50&+G&GA96I~0~>M=BP.O3$=SW-
~PGC00%<XMO%WHI'63Z&76U&<4$U1H1-JE1ZR3?OC$S+1WL-M&H1L:0NH49H6M%RGVD|NL:C$SIOUPTF14:|E1D|^>4&$~637IEMD
MO/>4G$2NG6"J(BJHFEW1&~W)~SC"GEQ7ME^02=ZNIUM2H15QOJG85-M=9H|=BF>WEOH-B=WHJNO+W:S>L^K~7EHLEI2BO-MZS-N~"IVBS
~"NW4%~HAKI8H$WBHK(231K5"K-~>6L3-MT-HURZM4+>+OBZ*H*NAZ*W*K|<AZ~>KV1(L/0==~#T/5@KAR"KH>@ZRH^A2#~MKFS.41C1A1V:DV:
~72>=57?X^A~52C^R/Q8G/6A5-E88K&~.~&~&C-M4-&~.15:~%ID14Y!>~53>B-U2369M25S-8A|J-E2AOD$*~JG&4>)2K5-M:3"B1EVP3R(T9
9P?>~B47+~JFFP#4F-9?QEG3&IW>A+~IPD=0B:=9J-M(2&G~WU&QO.9U/K$11F#NDG#M&Z%~>8DIARXAE(MCFXU1Z<=O1WVCS.HMX+
S$4D"11-9&Q-*2962$P7F<~>:CP0S>B>~>R(A#1=0NN%2:UP6O1L-B4082-MR(KY2%5Y3U&HJZ7B(1HAPX^@)D8E15~+2S#U12~F.A-XI
MJD4.9I8(G*F+&N+K15^<~>:KC6$~3B<~8S25UV(O432YV~4A1-2.G&~&MP1IB@MF~|0+~.E-FB1=7%74.E-$)M+~+1~P+&=Z41~6JH3:6H5^&
MCX-5:~#G~MCH&K(81)P5VA+Y+~1HBZ+~VYO:~P~PNSJY+8QAT~|10KJM-3Q=ZHE0F-LM(2VE%~W-(4:~#0G$N).Y59KE&J=KGD&X(O:11
<~*74UQC)XEP0W+57VHHA|9LMMEO@~Q74*H%-L5AZPIJAN&-IDK4(4E~3<=HS$ITS|N#52,RL1+90Z=H1;#S-MND9K=S&~|BT-#1:Q9A#39
T(8K5:RB9>~N1@<K~Z3REFJ:$TQO~$FN+&H1M9C:55~#8D0U025W#HW:P~1~M~1~Z>K<5JGGJX)~N=:T@S2DPO$O)B-M~|TPA-S7<~>K:~
N&2<N:SL#~#YQ-HL7~P~NM@~G~GOCMC91~AH.CP-M~#HFTU5.E5TQO~3$TP@/OWJ13M1@~#9/M4N?+SGW|VU0U8ZBZYOPH/B8(CMCMXP|H66
$|Q2M==~J4=~/SKBW4=#CV5)9G$~L^>TYI31UTK$~$ZIJHWQV?MGO$>>.TNU/P)0-2.YH15U&<2#QJ?7CB.EQHDFO"X$1.O+>2:BRR6LW14F
MJH?11Q@~&+~+1.6HJ$9SG+ENP#1:SD-4W$P-MMA<~>Q1OYEG<~G~GIV-9&U-MDV~="C~IEZ5N:(H1NQ~#MS19J8%(^08T1^=4~8ZIX-A3%|1|>K?
>11JBD1IH0-M02K1F1OJ>~1L#%2/12T?J&~.~YO+~1=CN0G)I3^E7S2:62.O-MH|^~|XXZJH~2VU5*OJA?>1O)KJZCVZ&O7I85&LSIPF%+2-8FJ?
B2T=06-M-0=4T72HD@O(83J|K|KGUE+~|2#Y90):Q>CVITGS.&N6.UY>R>~.~57S:85EQ+~DV~.ED^C6C4U~
|RZB1~|BIHJZC~1-O13LD9J)95B1U.CO9&~>S"<45(9)PG=E@~M)MB2Z%|<~1125/-BMTH1H0-1Y%$&>~8%2$~%62X2SUUY-SBJO+K535P912T.H2SF|ZFC(I
M$VXR9WXP|~17(RHX?LOP~.17%(GD|BR-&~&E&C(K8+OU9G60~D)-W(H-MV1)<L~
(1NY~1LZ12>~"JB~DLT@U=U=831HTG~=#47M&X-3TVTVKQ94#5M-5P4D1&2(CBPD3V1+OUT<|@3VUUI78F~*~HS;~)~*/@~QXFE97F7MD>|
(@~#SE2>UV>Y^Y(X,Y,K~C~O)DIO>+>JLD?2FO"(FT&~155)Y06(CKT-S#~M:L=4P1%~AIB2<@R~<G~K~.~71@5E)1.D>6EJRS~1~YVHBH6UQO.8NK%9SD2
ML|KR>~V2:P5A:=78-MY80D4|WNL@U9)Z@L=N06@S1M<~*X~MBE+N#-FKR*O.K-XF6FEZ>:53>=>G=M)W&D<L~2K=)>~
<~"F~M|JLBR3V)E@~(9J=S8128HW-E(8%FY&K.SJ(PD-SYB:AC(6~37@T~*KI~H)U)F7+4#>ET1#>3W2REA041$~GBRP8-MY9ZH102@L#T~RV4-
4GHLR87VNF0ES(W6+~<+T15|9$HT89M?%@NN@6-MQC9KWRKN:@5KMB@JH<~#%@$~.W6HIG1=7C4CQ~%FH(I:UF)"A#L~S%TG(O
M&L&Q8S53E/B#(66-116)<5HF@RJH~#8Y&V1F&H&R1S/KQO&A-X-O4-M-IUJ53L=BHS)&~%NBI6TU~G>+20Q>~*H6E>~$SIBK(16=S-Q.61^~
+G-QE-M1FM+~7L(1~1YU5:2UDHJ(12V)94N~WEO$P~GNWN.C~)Y5%VH(3>~1MABY?6G$G%QHV~>0~H~EA&ZXZXVLDHFI?~FJ:ML3M6$9:
M)2MN@3E)~.H1N1E?W+TE(NM6>|16:~%H~E20)Y~|F=|+5O.KD0~1XB1A3-M#~I-U2%W#(|$N.TQ#JW1#ZW1#ZW1&T~.~M~.2VQO-
8<6IOIRR~*9PB<~1O~M~N=W+H~VND9AB+1$TS-1OTD7KXZEW?)#(2-C1/EJB/KY-C.M)ZL1%~M19F%3LSUKYVQ222G@IZA%~H8KY~"+~F.C>
YRB11E~C~MM#M~W/E-JCE7~1
```


[illegible]

U#9J2E2ANKO(QZ-!!)<==PTE3#6#MTW>0AA1@@"Q22IK&B<6>:2L, FH6GHTZ&:I?2+F,2P6=?M3LL@DMA/92NXI'M'OK0">SWC>
1lq>95+14QWTDPEP.IN.PYI6R.YNU"038F&-EXQIX0"2@Z59+D.M9ACG9XX&8^KS1H6YI2MN=0.58.23#2>[A"W+!NXI+2P>RG.<2CI.G<:"%6]
M?Q>0U=U%NWLEBDS#M#6)QDN7%<#&A=RC[<#PW@I'>10^1HDI#H?MZ A?&JL6EZK'COQ?>T?31F4Y.O8X05SL6)IN1CGPPV>O+H.HH
3^OS M+^XY.2>ZEZ?Z. TJOLATET"OG7/TS.<K2/86F.#JH4S^0J0<?0*M2UU1.MR">N12M*%<#>1=7#1C4K19BE5.S0S1.BB/RUQCXY2J3#"X.HLL>A-
CM1N^+VVRV^EF\$RV.1)M%G3U9UN.4/@A.D>19#.@UHY@%TH@-H?>1^3<:"#12,JA.PC<-"X5E.M>D>TZV:01LOR'N;f2YH
HB3HCK&LG55/UBZZA+R+<#RIL30."/KGN.MF2X.M+1+9.M32@LQI.L9FG0X2'P.L+W^V^K=45<5<440.#T#>2/B>7LEPL9SQ.M>?
Q+BI^4FM4APBR7@%T%#2C<+<%7Z.9U^TUW.VY9Q8R'VY71.<L>H(HL#D#9^1LW\$S;IPK90J)=W/;>XTTYA^YI.MX%\$T:
A+D/HJWLN4B0T12G0'D\FJNB5\$SFIE05.T.C7L30HITL>4N!^T&M@OBJ/V^>1@7D)@I6V>.>@|ISBN%1LQ6CFTN7TVW@AFKQ:~#TWWV""(J3I
M)OF.%5IBBD48X9G.R^LD(#H.JY@-5&3.3P.XI\$%\$4/-R\$IM5OZ\$%18JN8.M0)T>HE\$U&~#HRO81=&K33+-,~.JNV.^%BP@LA\$@9;=NW/PT@?
DMF&K@~.RGA6=-M2<60B:6=<@EV6^KERIXOV.E3ZU@@.53OAT.K;89.AH'VU+U-!A|HNWOV/R.MWF0BO6V-
YFVD;G=6WTFMZS~+R)KWQ>4HJFQ0)6"21+1^2YO>4L. HCG2#MS.Z2F&6Y16U2.LXBA.2A7L#PUT>ES&K7,ZI(5%<C>@QTOH&FG\$8A>L
MCWM;EI/MAU^+(!~\$S|/NY9J.RPN3#EB.\$>ZAB^<^<VGM%R?IGD:IW=U%95Y.MDN2&8%\$1H.*OQ&4OI.*JYF>G5#3@.DG"7L.18GP?
YM\$>7493&HJU-U.M"#92=8P2U@PN;W.H6VE;=1#1VSS21L#P4M=U-7C.M29RI=H+2.5XM^&IYBK@CE60HR?M%;@.D1?2(D.HL.%C1=5OD@X(O1+
#.#&@A:O8&"0.(H.M6JTA6H7H+0.C1Z3P3S(Y3VYI+O*3M'Y9O+4U0C.UW11.RD.M:5RBVG5X%B*45UD1^N\$+.P#F:55<[AC9VK]<+>!?O-
D4HDN+1)WLN1N1YK1IX&WY25UC96MT4K#MY=S9%0:6U92UBPN.M2HJ)P^C#*#2.X9.P.KI<^A04V1.FD2JH>V<4ET.WITUJ9Y?Z.HEPN
M1A43@1VJGHTN58ZXY>EOOHR13XT3.ACG.55.=364E.9<3KN+4N^&PDK/9.M/65;&OKSW(V~8N39RY#%92?O-
AY3H^T3!^>B#ITS<9%8.T(\$|GSBB0~M.LVNNQ21VK.SCREB5/D@6FNFI[X;C/TNX"8"X^TR3Y?..DQW+P=TR^<C
M/LITXV%=<XX9.HM9W&AOYQ|...SOD+PIK>N.#H793:2CF\$61STW17NZ+..M.C"2ZJC07=6ESJ\$)DT*>9A1&M.6IU^#E"KX|+~.MZP9*
<@RHE|>~<#HNK/E.MB:~R:=10F\$H5K/Q&@.9N)<@.~?1-ME(61316-R=OP337XLUT:B0*C%ANL.MIN"3%|.#J9H~<@IN4A.XNKR3R<5#
<7L0XE"KLRR.A7G.M+AE3N@.@.VUH32+R+18.1D^N1L^1)HJOEEDB/KJA4V1#&1#&D+ZY-BR/HZBBWIK.MSS/E.U/PQ6:K05SM&+@L7E%
[C>SDD>(\$98WH\$D8A4FU688.M*BIB.X|,D5U\$G94<@L^MOS3P.)O.../S\$G.G.V3PD^1I20S>L3RIV^H(50L\$>H(H#9Y"5.MV14HD>NIZ,X8).15FIH=..A-
>K7H.J. Y0%<AP&6Y+0@19*8-IM1#&Q.M=B<B.HF2=AQTFH|)27FKF^ICTA1A0DB@&I<^1H
M>J@4RQ2JN@W|>~P+4.K4S0^ASH1^2#41G&AMH1O:O.C1&CT6R0/UH3JA1M\$#RR1P/C7I9Q#;=VA&HF>OTAW(&5>H-|SIC1Z.%ER)>N7S:
(N6:XO+A1% M.L.L-[K7BG%EJH/KNO%HP%VH3%>4IA<Y.2V+T^3VJAZNN+M.M@KR\$>?+A/A/F&:(3^G2E"HL<=>..8^CLSN6?13**C0&Q5
M6MVCYU=+<W@U|<K>?>O8BA.K0#^1H.H\$>@.A#Q@FIOL:15>P4Y<#MSJ^IEMJ433Q|H4J5\$W02@IPEZW?&br/>M1T8K\$PIY<K6D>|<@<E&S3L0W%G3G-MEYJPA\$A#@Q:FXQVZ21H93D>HN12+J.A'0DV.*A.S<@15@IY2.E@>MHO=7MM.HH^JYAZI.M8I4>4."A
O.XYH^8FH&14GA.H9I^N.0K\$18+?U0^TB#FICA+316*ZY@0.T.M1%.HD9?I9@)(Z\$9289+8V%0:0+Df#GYGF<-(OBO"C.OI^>W-4@O7D9)YMN-
IU#0HJDO>LNJ2M0|WR;4(C0K\$9NJ@.9FG<0F)X<#&JGZ>|=:22.MRRO=O&WM.C>5J4.5FJ.W.QCFH9K:1&/P3)3N@58A^C1R9Z<IWA9TM<
MC0/>#7MXHKZ00RBE;OBS!<PQI6(8+1H0N7KGR.J\$9:0^CX" M.95\$K)I0\$#G06<8FPA.3%4SH0M03WJ.MI)Z>TC1CIV/P(A&PVV>/(7>#6K
M*.90\$M6|<^1.502.OFK""H.L^&PQX|A'DGCO@H52/G29\$^UWB2^1M.2P5Z/N^..<P%\$EDEFRV2&9#0:171+1.MOGT&
I>_8LH^I>P#HRE75YQ:AD<"\$6S\$Z@98J4^DUPMSKY@<I/>C7Q74L@G.MCNKX42I2"U_F_(\$9U08(9WU99H^K@X13QJ^_E&+J)V<1MT(4ZK^K&3-
MA=70JYUO7EY\$=2I?95(3""NLH(16X.MT/=-8(L1PYGZ.8J+P^W7R.45.@12\$IRXRH.(H+1%W^I".PB.*IY0=G1@1HQ
ME(=H30S#EUL\$XOK>EZJ|+BVV>6GXF.A0(2)D4H.MLJ01(\$1/LJLH19^G=0J#G#D^&1CP(3>B|E@8B1XCE@IK^I".I"MKI=-8.0.H1+?
P_108P%6P.2A^WM.@J2/NGIW.XI<4T|BK.<P5CD)K"GCM@80?..9<#/\$HSI6I(O(BH&=#VYKU3J0.3.M8V.A1=L9KNAOD*#"5V\$28HD+T4f8=S+
HIXACQ(CX.M.C/S)<@I=IBOI.M0?22NDLEFLQF.MSP<=Y#T<C>@IVR+8^<@)IT=3IVT.XU5^79+M\$E&H|F@PXPJG;66?
I8H@C2IC6%80HJ4TSGI+18.P#M\$66Y\$-0.MS0&J25BCXGH@.<?QZ<3OI/^U.A:7<8E><1%SMHWO/BMB12M5ITLZ0.Z9W
MU.)X0B^KG.5A&^YOC9'0.?\$/Z%9.9X6H'E!U:BT/3.HI089NSU8^M2)17D.M=8W=I9)KSSEBJP%&&E1RRL%#"2@&4I09"GJH@Q.4.*6I^#.J+~7I
MLM.E7UN@#..HJ1>132FGU.H.3Z@>X3JDW@+Y4\$&13=(ZNP%\$@|NBY<9.M&?#~W?
(C>#YI9&7&CR|BTE.CJ|P)ERT<+Y3HMMWAAH01.E5@X|KX>R.;V2G.U896V0@O17@#..BV+7SM3U=JFW.1#~YTL3V1^R.&NDNP1\$9K/2.M|A-
^YI".NIGA405.8U|L=^H1PAEZ^Y.1?5N5\$H1W29I2.#8TCL5AYF(MR9.=*GF6)/@QS;U7IK.F\$X.F372FV<^<^A|G<1^R(318+L.#Q3HJP.MYX-
VF=.%:PKD1/TE"C0ISXB/OP%18RN)*M64L/1KHA3610GL\$1\$UG^TH7P.M(8)S0^6L2M10I.9ID#0I8FM8I2Z>7L51.7I\$&K@PH1/3N%1^B:E
M+T^V~#4C8025?X5Y1((E9D/CJW\$B<6F^N81D@.X6FJLTP1L^!O7AW70L^IF??#1X&TN&L\$N+R^I|AWG+MIG2V"W">+H-13.MX3.93@P;)1/56LJ<-@31U>V>?29N)@PAZL|H\$J^B9T#Q+VHB;S6E5.MD+3.2IP5Y66H.@C+OAF=^C@%1M9R^F6Y>Q7~#MAP3N|7&F7H.@BJ^DAF^M2?
3;CS\$#C2K^@%6%Q2W^F^M1%?W1*9JR5Z8+3.1%&6WAC^H#W)\$1.DG.OI^N3NCD)>RJ5?WJU.LL^F.M>4JOH.9IM5FN?
MP+512K)1ZK.1B#2+FB1WTU.M"<J@>WH89.YRY.H4(Q

@@@BDBA:RX\$55DB&UY^4E^|UT|)^|G^&^*?O M9K=9I.DN2+J/(4|MKR=KD&:#^@H^?EWTJZVM@UWATZ%+\$6::|UF^R5*X MND?
|>|MDN N>A\$P|ZP88" W@|J0|>S5F\$55XKL6%1QZ,\$%|SRFB\$ L MLM2L+4Z& #9/6ES<3.VQVS(W176DDQ%\$M1-FVD?BK <= 5F
0:8Z5LX4M(GI7EHY)DYXS&AIE ^1YX&261HX^Z,<@G5,%7JL: ^60 M1+2W^HQ:@OM@KF185LU^HDB.6 CJ^FH4<CEU^U|)|3.NY<0794K15N>9\$+;J00#
|STUJ&AA=3Y|)(MR^N>)(56F.OTSEU8;3P4OT0?9<=N44=5N?S>^X7=?;:|<V.D^7*8V| BGLN06P.|M1N4RO (T^7^EHJJB@:CQ^U|9^<EY
MWO/RU@^*HWIT>?3^NLS^P^GZRS5?&ZRIX@?Z\$40+;|J.P.FLGH<^120> MI89^Q^K|TU2>|R^P|FLM+T|7NM2N8R\$+J05:TRUXWV.P1
MG1HB<5.&+|>X^T08)=S+9Z%<=U5|^H97ONVX.F@R>>8+GE<E^089 0>2%1 M^M^06B^1L)&^*N(L&T^R|O9^5Q^O.DDT&T&R 3<.<Y7|
BH<=ZQ.DU^M^THY MDPY^GK3NGGFENJ=OHR<S^M|^|QBWW.35V|^<6.147LUF\$M^ M67@0<=>X0AK^M)^|Z%?5B J EJVFEW^K2E^M^5^U^
9LY+S<=MU5F5Q\$V=^RY+3|MDH6H7|>14 (XK(I2ONCHLZ.IX "E@-RY&)|J M8J\$=476<MMH^WD>T\$W/OLIZT.Y.&N^TW2'=Z.T.RUYALS^KRY6)^NBR\$
M,*^FTSOXC+|^|BNLIS^2'6<2#034<J^@-9L|T^FJ=^H03G@<3^/OENI^! M^8DZ^M(LXEO9;N<6|>+A^M^2^HJDT^JO@<9^WVGFQ^NN5=^KT8^*8@9<=^P
M^I^W^7.9^J6.3ZE(EOUL\$35AC^>V1+>\$/GRI^/D39IV3M^Y3<4+>O&E^!>:|H;G+Z6<=M^X&Z35CM^>^0^O^0^>^J4Y^JL
M+AGNN^<=NFK>3OY|/QV^EUQ9@6%?X1^CFOG6IGF#|@(|IOWRO|^|MI^17 MU|4CA.F:7D54EVX1>(>|^|H4|XP0FB GD49^0W\$N.>|^CV<60^JIVS|^
|FO>^X^H|^|>:VGM>+|^|2^3O2^M^QV;H|H5OUICUD^W^Z48>X\$ M^78^Q5B^>XOJE4^|^|3Y+|^|ES/YX3+80.4QU0PB|@KRR^C^9M.C3XH7CSL
MA&CND^R+|^HY^+<=|42JIE&MU^001K8^0^7^5%<3^M6 UN^AFA^@0|0^V^<M^MXI.0^V^2|^|MV|@4A:5^PQ.WI55\$3.8:2DRRM1 QY.8ZZCA
W^AO)Z^*A& MS^D9|+EK@=\$DS0.*BYT^UCZ^"(A4DUUIQ(7P6=HL?+M^%|^|QV(A7 O/Y3/0OP3GGKG-6<ORW|^W.@3AR=BAPC&7^FAS.73+4AP3
M\$^>ZZZ:~|JPA@S2K^T0A^#L&D^/75Z97I4G2)O8J7GJ|H@<6B=|F|^|TWJXN^Y^T8^>Y+X36^<MVIRS+^/3R|EYEN<N<=<G?F5>.R97JFH2(T&
|OOH4E^K9JOW>6RF>|<M^M^&M^SM6IX^K97LV DOO4YB&^6CCE&WFILT^>BH^C2@##.9D7M^O=^TMR&C^T.FE^N
|W^W^F9(0.))>=W\$^T(8=\$^SPBIO^M8L9-WY@|^|J.N<|^|Y^FNCFSE.S^2\$<M.Y.M.H9>^M78N5D^M=L12.(3|L\$4=A5V^O^D^J4WNJN^T^&|RMJGDCH^
KLY M^YHLE^E(GIQV|^|J^J Q3Z.HXJL^K15^<P^W0R^O6HBS^Y.K5C%&\$3_K>%|(2 M^UO_Q9^<C5^KUM6B1MO8VH2Y.4VE^
|<HDI^96H^<VOD4^>7)FW2L<^<D4&6C@ M^I0R^8O^G+V^YBW:O2|V@6A^IPL0^|^|W9@-A4154^N^1^N^86B^>#1%<^<HC^MON^<=^OD^HM4J&H^?
D^X^|96NIX^84Q^QXVCR^YYMM\$24VWBH17?D64S5 M^RQ|PG|^H|^O1E|^|@9EY@.4|G^>Y8>?N^F RTTN2\$^O10:5CEELP5 M^KSROL^9E78V
C@W7NMVA 9.\$=F4D:0^V^H+|^>Y=9FG4K M(2FLF^T^H2.9C7%>O%6(#8 ^M3=EC^@OB^L^<^3^ULKM@W)|FL; BO(2 M):W(E6M7
5UEM^T14U5ZWK6 MO2|^|89<3BJOLCD^IY@<6 KDPSB+1KN EB M^T^P^\$P&MPN2^M^7/3.\$1YD^F9A|^|T2 S6@S^X9 MISO=584F.E 5Z|^K5^DMH^
M+4C 7.K INSEMR^>|^|2HHK3WJXN^V^>^YH|^RV7 ^<^GHEY^Z GSHW^2\$ MX\$5\$N^H.GE7YF2S6HJ&@>6SR8TF|VWW^V^XZ>^|V^X^
RGX^<AX=O>?X9 M9KL830^>,\$+XZ>^<^KH8|^8@8|^>C<42.KNGBZ.6KHQ?? 33=VY|^|OSI^Z M^X|^|O7BU7?>5|YV7|^|W<6(T^<Y^|BQ#Z?
\$N|^ZEP23XU8L7KXJ^|WR6 M^2^G1^<+W.W^?OGV^I=OC^*KCS^WZ^<V^?> WE=60?DYGUW/59^FV M6^OIZY>?S^F6R.WHIZ>
M^N2&3^YBSG^*EW/RRS^FSN>8^C^W7U^K||^OIGSG.AP1=O7H0O P19N M^@HJ|^<^HYSI^H^6^>6)Z9R>T^I
(^<Q0^/WAYC(WB?>^PSXG4^<C;.(8\$<^%QXY+ M1SG^MUDY QY9 2\$Y6YPCRV.P7\$<^F2EWOY\$<5KZC^V^<^/OO<VX MO^>=2N^>>P^W^>^3^1^R|^?|^1?
^BMOFS^>=>O^L^+H|B|Q<?>="7ZGJ\$F\$40 M^DIBYQJ\$LL+^N8Q.1MP6XH3+1D#<^%P MR|E.FO@<AN3PB1 25GRO7W@MWO
RKD00MC56"H^|XQB88M^MAY5\$C^1H5:HV9QV^>^<M TE^<Y05EG^DHC0TU^>H^6F9JX^W5^|WV2|^|<GZ9==^AMF8LN&.\$" (XD4?H ML)^*
L^D@X15B3.4JOJCXB2U96UQ|TH9(^<+^WPT M993=Z+U ON9 M3V|Y^VYH^O.D.S4V B^FEMTWL^KK13.PH|9YJL^UUAO&LU|@^B^A1E+5\$W^I
M^T^VH^BE(|VW^B0@XIMP^<^&^&(4B^BXN" C GS^2P:9^W1^"@+|^|@VU0E^M17A|^|SGL^TGCOTP|^| %UB&4W|^|U\$TL+|^|(*Z^60.O&
H^FFTYN6I07^X.G.33 M6+567UO2A3VYQ7^C^<L^8^O@<K^<937E5C2\$4^<C|V.H+|^|0REB+N^O3C^M^ M^V\$ G9^M^<^
<8^>0.06GSB^<A708>=5G>^<3^414^12^YLO.&EY|O^<D^K^M|^IAB6I0D6/SC1^M^SOZU MRP MOH13BWB^<4#|^|E(B1^RUG|VLE4B>:PWG62 6@<5\$S^/33&^
|^>S5M^>|^2FIV)<Z5% |X|^>+LA4BKX|L 9 M\$^YWYRH1="FW.^LAW|Q< \$E= \$4BB B^V|^|7EB.16B^7^S EZG.A377D^05627@KJ|^8 ZT&< ML#<^
RISRBSO74^C.??O4@<S\$0K06M^MIX|8(T^PTMKR^<D TLX^D.TFE9Z.XHECSR@<G^K&CFI5I2^CDDPTW^SU|^NDCM^MZ=MNY@OH|^&^MHHT^
=DU|VBF5DRCT^O1^O<=<R>.>|^PICO.T6DQ^T^CDTR>^M|GP7 6A^F7|3>H5::UO|^|3S:REID8^?>2^R2.OP(2^9K0+8YIM&D\$M^%S=BE^&H
S&=IMST2U<S.ROL+<8.U9U0O MYN^P^<WD: 2^PXGX^>|^|Z6YLXWM^2P2L2W7Y^<O.B^4C^8Y7O|H.SF^|YU2>^ASA^I^N&^
M^<@^T6@W+|^|8&EOIH3XNRRR^Y18^<O4DH2M+R|^7= 6EY4E1^HJNS1SP^<B5Z^<M^V^L^P+OG.O^<^X|OZOK^2^J|A<^YUJY7^?M^<N=GN1^YPSYQ^MSJW^Y^
<6^PFD^UO.009F.BV^V^O|0BBWCBJH2HCN1+L^>^<H8W00XL3^<@-M<O^W^CSC^<8SGS^|TNXUC6DNNZUHOO13EMXU1^E4\$Q|ME|^<H^W8Z5^<A.I0:
ME+<B67&C^<E^<EQ+|4B^H5R13WF8|^>34CB8GEPIA8D25.DS^<+^%|^|3PU^M^M^|^|U^M^HJ

f.~P^(\$6N67U^J*KU0F+8,5%F9X1AY5NI{*-M?P5EGZ53J:0L*C\UJ#">Y MV*3CQTT"TDStL@f1)0I0.PCN95:1HR#-J9<\$40GZ3H:,V,i=")6Z0:=!* H\$-M1_R-?5IR6i>UHV!'\$NI@DI-GH\$%I!M051:;>--<=H>I
iK35X2L,'U1L?+F-8C-MIK=3NCAVB)W0<:,@=B30MXU.ZV.S#6R?)Q-A"4!E\$CAM>^0P\$/K.RNK)+\B;MGX-%G\05'N)?-Q102P\$""%,4"-,@FQ9\B5R>+; !+CP@-'@-M-@-\$-96\$P.C\$X-
S(X+3\$P<51T:65R87!E=7110W,N:!'1M4\$L!-M-A0#% @-#H)1L6::DF\$0X!@-"24-!P (-!'MP-65A-M,#(0.##:Q+3)?-M=6AE++3IP0-\0<-M"-7S3-!E03-R,3@W,C@P:65X,S(M,51T:65R87-N:!'1M4\$L!-A0#-M% @
#H)1L6<\EN1Z@!-A1-!P (-!7>\-65A,#(0-M.#6UD-M+3(P,C@P:3,P7VQA8BYX:6Q02P\$""%,4"-,@FQ9PP0,T#